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ABSTRACT
Colorectal cancer (CRC) is the third leading cancer in the United States with an
estimated 132,700 new cases and 49,700 deaths in 2015. Well-performed screening
colonoscopies prevent cancer by allowing visualization of the entire colon and removal of
precancerous polyps (adenomas). Persons with high-risk polyps at screening are therefore
advised to undergo periodic surveillance colonoscopy. Screening and surveillance
colonoscopy guidelines were updated by the U.S. Multi-society Task Force (USMSTF) in
2006, which emphasized risk stratification by polyp features at screening colonoscopy.
This is a retrospective cohort study of patients with screening colonoscopy at an
endoscopy center in South Carolina between September 2001 and February 2010,
followed through February 2011. The aims of the study are to: (a) assess the impact of
the 2006 USMSTF guidelines on CRC surveillance and re-screening timing, and, (b)
identify the predictors of guideline-concordant surveillance colonoscopy
recommendations, overuse or underuse.
We compared patients with screening colonoscopy in the pre- and post-2006 periods
for appropriate use (surveillance interval as per guideline), overuse (premature relative to
guideline) and underuse (delayed or not done). We classified patients by cancer risk, and
comparisons were made using chi-square tests, Kaplan-Meier (KM) approach with logrank test, and multiple regression modeling to identify factors associated with appropriate
surveillance.
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Of 16,897 study patients, 4,234 had adenomatous polyps (surveillance-eligible), of
whom 2,195 (51.4%) had a surveillance colonoscopy, 91.8% with inappropriate
surveillance timing. We observed underuse among ≤1-, and 3-year surveillance groups
(p<0.001), and overuse among 5-year recommended surveillance (p<0.001). Among
those without adenomas at initial colonoscopy, 14.3% (1,793 of 12,571 pre-period
patients) had premature second colonoscopy after a mean of 4.65 years. In multivariate
analysis, patients with large adenoma (≥ 10 mm) (OR: 1.81; 95%CI: 1.25-2.63), and ≥2
advanced characteristics (OR: 2.26; 95%CI: 1.30-3.93), and post-guideline period (OR:
1.73; 95%CI: 1.30-2.31) were associated with overuse. Delayed surveillance was more
likely in patients with the largest adenoma found in the right colon (OR: 1.49; 95%CI:
1.12-1.98) and Medicaid beneficiaries (OR: 3.22; 95%CI: 1.14-9.09).
Minimizing overuse among low-risk patients will spare provider time for high-risk
patients and reduce colorectal cancer incidence at no extra cost.
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CHAPTER 1
INTRODUCTION
This chapter describes background information on colorectal cancer (CRC) and
significance of the study objectives. There are four sections: (1) background, (2)
objectives, (3) significance of the study, and (4) limitations.

1.1 Background
Colorectal cancer (CRC) is the third leading cancer in the United States with an
estimated 132,700 new cases and 49,700 deaths in 2015(ACS, 2015). Incidence and
mortality rates vary by gender, age, and race/ethnicity. There has been an annual 4.3%
decline in CRC incidence among adults aged over 50, but there has been an increase of
1.8% per year in the below 50-age group from 2007 to 2011(ACS, 2015). Younger CRC
patients aged < 40 years typically have more advanced disease, estimated at more than
one-tenth of CRC cases (Ahnen et al., 2014; Bailey et al., 2015). However, patients in
this age group account for 6.5% of CRC-related deaths (Fairley, Li, Komar, Steigerwalt,
& Erlich, 2014; Siegel, Desantis, & Jemal, 2014).
Adenomatous polyps are the most frequent neoplasm found during colorectal
screening (Imperiale et al., 2000; Schoenfeld et al., 2005). At least ≥30% of men and
≥20% of women who undergo colonoscopic screening by experienced endoscopists
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are found to have ≥ 1 adenomas (Levine & Ahnen, 2006; Rex et al., 2015). Wellperformed screening colonoscopies prevent cancer by enabling visualization and removal
of precancerous polyps (adenomas). Therefore, the presence of adenomas on the most
recent colonoscopy can be an indicator for subsequently advanced adenomas (Imperiale
et al., 2014; Laiyemo et al., 2009; Pinsky et al., 2009; Robertson et al., 2009). Screening
colonoscopy can achieve 76-90% reduction in CRC incidence and mortality can be
reduced by 53-89% after colonoscopic polypectomy (Winawer et al., 1993; Xirasagar et
al., 2015; Zauber et al., 2012).
Persons with high-risk polyps at screening are advised to undergo periodic
surveillance colonoscopy. Surveillance guidelines have been updated by the U.S.
Multisociety Task Force (USMTF) Colorectal Cancer and the American Cancer Society
(ACS) in 2006. Risk stratification is a strategy to markedly reduce the intensity of followup evaluation in a substantial proportion of patients. The guidelines recommend the
following surveillance intervals post baseline screening: 2-6 months for patients with
sessile adenomas that are removed piecemeal; at 1 year for patients with hyperplastic
polyposis syndrome or > 10 adenomas; at 3 years for patients with 3-10 adenomas, ≥ 1
cm adenoma, or any adenoma with villous features, or high-grade dysplasia; at 5 years
for patients with 1 or 2 small tubular adenomas or any adenoma without advanced
features; and no surveillance (i.e., resume 10 year screening interval) for patients with
small rectal hyperplastic polyps or normal tissues(Winawer et al., 2006).
However, many studies reported that time to re-examination varied in clinical
practice (Kahn et al., 2015; Schoen et al., 2010; Sint Nicolaas et al., 2013). Many related
factors should be explored, including baseline polyp, patient, and/or colonoscopy
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procedure characteristics. A possible reason is that very few data sources are available
that are validated to have achieved polyp clearance at surveillance. Most of surveillance
studies focused on surveillance use among patients with polyps found at screening
examination but not those with no polyps found. (Laiyemo et al., 2009; Morelli,
Glowinski, Juluri, Johnson, & Imperiale, 2013; Pinsky et al., 2009; Robertson et al.,
2009) . Documenting timely surveillance and the rate of new polyp development may
increase the efficiency of surveillance use while decreasing the subsequent risk of cancer
for high-risk individuals (de Jonge et al., 2012; Winawer et al., 2006). Therefore, this
study explores the relationship between timely surveillance colonoscopy and baseline
findings on polyp, patient, and colonoscopy procedure characteristics. It uses secondary
data from a endoscopy center which has a documented higher CRC prevention rate than
any community-based series documented (Xirasagar et al., 2015).

1.2 Objectives
The aims of the study are to: (a) assess the influence of a change in colorectal cancer
surveillance guidelines and to characterize surveillance colonoscopy recommendations
after initial screening among patients with a near-complete polyp clearance on
colonoscopy at a community-based facility, and, (b) identify the predictors of guidelineconcordant surveillance colonoscopy recommendations, as well as those associated with
overuse or underuse relative to guidelines.
Using surveillance recommendations and risk stratification to examine the factors in
surveillance timing may enable identification of measures to optimize surveillance
colonoscopy use at endoscopy centers in the United States. We tested our objectives,
using adenoma features (number, size, location, and histology) at initial colonoscopy,
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patient characteristics (patient age, gender, race, and insurance status), and guideline date
(pre-2006 period, and 2006 and later).
The main study objectives are as follows:
1. To study the timing of surveillance colonoscopy relative to the recommended
intervals for patients with an initial colonoscopy in the pre-2006 period vs. 2006
and later.
2. To identify the factors driving the likelihood of guideline-concordant surveillance
in a total cohort of patients with an initial colonoscopy.

1.3 Significance of the study
The quality of baseline colonoscopy plays a major role in determining the
appropriate postpolypectomy surveillance interval (S. J. Winawer et al., 2006). Therefore,
without a good clearing of the colon at initial screening, patients are at increased risk for
subsequently advanced neoplasms(Barclay, Vicari, Doughty, Johanson, & Greenlaw,
2006). Following the surveillance guidelines can prevent the disease, and reduce the
burdens on medical resources. A large number of patients with adenomas have been
diagnosed as a result of the increased use of CRC screening, but adherence to
surveillance guidelines remains low. Therefore, the management of surveillance
colonoscopy appropriateness is very important.
This study aims to contribute the literature by:
1. Using over 10 years of clinical data on colonoscopy with the near-complete polyp
clearance and with nearly completed polyp information for analysis
2. Profiling surveillance in a community-based setting, stratifying risk groups based
on baseline adenoma features
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3. Determining the influence of a change in the 2006 guidelines for surveillance
colonoscopy on actual practice
4. Identifying the predictors at initial colonoscopy that predict guidelineconcordance: adenoma features (number, size, location, or histology), patient
characteristics (gender, age, race, and insurance status), and guideline date.

1.4Limitations
There are some study limitations associated with the data characteristics and study
design compared to other studies in the literature.
1. The clinical dataset comes from a single endoscopy center in South Carolina.
Therefore, the findings may not generalize to the US or other endoscopy centers.
2. The retrospective study design entails some loss to follow-up because some patients
may have chosen to undergo surveillance colonoscopy at other facilities. It also
precludes understanding the extent to which selection bias affects the composition
of the study cohort.
3. In the case of multiple polyps within one clinical segment sent for pathology
examination in a single jar, the pathology report may not have clearly identified the
number of polyps with different histology features.
4. The clinical dataset does not document information about a family history of CRC
or comorbidities. Those factors are also important because they may contribute to
potential overuse or underuse of surveillance colonoscopy.
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CHAPTER 2
LITERATURE REVIEW
This chapter includes 6 sections on colorectal cancer (CRC), including disease
background, strategies for CRC prevention, surveillance guidelines, and management,
colonoscopy quality indicators, patient characteristics affecting colonoscopy performance,
and prediction of adenoma recurrence. Finally, the current research and gaps in research
will be identified based on literature findings.

2.1 Colorectal cancer (CRC)
This section summarizes the background on CRC, including symptoms and risk
factors, incidence and mortality, prevention methods, recommended prevention
guidelines, utilization of CRC screenings, and barriers to CRC screenings.
2.1.1. Definition of colorectal cancer (CRC)
Colorectal cancer is cancer affecting the colon or rectum, and can be referred to
separately as colon or rectal cancer, depending on where it is located. Most colorectal
cancers develop very slowly over several years. Before cancer develops, the growth of
the tissue or tumor usually begins as a non-cancerous polyp in the inner surface of the
colon and rectum that may change into cancer. Certain kinds of polyps, called
adenomatous polyps or adenomas, occur in 30 to 50 % of adults and can be completely
and safely removed to prevent cancer. Fewer than 10% of adenomas will develop to
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cancer (Levine & Ahnen, 2006). At least 25% of men and 15% of women who undergo a
colonoscopic screening by experienced endoscopists are found to have one or more
adenomas (ACS, 2014; Winawer et al., 2006).
A polyp can be of two types: (1) non-adenomatous lesions (hyperplastic polyps)
and (2) adenomatous lesions (lesions composed of tubular and/or villous structures
showing intraepithelial neoplasia). Adenomas are classified as (1) non-advanced
adenomas (small, tubular adenomas) and (2) advanced adenomas (10mm in diameter or
larger, presence of high-grade dysplasia (including carcinoma-in-situ), or greater than
25% villous or tubulovillous features). CRC is diagnosed when the invasion of malignant
cells through the muscularis mucosa has taken place. Advanced colorectal neoplasia is
defined as lesions that are either benign advanced adenomas or invasive cancer (ACS,
2014; Martinez et al., 2009; Tholoor, Tsagkournis, Basford, & Bhandari, 2013; Winawer
& Zauber, 2002).
2.1.2. Incidence and mortality
CRC is the third leading cancer in both men and women in the United States, an
estimated 132,700 new cases and 49,700 deaths are expected in 2015(ACS, 2015) . In
South Carolina during 2015, an average of 2,130 adults is diagnosed and 840 adults die
from CRC(Siegel, Miller, & Jemal, 2015). Incidence and mortality rates vary by gender,
age, and race/ethnicity. From 2007 to 2011, there has been an annual 4.3% decline in
CRC incidence among adults aged over 50. However, there has been a concurrent 1.8%
annual increase in the below 50-age group, which is expected to amount to a 28-46%
increase in this age group by 2030(ACS, 2015; Bailey et al., 2015). Younger CRC
patients aged < 40 years typically present with more advanced disease, and younger CRC
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patients account for more than one-tenth of CRC cases (11% of colon cancers and 18% of
rectal cancers)(Ahnen et al., 2014; Bailey et al., 2015). However, patients in this age
group account for 6.5% of CRC-related deaths. By gender and race, CRC incidence and
mortality rates among men are 30% and 40% higher than in women, and 25% and 50%
higher among blacks than in whites(Siegel et al., 2014).
2.1.3. Signs and symptoms
Screening is important to prevent the disease and detect CRC early because
adenomas and early stage CRC have no symptoms. There are few than 10% of CRCs
begin as polyps (Levine & Ahnen, 2006). Symptoms may include bleeding from the
rectum, blood in the stool or in the toilet after having a bowel movement, having dark or
black stools, a change in the shape of the stool, cramping pain in the lower stomach, a
feeling of discomfort or urge for bowel movement when there is no need to have one,
recent onset of constipation or diarrhea that lasts for more than a few days, and
unexplained weight loss (ACS, 2015).
2.1.4. Risk factors
A risk factor is defined as anything that affects the chances of developing CRC that
may increase or decrease the likelihood of colorectal polyps or cancer. The risk of CRC
increases with age: about 90% of cases are diagnosed in adults aged 50 or older (Siegel et
al., 2014). Hereditary factors also play a role, including family history of CRC or
adenomatous polyps. About 5% of CRCs are associated with well-defined inherited
syndromes, such as Lynch syndrome and familial adenomatous polyposis (FAP)
(Jasperson, Tuohy, Neklason, & Burt, 2010). These conditions cause cancer typically at a
younger age. About 25% of adults who develop CRC have family members who have
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been affected by the disease without a defined inherited syndrome (Jasperson et al., 2010).
Personal medical factors associated with increased cancer risk include a personal history
of colorectal polyps or CRC, inflammatory bowel disease, or history of other cancers.
Lifestyle-related factors also play an important role such as obesity, physical inactivity,
smoking, dietary factors, and alcohol use(ACS, 2014).

2.2 Colorectal cancer (CRC) prevention and screening
recommendations
This section describes common CRC screening types and recommended guidelines
for different risk groups, the rationale for screening guidelines, screening examinations
that can find colorectal polyps and cancer, screening recommendations, and utilization
and barriers of CRC screening.
2.2.1. Background of CRC screening
Over several decades, CRC screening methods have improved significantly and can
prevent cancer effectively. In the early years, the screening guidelines were reviewed and
approved by the Practice Parameters Committee of the American College of
Gastroenterology (ACG) and by the ACG Board of Trustees. It was also the first
organization to recommend colonoscopy as the preferred screening tool to prevent CRC.
In 2006, the guidelines were revised by a joint committee of the USMSTF and the ACS,
and then again revised in 2008 in partnership with the American College of Radiology
(Rex et al., 2009; Winawer et al., 2006).
The guidelines draw a distinction between screening tests that primarily detect cancer
after it has developed (e.g., stool tests), and those that are more likely to detect both
cancer and precancerous growths. The latter are called structural examinations that
9

visualize the growths. These include the flexible sigmoidoscopy, colonoscopy, CT
colonography, and double-contrast barium enema (Levin et al., 2008). The screening
recommendations emphasize that cancer prevention should be a main goal of screening.
Thus, regular colorectal cancer screening is one of the most powerful weapons for
preventing CRC because it is a process of looking for pre-cancer in adults who have no
symptoms, as well as in adults with symptoms of CRC and other digestive diseases.
Despite many options for CRC screening, the screening rates remained low. There are
65% of US adults had CRC screening, which are lower than the target of 80% by 2018
(CDC, 2013; Meester et al., 2015). Thus, the preferred strategy emphasizing the use of
colonoscopy in CRC screening recommendation has been replaced by the “menu of
options” approach (Rex et al., 2009). The U.S. Preventive Services Task Force (USPSTF)
recommends routine screening from this “menu” including colonoscopy, flexible
sigmoidoscopy, and fecal blood test (FOBT or FIT). It recommends 10-year for
colonoscopy, 5-year for flexible sigmoidoscopy, and 1-year for FOBT or FIT (CDC,
2013; USPSTF, 2008).
2.2.2. Tests that can detect both colorectal polyps and cancer
There colorectal cancer screening can visualize the colon physically to find abnormal
areas. It can be done with an endoscope inserted through the rectum or by special
imaging (x-ray) tests. Polyps found can be removed by endoscopy before they become
cancerous. Therefore, these tests are the preferred tools for polyps and cancer detection.
Table 2.2.1 shows the comparative features and advantages/ disadvantages of the widely
used screening methods.
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(1) Colonoscopy
A colonoscope is similar but more complex than a sigmoidoscope; it is, longer and
can be used to examine the entire length of the colon and rectum than a sigmoidoscope. A
high-quality of bowel preparation by thorough cleaning is required for the physician to
view the colon clearly. It involves taking medication that causes diarrhea, and then to
empty the colon. The medication is taken by mouth, and comes in liquid or tablet form
(ASGE, 2016). Moreover, sedation is usually provided during the examination to
minimize discomfort (Levin et al., 2008). If a polyp is found, it may be removed by
passing a wire loop through the colonoscope either to cut the polyp from the wall of the
colon (via hot or cold biopsy) or destroy it in place using an electric current (ACS, 2011).
This may be done in a hospital outpatient department, clinic, or physician’s office (ACS,
2014).
Since colonoscopy has the advantage of detecting polyps throughout the entire colon
and rectum, it has become the most commonly recommended strategy to prevent the
disease (Rex et al., 2009). Screening colonoscopy can reduce the incidence of CRC by
67-83% and CRC mortality by 65-89% (Kahi, Imperiale, Juliar, & Rex, 2009; S. J.
Winawer et al., 1993; Xirasagar et al., 2015; Zauber et al., 2012) . A reduction in the
incidence of CRC is documented at 76-90%, with 53% reduction in mortality by
colonoscopic polypectomy (Winawer et al., 1993; Zauber et al., 2012).
(2) Flexible sigmoidoscopy
Flexible sigmoidoscopy is used to visualize part of the colon and rectum with a
flexible sigmoidoscope. Using the sigmoidoscope, the doctor can view the inside of the
rectum and the left part of the colon to detect any abnormality and remove polyps.
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Because this scope is only 60 cm long, the doctor can see the entire rectum but less than
half of the colon. Simple bowel preparation is needed before the test and the procedure is
typically performed without sedation. However, this test may be uncomfortable because
of the air injected into the colon. If a pre-cancerous adenoma or colorectal cancer is found,
the patient needs to be referred for a colonoscopy so that the entire colon can be
examined (ACS, 2011, 2014).
This test can detect 17.3% of adenomas, achieves 33-45% CRC prevention and
reduces CRC mortality by 43% (Atkin et al., 2010; Brenner, Chang-Claude, Seiler,
Sturmer, & Hoffmeister, 2007; Holme et al., 2014). Cancer prevention is increased to 5055% when a sigmoidoscopy with abnormal findings is followed by a colonoscopy
(Brenner et al., 2007).
2.2.3. Tests that mainly find colorectal cancer
These types of test examine the stool for secondary signs of cancer such as bleeding
or shedding of cells and are less invasive and easier to conduct. However, positive results
on one of these screening tests will require an invasive test such as a colonoscopy to find
the lesions (Table 2.2.1).
The fecal occult blood test (FOBT) is a widely-used test because it is approximately
equally effective in life-years gained when done regularly annually, comparable to
colonoscopy and sigmoidoscopy. Use of annual high-sensitivity FOBT (sensitivity for
cancer 70%) has a false-positive rate less than 10% (specificity >90%) (USPSTF, 2008;
Zauber et al., 2008). The idea behind this test is that blood vessels at the surface of larger
colorectal polyps or cancers are often fragile and easily damaged by the passage of feces.
The damaged vessels usually release a small amount of blood into the feces, however,
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rarely enough to be visible in the stool. In addition, the FOBT kit can be obtained from a
health care provider for use at home. It is used to find occult blood which cannot be seen
with the naked eye in feces, but which can be detected in the stool through a chemical
reaction. Some foods or drugs may affect the test, so patients require a physician’s advice
on diet and medication before the examination. If the test is positive, a colonoscopy will
be needed to find the reason for the bleeding (ACS, 2014).
An annual FOBT can reduce CRC by 20% by detecting cancer or a polyp early,
resulting in their subsequent removal by colonoscopy(Mandel et al., 2000). In terms of
mortality, it reduces approximately 15% of CRC deaths (Hardcastle et al., 1996;
Scholefield, Moss, Sufi, Mangham, & Hardcastle, 2002). See Table 2.1.
2.2.4. Screening recommendations
The USPSTF and ACG have recommended CRC screening guidelines for different
risk groups. For average-risk individuals, CRC screening should begin at age 50.
Average-risk persons are those without a family history of colorectal neoplasia, except
average risk African Americans (AAs) who should begin screening at age 45 (Rex et al.,
2009; USPSTF, 2008) . However, adults after 75 years of age do not need to take routine
screening because the potential benefits of screening may be outweighed by the harms
and other competing causes of mortality (USPSTF, 2008). Regarding test characteristics,
the different CRC tests have different time intervals for follow-up screenings:
colonoscopy every 10 years, sigmoidoscopy every 5 years, and FOBT (or FIT) every year.
Conversely, high-risk groups should have intensive screening. High-risk groups are
those with a family history of multiple relatives affected by CRC, FAP, and Hereditary
Non-Polyposis Colorectal Cancer (HNPCC). A person with a first-degree relative with
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CRC or advanced adenoma (adenoma ≥1cm in size, or with high-grade dysplasia or
villous elements) diagnosed after 60 years of age should have a colonoscopy every 10
years beginning at age 50 years. For those with relatives diagnosed before 60 years of age
or having multiple first-degree relatives with CRC or advanced adenomas should have a
colonoscopy every 5 years beginning at age 40, or 10 years younger than the age at which
the youngest affected relative was diagnosed (Rex et al., 2009).
2.2.5. Utilization and barriers of CRC screening
The prevalence of CRC screening in the general population has been steadily
increasing since 2000. In the United States, the CRC screening rate increased 15.5%
between 2005 and 2013 (Smith et al., 2015). The percent of the population that is up-todate with CRC screening has also increased from 42.5% in 2000 to 58% in 2010(T. F.
Imperiale et al., 2014; Seeff et al., 2004; J.A. Shapiro et al., 2012; J.A. Shapiro et al.,
2008). Another population-based survey identified 65% of US adults had CRC screening
within the recommended time in 2012 (CDC, 2013).
Despite rising CRC screening rates, screening completion rates are still significantly
lower than the target of 80% by 2018 set by the National Colorectal Cancer Screening
Roundtable (Meester et al., 2015). Well-established barriers to colorectal cancer
screening include lack of health insurance, low education levels, low income, without
routine doctor's visits, and inadequate communication between physicians and patients
(CDC, 2013; Doubeni, Laiyemo, Klabunde, et al., 2010; Doubeni, Laiyemo, Young, et al.,
2010; Ioannou, Chapko, & Dominitz, 2003; Klabunde et al., 2011; Seeff et al., 2004;
Shapiro et al., 2012; Shapiro et al., 2008).
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Table 2.1 Advantages and disadvantages of the widely used screening methods: flexible sigmoidoscopy, colonoscopy, and FOBT
Screening
Advantages
Disadvantages
Screening
Prevention
interval*
rate
Flexible
5 years
33-45%
 Fairly quick
 Views only 1/3 colon
sigmoidoscopy
 Few complications
 Cannot remove large polyps
 Minimal bowel preparation
 Small risk of infection or
bowel tear
 Minimal discomfort
 Colonoscopy necessary if
 Sedation or a specialist needed
positive findings
Colonoscopy
10 years
67%
 Examine entire colon
 May miss some polyps or
cancer
 Can biopsy and remove polyps
 Full bowel preparation needed
 Can diagnose another disease
 Expensive
 Required for positive findings
by all other tests
 Bowel tears or bleeding
 Highly sensitive
 Patient may miss a day of
work
 Less frequent interval
FOBT
1 year
20%
 No bowel preparation
 Multiple stool samples needed
 Sampling is done at home
 Miss most polyps and some
cancers
 Low cost
 Have false-positives results
 Noninvasive
 Colonoscopy necessary if
positive findings
Abbreviations: FOBT, fecal occult blood test.
*
Time intervals for these CRC screenings are for the average-risk population.

2.3 Surveillance management and rationale for the recommendations
This section describes the purpose of surveillance screening, the role of adenomatous
polyps in surveillance management, and some evidence related to the rationale of the
guidelines and predictors for surveillance behaviors.
2.3.1. Purpose of surveillance management
Patients who’ve had a CRC removed are at risk for recurrent cancer and
metachronous neoplasms in the colon, which are the main reasons that surveillance is
needed. However, many patients with low-risk adenomas found at initial colonoscopy
are more likely to have early surveillance colonoscopy (Schoen et al., 2010; Sint Nicolaas
et al., 2013). This places a huge burden on medical resources applied to surveillance. The
efficiency of surveillance colonoscopy can decrease the cost and risk of resources for
unnecessary examinations. Thus, USMSTF and ACS updated joint guidelines on
postpolypectomy and postcolorectal cancer resection surveillance in 2006, trying to shift
some available resources from surveillance purposes to screening (Rex et al., 2006;
Winawer et al., 2006).
There are two fundamental goals of surveillance of patients with cancer or a history
of polyps. One goal is the detection of early recurrences of the initial primary cancer at an
early stage, and another is the detection of metachronous colorectal neoplasms. The most
important purpose is to resect synchronous adenomas missed during the initial
colonoscopy (Bond, 2000; Rex et al., 2006). However, it is not always beneficial to those
patients when they have a colonoscopy annually because of the huge burden on medical
resources (Rex et al., 2006). The cumulative burden of subsequent surveillance
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colonoscopies on the health care system becomes substantial and should be well
established.
2.3.2. Roles of adenomas and serrated lesions
There are two major classes of lesions: polyps and serrated classes of colorectal
adenomas. The best-known class is adenomatous polyps (adenomas). It may be
characterized pathologically as high or low-grade dysplasia, tubular, or villous.
Adenomas with those features are widely understood to be premalignant lesions,
particularly at risk for increasing in size, acquiring high-grade dysplasia features, or
villous elements (Vogelstein et al., 1988). Another class of colorectal lesions is distinct
from adenomas, called serrated lesions. It includes 3 major subtypes termed as (1)
hyperplastic polyp (HP), (2) sessile serrated adenoma/polyp (SSA/SSP), and (3)
traditional serrated adenoma (TSA) (Snover, Ahnen, & Burt, 2010). Only HPs of serrated
classes have the potential for malignancy.
Because all adenomas are dysplastic in contrast to serrated lesions, which are
generally non-dysplastic, adenoma detection rates (ADRs) have become the most
important quality indicators in colonoscopy performance (Hewett, Kahi, & DK., 2010;
Hewett & Rex, 2010; Rex et al., 2015). Adenomatous polyps are the most common
neoplastic findings in adults who have a colorectal screening or diagnosed symptoms, the
characteristics of which can be a marker to determine risk level (Lieberman et al., 2012;
Rex et al., 2006; Winawer et al., 2006). These adults still have a lifelong risk of
subsequent adenomas and colorectal cancers despite adequate polypectomy (Blumberg,
Opelka, Hicks, Timmcke, & Beck, 2000; Marae & Williams, 1982; Waye & Braunfeld,
1982). Surveillance colonoscopy to detect subsequent neoplasms has therefore become
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the standard of care for those patients, particularly for these with advanced adenomas
(Blumberg et al., 2000; Levine & Ahnen, 2006; Lieberman et al., 2007).
The presence of low- or high- risk adenomas determines the recommended
surveillance interval. The presence of an advanced adenoma is adopted as an outcome
measure requiring early surveillance tests because there are more associations with
cancer development. Advanced adenomas can be a surrogate biological indicator of
cancer risk (Winawer et al., 2006; Winawer et al., 1993; Zauber et al., 2012). However,
the true rate of polyp recurrence is unknown since polyps detected during follow-up
examinations may be cumulative (missed at the previous examination), or could be new
polyp growth. The estimated miss rate for HPs is 31% versus 20% for adenomas, while
miss rates for serrated lesions may be higher than for adenomas (Heresbach et al., 2008).
Missed lesions may also have occurred among patients with interval CRCs (86%) (le
Clercq et al., 2014). Despite missed adenomas leading to cancer, adults with serrated
lesions or an advanced adenoma are shown to have a higher risk of neoplasia at follow-up
(Schreiner, Weiss, & Lieberman, 2010). Appropriate follow-up screening thus becomes
imperative.
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2.3.3 .Surveillance methods and recommendation
A colonoscopy is a common tool for surveillance of previously developed polyps
or cancers: about 24% of all colonoscopy patients and 22% of patients aged ≥ 50 years
had a colonoscopy for surveillance purpose (Lieberman, De Garmo, Fleischer, Eisen, &
Helfand, 2000; Lieberman, Holub, Eisen, Kraemer, & Morris, 2005). In the 1970s to
early 1990s, physicians commonly recommended annual follow-up colonoscopies
following all polypectomies despite there were no guidelines providing guidance on this
issue (Rex et al., 2006). In order to reduce resource utilization and improve the efficiency
of examination, the guidelines are continuously updated by new evidence. The results of
the National Polyp Study in 1993 led to the recommendation that the first
postpolypectomy examination should be done 3 years after polypectomy for most
patients with large (>10mm) or multiple adenoma, published by a gastrointestinal
consortium in 1997. In 2003 and 2006 the guidelines were updated, and colonoscopy is
now the only follow-up examination recommended because it is the most effective tool to
prevent disease (Winawer et al., 2003; Winawer et al., 2006). The 2006 guidelines are
shown in Table 2.2.
Since 2006, researchers have focused on the histology and number of polyps
detected, the risk of interval CRC, CRC found in the proximal colon, and the role of
serrated polyps (Lieberman et al., 2012; Winawer et al., 2006). In 2012, the 2006
guidelines were reaffirmed based on stronger evidence and refined features based on risk
stratification principles. Specifically, the researchers updated their recommendations for
follow-up exams following a finding of no polyp, 1-2 small tubular adenomas, 3-10
tubular adenomas, one or more tubular adenomas (≥ 10 mm), or one or more villous
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adenomas at baseline examination (Lieberman et al., 2012). An update of the 2012
USPSTF and ACS surveillance guidelines is currently under progress.
Individuals are recommended a 10-year follow-up colonoscopy if they have small
rectal hyperplastic polyps or hyperplastic polyps without advanced features, considered
normal. A 5 to 10-year follow-up is recommended when they have only 1 or 2 small (<
1cm) tubular adenomas with only low-grade dysplasia. A 3-year follow-up is
recommended when they have 3 to 10 adenomas, any adenoma ≥ 1 cm, any adenoma
with villous features or high-grade dysplasia, any sessile serrated polyp ≥ 1 cm, any size
of the sessile serrated polyp with high-grade dysplasia, or a traditional serrated adenoma
(TSA). The TSA are a type of colorectal polyp with neoplastic potential. It is a rare lesion
located primarily in the left colon and rectum, and the only member of the serrated class
that is uniformly dysplastic (Chetty, Hafezi-Bakhtiari, Serra, Colling, & Wang, 2015). If
the follow-up colonoscopy is normal or shows only 1-2 small tubular adenomas with
low-grade dysplasia, then the interval should be 5 years. The shorter (<3 years) interval is
recommended when they have > 10 adenomas at the screening examination. A 2 to 6month follow-up is recommended if they had sessile adenomas removed piecemeal.
People with serrated polyposis syndrome should have surveillance colonoscopy at a 1year interval. The intensive surveillance is indicated when the family history may
indicate HNPCC, which is recommended every 2 years follow-up beginning at age 20-25
years until age 40 years, and then annually (Lieberman et al., 2012; Winawer et al., 2003;
Winawer et al., 2006). The time intervals of surveillance colonoscopy by index polyp
characteristics are summarized in Table 2.3 and Figure 2.1.
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2.3.4 .Adherence to surveillance screening
The importance of optimal surveillance colonoscopy consistent with
recommendations is to achieve higher ADRs in contrast to over-utilization of procedures
(Sint Nicolaas et al., 2013). Although recent evidence supports that colonoscopic
polypectomy reduces subsequent colorectal cancer incidence, adherence to surveillance
guidelines is variable with reports of overutilization in the low-risk groups and
underutilization in high-risk groups. Over 50% of early surveillance colonoscopies were
conducted for low-risk populations (Mysliwiec, Brown, Klabunde, & Ransohoff, 2004).
Another clinical trial followed participants for 5 years and demonstrated overuse of
surveillance among low-risk adults and underuse among high-risk adults. For example,
approximately 70-80% of low-risk adults underwent surveillance screening at 3-4 years
(Schoen et al., 2010). Medicare beneficiaries who underwent colonoscopy with
polypectomy (<50% received surveillance) also reported underuse of follow-up
colonoscopy at 5 years, but >30% of the follow-up colonoscopies were overused in adults
without any polyp (Cooper, Kou, Barnholtz Sloan, Koroukian, & Schluchter, 2013).
Other studies from other countries reported consistent findings: around 20-30% of
surveillance colonoscopies were consistent with the guidelines (Schreuders et al., 2013;
van Heijningen et al., 2015). However, Menees et al and Kahn et al reported ≥ 75 %
higher adherence to surveillance recommendations (Kahn et al., 2015; Menees, Elliott,
Govani, Anastassiades, & Schoenfeld, 2014).
These findings can provide directions for closer surveillance colonoscopies after
initial examination among high-risk individuals, and longer periods between follow-ups
among low-risk individuals (Ahnen et al., 2014; Morelli et al., 2013). For adults with
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potential missed adenomas found in the proximal colon, more frequent follow-up
examinations may helpful (Nakao, Fassler, Sucandy, Kim, & Zebley, 2013).
2.3.5. Factors are associated with surveillance behaviors
Several demographic characteristics such as race, age, and smoking behavior, are
associated with behaviors using surveillance colonoscopy. Black or other race, older age
groups (65-plus years), and past or current smokers were less likely to have repeat
examinations (Rolnick et al., 2005; Weissfeld et al., 2002). Of patients with screening
colonoscopy who had Medicare coverage, about 42.5% had early repeat examinations.
Black adults who had their procedures performed by surgeons or experienced
colonoscopists also underwent early examinations (Goodwin, Singh, Reddy, Riall, & Kuo,
2011). However, Kahn et al reported different findings: patients aged >65 years or with
incomplete polyp resection had higher guideline-concordant surveillance(Kahn et al.,
2015). A possible explanation for this behavior is a lack of knowledge of guidelines by
providers: around 76% of physicians are documented to disagree or ignore guidelines
(Kruse, Khan, Zaslavsky, Ayanian, & Sequist, 2015; S. D. Saini, Nayak, Kuhn, &
Schoenfeld, 2009).
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Table 2.2 2006 U.S. Multi-Society Task Force guidelines for surveillance colonoscopy*
Colorectal neoplasm characteristics and surveillance recommendations
Patients with small rectal hyperplastic polyps should be considered to have normal
colonoscopies, and therefore the interval before the subsequent colonoscopy should be 10
years; an exception is patients with a hyperplastic polyposis syndrome**; they are at
increased risk for adenomas and colorectal cancer and need to be identified for more
intensive follow-up evaluation
Patients with only 1 or 2 small (<1 cm) tubular adenomas with only low-grade dysplasia
should have their next follow-up colonoscopy in 5–10 years; the precise timing within
this interval should be based on other clinical factors (such as prior colonoscopy findings,
family history, and the preferences of the patient and judgment of the physician)
Patients with 3 to 10 adenomas, or any adenoma <1 cm, or any adenoma with villous
features, or high-grade dysplasia should have their next follow-up colonoscopy in 3 years
providing that piecemeal removal has not been performed and the adenoma(s) are
removed completely; if the follow-up colonoscopy is normal or shows only 1 or 2 small
tubular adenomas with low-grade dysplasia, then the interval for the subsequent
examination should be 5 years
Patients who have more than 10 adenomas at 1 examination should be examined at a
shorter (<3 y) interval, established by clinical judgment, and the clinician should consider
the possibility of an underlying familial syndrome
Patients with sessile adenomas that are removed piecemeal should be considered for
follow-up evaluation at short intervals (2–6 mo) to verify complete removal; once
complete removal has been established, subsequent surveillance needs to be
individualized based on the endoscopist’s judgment; completeness of removal should be
based on both endoscopic and pathologic assessments
More intensive surveillance is indicated when the family history may indicate HNPCC
*
Reference: Winawer et al (2006). Guidelines for colonoscopy surveillance after
polypectomy: a consensus update by the U.S. Multi-Society Task Force on Colorectal
Cancer and the American Cancer Society. CA Cancer J Clin. 2006;56(3):143-59.
**
Hyperplastic polyposis was defined by Burt and Jass for the World Health Organization
International Classification of Tumors as: (1) at least 5 histologically diagnosed
hyperplastic polyps proximal to the sigmoid colon, of which 2 are greater than 1cm in
diameter, or (2) any number of hyperplastic polyps occurring proximal to the sigmoid
colon in an individual who has a first-degree relative with hyperplastic polyposis, or (3)
more than 30 hyperplastic polyps of any size distributed throughout the colon. Studies
have found an increased risk for colorectal cancer in these patients (Burt & Jass, 2000).
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Table 2.3 Up-to-date guidelines for surveillance colonoscopy, 2012 guidelines
Colorectal neoplasm characteristics
Time interval (years)
Hyperplastic polyps (no adenomas)
10
Small (< 10 mm) rectal or sigmoid hyperplastic polyps
1 or 2 tubular adenomas ( < 1 cm)
5-10
Small SSP (<10 mm) without dysplasia
5
≥3 adenomas
3
Any adenoma ≥10 mm
Any adenoma with villous features
High-grade dysplasia
SSP≥10 mm
SSP with dysplasia
TSA
>10 adenomas
<3
*
Serrated polyposis syndrome
1
Abbreviations: SSP, Sessile serrated polyp; TSA, Traditional serrated adenoma.
*
Based on the World Health Organization definition of serrated polyposis syndrome, with
one of criteria: (1) at least 5 serrated polyps proximal to sigmoid, with 2 or more ≥ 10
mm; (2) any serrated polyp proximal to sigmoid with family history of serrated polyposis
syndrome; and (3) >20 serrated polyps of any size throughout the colon.
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Figure 2.1 Time intervals to surveillance colonoscopy by polyp status at index colonoscopy. *High-risk findings are defined
as ≥3 adenomas, any adenoma ≥10 mm, any adenoma with villous features, high-grade dysplasia, SSP≥10 mm, SSP with
dysplasia, or TSA. Low-risk findings are defined as hyperplastic polyps, small (< 10 mm) rectal or sigmoid hyperplastic
polyps, and small SSP (<10 mm) without dysplasia. Abbreviations: SSP, Sessile serrated polyp; TSA, Traditional serrated
adenoma.

2.4 Quality indicators of colonoscopy and patient characteristics
associated with colonoscopy findings
This section describes evaluation methods for improving the quality of colonoscopies.
Many indicators are documented to measure the CRC screening performance, including
interval CRC rates, serrated polyp detection rates, adenomatous polyps (adenoma
detection rates), procedure indicators, endoscopist factors, and patient characteristics.
2.4.1. Quality of colonoscopy
Colonoscopy is the most effective screening tool to prevent CRC because it allows
colonoscopic removal of polyps (Rex et al., 2009). However, the effectiveness of
surveillance colonoscopy intervals assumes that high-quality examination was performed
at screening and later colonoscopy. Failure of colonoscopy to consistently detect existing
adenomas or other precursors of CRC is threatening the effectiveness of colonoscopy for
the prevention of CRC. Good quality of colonoscopy with near-complete can prevent >
80% of early and advanced CRCs for detection of early CRCs (Xirasagar et al., 2015).
The American Society for Gastrointestinal Endoscopy (ASGE) and American College
of Gastroenterology (ACG) published measures for reporting endoscopic performance in
2006 (Rex et al., 2009), including pre-procedure, intra-procedure, and post-procedure
measures. Pre-procedure represents nontechnical aspects of colonoscopy, such as the use
of recommended surveillance intervals. Intra-procedure focuses on technical aspects of
colonoscopy, such as bowel preparation, cecal intubation rate, adenoma detection and
histology, and the provider’s experience (Lee, Levin, & Corley, 2013). Colonoscopic
complications post-procedure are also measured for quality purposes (Hewett et al., 2010;
Hewett & Rex, 2010).
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Overall, the adenoma detection rate (ADR) is always the priority indicator to
measure colonoscopy performance. Consideration of other indicators together is needed
for detecting subsequent adenomas because each indicator may be associated with others.
Although patient characteristics do not directly affect the quality of performance, it may
be necessary to adjust for them to account for patient mix complexity.
2.4.2. Interval CRC
Interval CRC is defined as CRC diagnosed in the time interval between an initial
and surveillance colonoscopy (Fayad & Kahi, 2014). After the first colonoscopy, patients
with adenomas receive follow-ups with surveillance guidelines to identify and remove
subsequent adenomas before they develop into cancer. However, colonoscopy is not
always perfect, and thus interval cancers might be diagnosed between surveillance
colonoscopies (Leung et al., 2010). Approximately 54- 79% of CRC patients had
potential CRC at the screening or surveillance colonoscopy. The reason might relate to
incomplete removal or missed cancer at prior examinations (Pabby et al., 2005;
Robertson et al., 2005). About 78% of person with a history of an advanced adenoma
also had a higher risk of developing cancer (Leung et al., 2010). Therefore, interval
check-ups may potentially prevent cancer by improving the baseline quality of
colonoscopy and can be considered a “silver standard” for performance measurement
(Fayad & Kahi, 2014).
2.4.3. Serrated polyps
Non-neoplastic polyps have no malignant potential, including hyperplastic polyps
(HPs) and inflammatory polyps. However, recent studies identified serrated polyps which
are characterized by a saw-toothed (serrated) appearance of the crypt epithelium and may
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have malignant potential. By histologic features, it can be classified as HPs, traditional
serrated adenomas (TSAs), or sessile serrated adenomas (SSAs). These polyps are
difficult to detect at endoscopy because they show the same color as the surrounding
colonic mucosa may not be elevated and also may have a layer of adherent mucus which
obscures the vascular pattern. It may need to be resected by colonoscopy several times
(Bond, 2000; Kahi, 2015; Rex et al., 2012). Patients with serrated polyps had a 30%
higher risk of developing CRC (Boparai et al., 2011; Chow et al., 2006). Particularly, the
large serrated polyps (≥ 10 mm) are associated with advanced neoplasia with an
estimated a 3-fold risk to be diagnosed with cancer (relative to patients without large
serrated polyps) (Hiraoka et al., 2010; Holme et al., 2014).
2.4.4. Adenomatous polyps (adenomas)
Those polyps are classified as neoplastic with malignant potential. Most colorectal
cancers arise from neoplastic adenomatous polyps (adenomas). The adenoma detection
rate (ADR) is the main indicator to measure the effectiveness of screening and
surveillance colonoscopies as mentioned previously. ADR is defined as the proportion of
screening colonoscopies with at least one adenoma found, and is the prime metric for
quality measurement (Fayad & Kahi, 2014). Patient status at initial examination predicts
adenoma recurrence, particularly advanced adenomas influence. Adenoma features are
also used to stratify the risk. Risk features are multiple adenomas, large adenoma (≥ 1cm),
adenoma in the proximal colon, high-grade dysplasia, tubulovillous adenomas, and
villous adenomas. The literature on advanced adenoma and any adenoma findings at
surveillance examinations as related to baseline findings are summarized in Table 2.4 and
Table 2.5, respectively.
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(1) Number of adenomas
Adults with multiple adenomas had a higher risk of developing advanced adenomas,
accounting for 2-4 fold higher risk among adults with at least 2 adenomas (compared to
no adenoma). The risk of advanced adenomas found increased with increasing adenoma
numbers (Bertario et al., 2003; Fairley et al., 2014; Martinez et al., 2009; van Heijningen
et al., 2013). A meta-analysis identified adults with ≥ 3 adenomas as more likely to have
advanced adenomas at follow-up examinations (RR: 2.52; 95% CI: 1.07-5.97) (Saini,
Kim, & Schoenfeld, 2006). Chinese and Korean studies reported an adjusted hazard ratio
(HR) of 2-3 with statistical significance among such adults (Chung et al., 2011; Huang et
al., 2010).
Adenoma (any type) recurrence was reported among adults with ≥ 3 adenomas at
baseline, an adjusted OR of 1.4 -2.4 showing statistical significance (Miller, Mukherjee,
Tian, & Nagar, 2010; van Stolk, Beck, Baron, Haile, & Summers, 1998; S. J. Winawer et
al., 1993), as also reported by Korea and Japan studies (Ji et al., 2009; Taniguchi et al.,
2014).
(2) Size of adenoma
Adults with large adenoma (≥1 cm) were more likely to develop advanced adenomas
at their next examination, with 2-4 fold higher risk of advanced adenoma recurrence
(Bertario et al., 2003; Fairley et al., 2014; Laiyemo et al., 2008; Laiyemo et al., 2009;
Martínez et al., 2001; Noshirwani, van Stolk, Rybicki, & Beck, 2000; Taniguchi et al.,
2014). A meta-analysis identified a pooled relative risk (RR) of 1.39 with statistical
significance (Saini et al., 2006). A study from Korea reported similar findings, a 3-fold
risk of advanced adenoma outcomes among this population (Chung et al., 2011).
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Having a large adenoma at initial examination was also associated with any adenoma
recurrence. About 60% of adults with any adenoma >1 cm had developed an adenoma at
follow-up (Winawer et al., 1993).
(3) Location of adenoma
Advanced adenoma at follow-up was more likely to happen with adenomas in the
proximal colon at initial examination. About 58-65% of adults with proximal adenomas
had a higher risk of having an advanced adenoma at follow-up examination (Laiyemo et
al., 2008; Martinez et al., 2009; Martínez et al., 2001; van Heijningen et al., 2013).
Overall, those with adenomas in the proximal colon had higher risks of developing any
adenoma at surveillance, with 12.4-fold higher risk than those with adenomas in the distal
colon (Miller et al., 2010). These findings were echoed by a Japanese study (Taniguchi et
al., 2014).
(4) Histology of adenoma
Histology is a particularly difficult predictor to evaluate because of different
growth patterns of cancer cells and should be identified by the pathologist. Adenomas are
classified as tubular (TA), tubulovillous (TVA), and villous adenomas, with about 4.8%,
19%, and 38.4, respectively, showing malignant transformation (Bond, 2000; O'Brien et
al., 1990). Patients with TVA or villous adenomas were more likely to develop advanced
adenomas at surveillance examination, an adjusted RR of 1.26 - 2.43 (Laiyemo et al.,
2008; Saini et al., 2006). Lieberman et al reported much higher risks among adults with
villous adenomas (RR=6.05), compared to no adenomas neoplasia (Lieberman et al.,
2007), and others reported 1.3-1.8 higher risk with TVA or villous adenomas at baseline
(Bertario et al., 2003; Martinez et al., 2009). Similarly, a Chinese study reported an
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adjusted HR of 2.57 (Huang et al., 2010). The risk of any adenoma recurrence was 2-fold
among those with TVA compared to TA in another study (OR: 2.12; 95% CI: 1.12-4.02)
(van Stolk et al., 1998).
Another pre-cancerous status is dysplasia in the colon or rectum mucosa with cells
showing abnormal features. By definition, all adenomas have some levels of dysplasia
(ACS, 2014; S. Winawer et al., 2003). Patients with high-grade dysplasia (HGD) were
significantly more likely to develop advanced adenomas at surveillance, with an adjusted
RR of 2-fold (Laiyemo et al., 2008; Saini et al., 2006). Martinez et al pooled data from 8
prospective studies and reported 5% developing advanced lesions (Martinez et al., 2009),
similar to Huang et al 2010. Another study reported much higher risk among those adults
with HGD in a randomized controlled trial, with 6.89 relative risks of advanced
adenomas, compared to adults without any neoplasia at baseline. The key difference is
that this study used “no neoplasia” as the reference group, in contrast to other studies
(Lieberman et al., 2007).
Overall, advanced adenoma at baseline examination is associated with a standardized
incidence rate (SIR) of 2.23 (95%CI: 1.67-2.92) for subsequent advanced lesions and
higher hazard ratio (HR: 5.95; 95%CI: 3.66-9.68) (Chung et al., 2011; Cottet et al., 2012).
2.4.4. Procedure factors
Recently, the role of quality of initial colonoscopy in procedure-related factors has
been studied. These features include bowel preparation status at initial colonoscopy and
cecal intubation status.
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(1) Bowel preparation status
Bowel preparation is a process before colonoscopy to obtain a clean bowel, allowing
for examination of the whole mucosal surface. Inadequate cleansing can result in missed
lesions and increased risk for subsequent adenomas. Thus, there is a strong relationship
between detection of any significant lesions and bowel preparation quality (Froehlich,
Wietlisbach, Gonvers, Burnand, & Vader, 2005; Harewood, Sharma, & de Garmo, 2003;
Parra-Blanco et al., 2006).
Preparation adequacy can increase the detection of the colonic lesion by 21% (OR:
1.21; 95%CI: 1.16-1.25) (Harewood et al., 2003). Froehlich et al reported lesion detection
rates by the quality of preparation. About 47% and 81% were patients with high-quality
preparation and intermediate-quality cleansing had detectable lesions than those with
poor cleansing (Froehlich et al., 2005). A recent community-based study also reported
that good bowel preparation was associated with adenoma detection (30%), compared to
insufficient cleaning (OR: 3.4; 95%CI: 1.6-7.4) (van Heijningen et al., 2013).
(2) Cecal intubation status
Cecal intubation is defined to be achieved if the tip of the colonoscope is advanced to
a point proximal to the ileocecal valve so that the entire cecum is visualized. Incomplete
cecal intubation status may result in missed adenomas or cancer. It is an important quality
metric and relatively easy to measure, and can be a marker of a complete colonoscopy
(Fayad & Kahi, 2014; Rex et al., 2015). Skilled colonoscopists should be able to apply
techniques to overcome the difficulties in most instances and reach the cecum in ≥ 90%
of all cases, and ≥ 95% of screening colonoscopies in healthy adults (Rex et al., 2015).
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Reaching the cecum is lower for providers with low procedure volumes. Volumes of
less than 500 in the previous year were associated with suboptimal rates of cecal
intubation (OR range, 0.68-0.82) (Radaelli, Meucci, Sgroi, Minoli, & Italian Association
of Hospital, 2008). It is also reported for procedures performed by nongastroenterologists, about 60-70% of patients whose procedures performed by surgeons
and internists did not achieve intubation (OR, 0.3 and 0.4, respectively) (de Jonge et al.,
2012). Although cecal intubation is an important indicator of a complete colonoscopy, it
is a process indicator of quality performance but not suggest determining high-quality
colonoscopy.
2.4.5. Endoscopist factors
Recently, there is increased awareness that the success of colonoscopy in preventing
CRC is dependent on the skill and competence of the endoscopists to detect adenoma,
currently a surrogate marker for quality (Lee et al., 2013). Studies from the US reported
their endoscopists’ procedure volumes are associated with polyp detection and removal.
About 10% of providers with the middle 50% of annual procedure volume were more
likely to detect and remove polyps (Ko, Dominitz, Green, Kreuter, & Baldwin, 2010).
Physicians performing > 100 colonoscopies per year also had a higher polyp detection
rate (OR: 1.22; 95%CI: 1.04-1.43) in the UK (Bhangu et al., 2012).
Another driver of polyp detection and removal is the involvement of non-specialist
endoscopists. The approximate rate of polyp detection and removal ranged from 7-25%
when procedures are performed by non-gastroenterologists (Ko et al., 2010), rates that
are validated by studies from other countries. A Canadian study reported that only 2752% of polypectomies were complete when performed by surgeons in Canada (OR: 0.48,
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0.73) (Jiang, Sewitch, Barkun, Joseph, & Hilsden, 2013). Higher polyp detection rates
were reported for procedures by surgeons (OR: 1.15; 95%CI: 1.05-1.27) in the UK
compared to non-gastroenterologists (Bhangu et al., 2012). Procedure performance by
different specialty endoscopists is also associated with CRC detection. This is a 2-3-fold
risk of missing polyps when procedures are performed by internists, general practitioners,
or family physicians (Singh, Nugent, Mahmud, Demers, & Bernstein, 2010), and
approximately 30-90% of missed CRC cases when performed by non-gastroenterologists
(Baxter et al., 2011; Rabeneck, Paszat, & Saskin, 2010).
These studies confirm differences between specialists in polyp detection rates and
removal, and therefore, the effectiveness to prevent early CRC. This may be due to
differences in training because gastroenterologists generally receive the most intensive
training in colonoscopy of all specialists. However, training in colonoscopy for primary
care specialties is not required (American Association for the Study of Liver, American
College of, American Gastroenterological Association, & American Society for
Gastrointestinal, 2007)(Table 2.6).
Although colonoscopy screening performed by gastroenterologists shows higher
adenoma detection rates, questions arise about whether crescent workloads are too high
and may cause long waiting times for patients, particularly due to increasing caseloads
for surveillance colonoscopy. Recent literature suggests shifting the workload to
practitioners others than gastroenterologists, or involving assistants in procedures to
increase the effectiveness of colonoscopy. Involving assistants may increase ADRs,
accounting for 25-63% higher detection rates than without an assistant (23-59%),
especially for small polyps (Table 2.7) (Aslanian et al., 2013; Chalifoux et al., 2014;
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Dellon, Lippmann, Sandler, & Shaheen, 2008; Peters, Hasan, Jacobson, & Austin, 2010;
Rogart, Siddiqui, Jamidar, & Aslanian, 2008; Xirasagar, Hurley, Sros, & Hebert, 2010).
Other innovative approaches are also documented such as involving primary care
physicians (PCPs), polyps search and removal during both scope insertion and
withdrawal, and ensuring rescue assistance by experts if there is a difficulty during the
procedure (Xirasagar et al., 2010).
In order to improve access to CRC prevention, shifting workloads to PCPs may be
helpful because they are shown to perform consistent quality of CRC screening when
they have the same training, about ≥25% ADR (46% among males and 30% among
females) (Kolber, Wong, Fedorak, Rowe, & on behalf of the, 2013; Wilkins et al., 2009).
Those findings are consistent with the USMSTF benchmark target average-risk
individuals, an ADR of ≥25%, ≥30% among average-risk males and ≥20% among
females (Rex et al., 2015).
2.4.6. Patient characteristics
Patient characteristics are required control variables for predicting subsequent
adenomas at surveillance examinations, especially gender and age. However, most
studies do not take into account patient characteristics. A few studies have reported race
and education to be associated with adenoma detection and features at CRC screenings.
The related studies and findings are presented in Table 2.8.
(1) Gender
Studies have reported a relationship between gender and adenoma detection. Males
have a higher risk of advanced and non-advanced adenomas. The risk was nearly 2-fold
with adenomas (HR, 1.6-1.9) (Bertario et al., 2003; Imperiale et al., 2008; Leffler et al.,
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2012). Males were 6.5 times more likely to develop advanced metachronous adenomas at
surveillance colonoscopy (Bertario et al., 2003). A Japanese study also identified an
association of neoplasias with male gender (HR, 1.8; 95% CI: 1.6-2.0) (Yamaji et al.,
2004). Males were more likely to have adenomas (OR, 1.44-1.59) (Thornton, Morris,
Thornton, Flowers, & McCashland, 2007). However, males were less likely to have
adenomas in the proximal colon (OR, 0.88; 95%CI: 0.79-0.98) (Lieberman et al., 2008).
(2) Age
Some studies reported a relationship between age and adenoma detection,
particularly older age. Advanced and non-advanced adenoma detection rates increase
with age (Leffler et al., 2012; D. A. Lieberman et al., 2008; Thornton et al., 2007; Yamaji
et al., 2004). Adults aged > 60 years were evaluated as a risk factor of finding an
adenoma on surveillance examination (Jorgensen, Kronborg, & Fenger, 1995; Taniguchi
et al., 2014; S. J. Winawer et al., 1993). Much older adults (aged >70) were about 4.1
times more likely to have advanced metachronous adenomas at surveillance colonoscopy
(Bertario et al., 2003) even if patients had begun screenings at the age of 40 years.
(3) Other patient factors
Few studies here examined the impact of race, education, and insurance in adenoma
findings. Thornton et al reported that blacks were less likely to have any polyp at
screening colonoscopy (OR, 0.77; 95% CI: 0.70-0.84). However, they were more likely
to have tumors (OR, 1.78; 95%CI: 1.14-2.77) compared to whites (Thornton et al., 2007).
Combining of those factors, about 62% and 16% of black females and males had a higher
risk of large polyps than white females and males (Lieberman et al., 2008). Education is
also associated with adenoma findings in that there was an increased risk for blacks with
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a postgraduate education compared to whites with the same degree (RR, 1.29; 95%CI:
1.09-1.54) (Laiyemo et al., 2010). Although blacks had a higher prevalence of advanced
adenoma at initial examination, the risk of any adenoma recurrence was not different
from whites (Laiyemo et al., 2013).
2.4.7. Summary of literature findings
The totality of evidence suggests that adenomas with HGD, TVA/ villous adenomas,
multiple adenomas, large adenoma, adenomas in the proximal colon, or serrated polyps
are predictors of future advanced adenomas, non-advanced adenomas, or interval cancers.
Particularly adenomas combining different features, such as having multiple adenomas
with at least one of a large size, were more likely to develop advanced neoplasia
(Vemulapalli & Rex, 2014). Although initial adenoma features can predict subsequent
adenomas by multivariate analysis, there was a paucity of studies accounting for
endoscopist-related or patient- related factors which might help to target patients before
regarding the timing of surveillance colonoscopy.
Each indicator of colonoscopy quality has different roles: (1) quality of colon
preparation and cecal intubation status are basic quality indicators for colonoscopy, and
(2) adenoma detection rate (ADR) is a key index. The ADR may be associated with
endoscopist skill and patient demographic characteristics (e.g., genetic factors,
environmental factors, diet, cultures, etc.) (Hewett et al., 2010; Hewett & Rex, 2010; Lee
et al., 2013; Vemulapalli & Rex, 2014).
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Table 2.4 Risk of advanced neoplasia at surveillance among adults by adenoma characteristics at initial screening
Primary author
Location
Study design
N
Time interval
Adenoma characteristics
(year)
(years)
Noshirwani
US
Retrospective cohort
697
<3
Per 1 adenoma increased*: OR ,1.25/1.45
(2000)
study
≥ 1cm adenoma* (vs. < 1 cm): OR, 3.68/4.08
Martinez
US
Randomized
1,287
3
>1cm adenoma (vs. <0.5cm): OR, 2.27
(2001)
controlled test
Proximal (vs. distal): OR, 1.65
(RCT)
Bertario
Milan
Prospective study
1,086
5(Mean)
≥ 2 adenomas (vs. 1 adenoma): OR, 1.6
(2003)
>2cm adenoma (vs. ≤ 1cm): OR,1.5
TVA/ villous (vs. TA) : OR,1.3/1.8
Saini
US
Meta-analysis
5 studies
3
≥3 adenomas (vs. 1-2 adenomas) : RR, 2.52
(2006)
HGD (vs. LGD) : RR, 1.84
≥ 1cm adenoma(vs. < 1cm) : RR, 1.39
Villous (vs. no villous): RR, 1.26
Lieberman
US
RCT
3,121
5.5
TA < 10mm (vs. no neoplasia) : RR, 2.56
(2007)
Villous (vs. no neoplasia) :RR, 6.05
HGD (vs. no neoplasia) : RR, 6.87
Laiyemo
US
RCT
1,905
5
HRA (vs. LRA) ** : RR, 1.68
(2008)
Advanced adenoma (vs. non-advanced) :
RR,1.94
Villous (vs. non-villous): RR, 2.43
≥ 1cm adenoma (vs. < 1cm): RR,1.57
HGD (vs. LGD) : RR, 1.73
Proximal (vs. distal): RR,1.58
Martinez
US
Prospective study
8 studies
4(Median)
HGD (vs. LGD) : OR, 1.05
(2009)
≥2 adenomas (vs. 1 adenoma) # : OR, 1.39-3.87
Proximal (vs. distal) : OR, 1.68
TVA/villous (vs. TA) : OR, 1.28
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Table 2.4 Risk of advanced neoplasia at surveillance among adults by adenoma characteristics at initial screening (continued)
Primary author
Location
Study design
N
Time interval
Adenoma characteristics
(year)
(years)
Huang
China
Retrospective study
1,356
20
TVA /villous (vs. TA) : HR, 2.57
(2010)
HGD (vs. LGD) : HR, 1.61
≥3 adenomas (vs. 1 adenoma) : HR, 1.87
Cottet
France
Retrospective cohort
5,779
7.7
Advanced adenoma: SIR, 2.23
(2011)
study
Chung
Korea
Prospective study
2,452
5
HRA (vs. LRA) ** : HR, 5.95
(2011)
≥3 adenomas (vs. 1-2 adenomas) : HR, 3.06
≥ 10mm adenoma (vs. < 10mm): HR, 3.02
Fairley
US
Retrospective study
25,635
10
≥3 adenomas (vs. 1-2 adenomas) : OR, 2.4
(2014)
≥ 10mm adenoma (vs. < 10mm): OR, 3.6
HGD (vs. no HGD) : OR, 4.3
Villous (vs. no villous): OR, 3.7
Vemulapalli
UK
Retrospective study
1,414
Over 10
≥3 adenomas with 1 ≥ 10mm(vs. 1-2
(2014)
adenomas <10 mm) : OR, 5.6-10.8
≥5 adenomas with all < 10mm(vs. 1-2
adenomas <10 mm) : OR, 3.1
≥2 adenomas (vs. 1 adenoma) : OR, 1.6-3.3
≥ 10mm adenoma (vs. < 10mm): OR, 1.7
Villous (vs. no villous): OR, 2.0
Proximal (vs. not proximal): OR,1.6
Abbreviations: HGD, high-grade dysplasia; LGD, low-grade dysplasia; TA, tubular adenoma; TVA, tubulovillous adenoma.
*
Outcome variable, advanced neoplasia includes tubulovillous adenoma, villous adenoma, high-grade dysplasia, carcinoma in situ,
invasive cancer or size of 1cm or greater / 4 or more adenomas.**HRA, 3 or more adenomas or any advanced adenoma; LRA, 1 or 2
non-advanced adenomas.#Risk increased by per 1 adenoma increased.
Van Heijning
(2013)

Dutch

Retrospective study

2,990

6
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Table 2.5 Recurrence of any adenoma at surveillance among adults by adenoma characteristics at initial screening
Primary author
Location
Study design
N
Time interval
Adenoma characteristics
(year)
(years)
Winawer
US
RCT
1,418
3
≥3 adenomas (vs. 1 adenoma):OR,2.4
(1993)
>1cm adenoma(vs. ≤ 0.5 cm) : OR, 1.6
Van Stolk
US
RCT
479
4
≥3 adenomas (vs. 1, 2 adenomas): OR, 2.25
(1998)
TVA (vs. TA) : OR, 2.12
Ji
Korea
Prospective study
667
3(Mean)
≥3 adenomas (vs. 1 adenoma): HR, 3.19
(2009)
Miller
US
Retrospective study
399
5 /6-10
≥3 adenomas (vs. 1 adenoma) : OR, 1.4
(2010)
Proximal (vs. distal) : OR, 12.4
Taniguchi
Japan
Retrospective study
1,111
1/2
HGD :OR, 2.40
(2014) *
Right-side colon :OR, 1.43
≥ 10mm adenoma :OR, 2.89
≥3 adenomas: OR,6.12
Abbreviations: HGD, high-grade dysplasia; LGD, low-grade dysplasia; TA, tubular adenoma; TVA, tubulovillous adenoma.
*
Used scoring system to calculate the recurrence rate of colorectal adenoma and followed by 1 and 2 years.

Table 2.6 Physician characteristics associated with quality of screening and surveillance examination
Primary author
Location
N
Measures of
Procedure volume of
(year)
quality
physician
*
Radaelli (2008)
Italy
12,835 Cecum intubation 300-500 (vs. >500): OR, 0.82
rate
< 300 (vs. >500): OR, 0.68
Canada

45,985

CRC rate

-

Rabeneck (2010) *

Canada

110,402

CRC rate

-

Ko
(2010)1

US

328,167

PDR/ removal

Baxter
(2011) *
Bhangu
(2012)

Canada

14,064

CRC rate

UK

10,026

1.ADR
2. PDR

de Jonge (2012) *

Netherlands

4,738

1.Cecum
intubation rate
2.ADR

-

Jiang(2013) *

Canada

2,651

Polypectomy

-
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Singh
(2010) *

Middle annual colonoscopy
volumes (vs. low volumes)
#
:RR,1.1

>100 colonoscopy per year
(vs. no): OR, 1.22

Specialty of endoscopist
-

Rural surgeons (HR,3.38),
Urban surgeons (HR,1.78),
Internists (HR,2.25),
Family practices (HR,3.01)
General surgery (HR, 1.4),
Other2 (HR,1.3)
General surgery (RR,0.8),
Colorectal surgery(RR,0.91),
Family medicine(RR,0.86),
Internal medicine (RR,0.93)
Others** (HR, 1.7-1.9)
Surgeons (vs. physicians) : OR,
1.15
1.Surgeons (OR,0.3),
Internists (OR,0.4)
2.Surgeons (OR,0.2),
Internists (OR,0.71)
Surgeons (OR,0.48, 0.73)

Abbreviations: PDR, polyp detection rate; ADR, adenoma detection rate.
*
Reference group for comparing types of endoscopy is gastroenterologists.
**
Others include internists, general practitioners, and family physicians.
#
Annual colonoscopy volumes by quartile; middle volumes are 50 % of claims and low volumes are 25 % of claims.

Table 2.7 Gastroenterology fellow/assistant involvement in colonoscopy vs. adenoma detection rates (ADRs)
Primary author (year)
Type of assistant
N (ADRs, %)
Without assistant
With assistant
Dellon (2008)
GI endoscopy nurses
3,631 (24.8%)
Rogart (2008)
GI fellows
126 (23%)
183 (37%)
Peter (2010)
GI fellows
2,895 (27.7%)
699 (34.3%)
Xirasagar (2010)
PCPs
10,958 (29.9%)
Aslanian (2013)
Nurses
256 (58.6%)
336 (57.5%)
Chalifoux (2014)
GI trainees
339 (51%)
617 (63%)
Abbreviations: N, the number of colonoscopies; ADRs, adenoma detection rates; GI, Gastroenterology; PCPs, primary care physicians.
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Table 2.8 Patient characteristics associated with adenoma findings at screening or surveillance examination
Primary author Location
N
Measures
Patient characteristics
(year)
Winawer(1993)
US
1,418
Adenoma
Aged ≥ 60(OR, 1.4)
Jorgensen(1995)
Denmark 673
Adenoma
Aged > 60(HR, 1.3)
Bertario(2003)
Milan
1,086
1.Metachronous adenoma
1. Male(HR,1.6)
2.Advanced metachronous
2. Male(HR,6.5);
*
adenoma
Aged >70 (vs. <60):HR,4.1
Yamaji(2003)
Japan
6,225
1.All neoplasias
1. Aged ≥ 40 (HR, 1.5-2.2);Male (HR,1.8)
2.Advanced neoplasias
2. Aged ≥ 50 (HR, 3.6-5.5)
Thornton(2007)
US
46,726
1.Polyp
1. AA (OR,0.77); Age(OR,1.05); Male (OR, 1.59)
2.Tumor
2. AA (OR,1.78); Male (OR,1.44)
Lieberman(2008)
US
85,525
1.Large polyp
1. Aged ≥ 50 (vs.<50): OR, 1.23-1.81;
2.Proximal large polyp
Black female (vs. White female): OR, 1.62;
Black male (vs. White male): OR, 1.16
2. Male (OR,0.88);
Aged ≥ 60 (vs.<50): OR, 1.23-1.81
Imperiale(2008)
US
2,983
Adenoma
Male (HR, 1.92)
Laiyemo(2010)
US
60,572
Adenoma
Black, postgraduate (vs. whites, postgraduate ): RR, 1.29
Leffler(2012)
US
2,139
1.Adenoma
1. Female (OR, 0.77);
2.Advanced adenoma
Increase patient age per year (OR, 1.04)
2. Increase patient age per year (OR, 1.03)
Tanignchi (2014)
Japan
43,195
Adenoma
Age≥ 65(OR, 1.38)
*
Advanced metachronous adenoma is defined as CRC or severe dysplasia.

2.5 Prediction of subsequent adenomas by baseline adenoma status
This section reviews the literature on the timing of surveillance CRC screening, and
adenoma findings at baseline examination that predict surveillance findings. Using
previous screening information to predict the probability of high-risk findings on later
examinations can help to optimize the finding of surveillance appropriately (Loberg et al.,
2014). Adenoma features are classified into high-risk, low-risk, and average-risk groups.
The main concerns are whether any advanced adenoma predicts advanced adenoma
findings at surveillance. However, negative findings at initial colonoscopy do not
guarantee that patients will not develop adenomas at surveillance.
2.5.1. Findings of serrated polyp at the surveillance colonoscopy based on present at
baseline examination
Having serrated polyps is a rare colorectal condition associated with higher CRC risk,
and their polyps are often sessile serrated adenomas/ polyps (SSAs/Ps). A recent study
reported that recurrent sessile serrated adenomas or polyps occurred in 68% of patients at
surveillance colonoscopy (Edelstein et al., 2013). Another study reported 15% of the
SSA/P patients developed subsequent CRCs or adenomas with high-grade dysplasia (Fu,
Qiu, & Zhang, 2014).
2.5.2. Adenomatous polyp at surveillance colonoscopy associated with adenomas at
baseline examination
The findings at initial colonoscopy are associated with the findings at surveillance.
Risk stratification of adenomas has been reported. Four studies in the US and two studies
from Korea and the Netherlands reported on recurrence of adenomatous polyps based on
adenoma status at the initial screening (Suh et al., 2014; van Heijningen et al., 2013). The
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studies had differing approaches with regard to demographics, study design, and findings
at surveillance colonoscopy as related to findings at the initial colonoscopy. Risks based
on adenoma status are defined similarly: (1) high-risk is defined as having advanced
adenomas, including high-dysplasia, villous or tubulovillous histology, size ≥ 1 cm, ≥3
non-advanced adenomas, and invasive carcinomas, (2) low-risk is defined as nonadvanced adenomas, including 1 to 2 non-advanced adenomas, and (3) normal results are
defined as hyperplastic polyps (not adenomas) or no polyp. The finding of studies on the
percentage of adenomas found at surveillance colonoscopy by risk-level at baseline
screening in the US and others are summarized in Table 2.9 and Table 2.10, respectively.
(1) Findings in the US
One of the studies examined a sample of patients in the Prostate, Lung, Colorectal,
and Ovarian (PLCO) cancer screening trial with surveillance colonoscopy use based on a
history of adenoma. Study criteria for eligible patients included no current treatment for
cancer and no known prior cancer of the colorectum, prostate, lung, or ovaries. Those
patients were classified into 4 groups based on findings at the initial colonoscopy: (1)
advanced adenoma (AA), (2) non-advanced adenoma (NAA), (3) non-adenomatous
polyps (NAP), and (4) no polyp. There were 2,607 patients who met the requirements and
had surveillance colonoscopy within 6 months to 10 years from the baseline colonoscopy.
Significant findings are that around 19% of individuals with advanced adenomas found at
baseline colonoscopy had adenoma recurrent, but recurrence rates were fairly constant
from 1 year through 10 years after initial screening (Pinsky et al., 2009).
A randomized trial examined the findings at surveillance colonoscopy and evaluated
adenomas found after a mean follow-up of about 4 years in 1991-1994, the Polyp
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Prevention Trial (PPT) and the PPT-Continued follow-up Study (PPT-CFS). Criteria for
study eligible patients were: no history of surgical resection of adenomatous polyps,
bowel resection, CRC, polyposis syndrome, or inflammatory bowel disease. The
adenoma findings at baseline colonoscopy were grouped into low-risk and high-risk. Of
1,905 individuals who had adenomas removed or had a diagnostic colonoscopy who
participated in the PPT, 1,297 completed the follow-up Study. The results showed
approximately 31% of individuals with high-risk adenomas also had high-risk findings at
surveillance (Laiyemo et al., 2009).
The same author used the same data sources to assess the utilization of the riskstratification recommended by the 2006 guidelines. Ranges of 19.6% -46.2% of patients
with a high-risk of adenoma status at initial colonoscopy have a recurrence of high-risk
adenoma status at surveillance. However, they mentioned that adenoma-based risk
stratification has limited predictability for findings at surveillance because demographic
and lifestyle characteristics may affect the outcome (Laiyemo et al., 2008).
Another study used a different study design, but discussed similar issues in
studying participants of an adenoma chemoprevention trial. All participants had
screening and two surveillance colonoscopies at roughly 3 or 5 years as recommended.
The risk of clinically significant adenoma recurrence was stratified based on the results of
the first colonoscopy. The criterion for eligible patients was that they had a histologically
documented large-bowel adenomas removed (n=564), and the study excluded those with
an adenoma detected before their baseline colonoscopy and with cancer found at or
before the second colonoscopy. The initial adenoma status was classified into high-risk,
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low-risk, and no adenoma. About 18% of high-risk individuals had a recurrence of highrisk adenomas (Robertson et al., 2009).
Finally, another retrospective study renewed 965 patients from a single specialty
gastroenterology practice between 1985 and 2010, and then quantified the risk of
advanced adenomas/ high-risk findings on surveillance colonoscopy. Patients with a
family history of CRC, personal or family history of FAP or HNPCC, and second and
third colonoscopies performed for any reason other than surveillance purpose were
excluded.
Adenomas at the index colonoscopy were categorized into high-risk, low-risk, and
non-neoplastic categories. They reported that high-risk findings at the second
surveillance colonoscopy were best predicted by high-risk findings at the first
surveillance (22% of cases) (Morelli et al., 2013).
(2) Findings from other countries
A study from Korea estimated the risk of high-risk findings at the second
surveillance colonoscopy based on the prior two results. Eligible subjects included those
who underwent screening colonoscopy and also completed their second surveillance
colonoscopy. Those with CRC, polyp, inadequate bowel preparation or incomplete
colonoscopy at baseline, invasive CRC, or history of inflammatory bowel diseases (IBD)
were excluded. The results showed that high-risk findings at the second surveillance
colonoscopy were significantly associated with high-risk findings from the previous two
examinations (Suh et al., 2014).
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Another study from the Netherlands also reported that adenoma characteristics are
associated with recurrent colorectal neoplasia. They included patients with the first
adenoma diagnosed and with follow-up data (van Heijningen et al., 2013).
(3)Findings of the US vs. other countries
Although those studies have different study designs and sample characteristics, the
common finding is that adenoma features observed at previous examinations are
associated with subsequent adenomas. A range of 18-31% of patients with high-risk
findings at previous examinations has high-risk findings at the last surveillance
examination. Moreover, a range of 5-10% of patients with low-risk findings at
surveillance colonoscopy had low-risk adenomas at previous examinations in the US. In
comparison, the studies from Korea and the Netherlands reported around 46% and 4% of
adults with high-risk findings at follow-ups, respectively. The variance of these
recurrence rates may be explained by the differences in surveillance guidelines and
cultures which impact patients CRC risk behaviors.
2.5.3. Likelihood of advanced neoplasia after negative screenings
Even for adults with negative findings at initial examination, the risk still exists to
develop advanced adenomas because of missed lesions. Six studies examined the findings
of advanced neoplasia after negative screenings, defined negatively as no polyp or
adenoma found (Table 2.11).
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Most of the studies involved surveillance screening at 5 years after negative
findings at baseline examination. About 0.6-2.0% of these patients developed advanced
neoplasia (Chung et al., 2011; Imperiale et al., 2008; Leung et al., 2009; Rex et al., 1996).
Compared to these studies, one study had a more frequent surveillance interval of 3 years,
and identified 0.8% of adults with negative findings having advanced neoplasia (Schoen
et al., 2003). The studies with longer periods between follow-ups showed that risk
findings occurred in 4.4-6.7% of cases per year of increased intervals (Brenner et al.,
2007).
2.5.4. Summary of significant findings
These studies confirm the relationships between baseline findings and findings at
surveillance colonoscopy. Information on baseline colonoscopy can predict subsequent
adenomas. The risk of adenoma recurrence increases among individuals with high-risk
adenomas at baseline examination, and adenoma recurrence is cumulative with a longer
surveillance interval. In contrast, low-risk individuals did not predict low-risk or averagerisk at later follow-ups. Sometimes high-risk findings or interval CRC occur between
scheduled examinations due to missed lesions at previous examinations. Therefore, using
findings from all previous colonoscopies to determine the probability of high-risk
findings at the last surveillance colonoscopy could assist with developing optimum
timing recommendations.
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Table 2.9 Findings of advanced neoplasia at the last surveillance colonoscopy by findings at baseline colonoscopy in the US (by risk
stratification)
Primary author
Pinsky
Laiyemo
Robertson
Morelli
Year
Type of study
Sample Size#
1st colonoscopy
outcome
High-risk**

2009
PLCO*,
randomized trial
2,607
(%)

2009
PPT*,
randomized trial
1,297
(%)

2009
Medical center,
prospective study
564
(%)

2013
Specialty practice,
retrospective study
965
(%)
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Outcome at
surveillance
High-risk**
19.3
30.6
18.2
22.0
**
Low-risk
6.7
8.9
13.6
11.0
No adenoma
5.9
4.8
12.3
**
**
Low-risk
High-risk
15.6
6.9
20.0
18.0
Low-risk**
5.7
4.7
9.5
8.7
No adenoma
3.9
2.8
4.9
No adenoma
High-risk**
11.5
**
Low-risk
4.7
No adenoma
3.1
*
PLCO: the Prostate, Lung, Colorectal, and Ovarian cancer screening trial; PPT: the Polyp Prevention Trial.
**
High-risk is defined as 3 or more adenomas, tubular adenoma ≥ 10 mm, adenoma with villous histology, or high-grade dysplasia
(HGD); Low-risk is defined as 1-2 tubular adenomas <10 mm.
#
Subjects completed baseline colonoscopy and follow-up examinations.

Table 2.10 Findings of advanced neoplasia at the last surveillance colonoscopy by baseline colonoscopy findings in other countries
(by risk stratification)
Primary author
Suh
Van Heijningen
Year
Location
Type of study
Sample Size*
1st colonoscopy outcome
High-risk**

2014
Korea
Single medical center,
retrospective study
852
(%)
46.2
23.6
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2013
Dutch
Registry data,
community-based study
1,482
(%)
4.0
3.0
4.0
0
1.0
1.0
-

Outcome at surveillance
High-risk**
Low-risk**
No adenoma
**
Low-risk
High-risk**
30.8
Low-risk**
32.5
No adenoma
No adenoma
High-risk**
23.1
Low-risk**
43.8
No adenoma
*
Subjects completed baseline colonoscopy and follow-up examinations.
**
High-risk is defined as 3 or more adenomas, tubular adenoma ≥ 10 mm, adenoma with villous histology, or high-grade dysplasia
(HGD); Low-risk is defined as 1-2 tubular adenomas <10 mm.

Table 2.11 Findings of advanced neoplasia at the last surveillance colonoscopy after negative findings at initial screening*
Sample size**
Primary author
Time interval
Advanced neoplasia (%)
(year)
(years)
Rex (1996)
154
5
0.6
Schoen (2003)
9,317
3
0.8
Imperiale (2008)
1,256
5.3(Mean)
1.3
Leung (2009)
401
5
1.4
Brenner (2010)
533
11.9(Mean)
4.4-6.7#
Chung (2011)
1,242
5
2.0
*
Negative screening is defined as no any polyp or adenoma detected at baseline examination.
**
Number of adults with negative findings at initial examination and rescreen at interval time.
#
Percentage with advanced neoplasia findings increased with each year (1-≥16 year).
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2.6 Original contributions of the current study, research gaps addressed
A colonoscopy is a high risk and costly procedure. It is not always perfect for
preventing cancer despite the fact that it has been a dominant CRC screening modality in
the United State since the 1990s. Having a surveillance colonoscopy administered
appropriately after the initial examination is necessary.
Adenoma features are widely used to predict subsequent adenomas by risk
stratification. Although adults with high-risk adenomas at initial screening are more
likely to develop subsequent adenomas, adults with high-risk findings after negative
screenings still occur. A possible explanation is that residual neoplastic tissue was left
behind at prior examinations. About 20% of polyps and more than 70% of interval CRC
cases were attributed to missed lesions (Ji et al., 2009; Pohl & Robertson, 2010; van Rijn
et al., 2006). Moreover, high-risk adenoma characteristics (large adenomas, multiple
adenomas, proximal adenomas, the presence of HGD, and TVA /villous adenomas) are
associated with recurrence and advanced adenoma risk at follow-up features.
The pattern of surveillance practice is still highly rationale despite guidelines
having been updated. Using only adenoma-based risk stratification in the current
surveillance guidelines is a limitation to study recurrence due to underuse among highrisk adults and overuse among low-risk adults (Laiyemo et al., 2008; Schoen et al., 2010).
Underuse may harm at-risk adults, but overuse may result in reducing colonoscopy scene
capacity for screening and surveillance (Johnson et al., 2015). Understanding the factors
contributing to overuse or underuse of surveillance colonoscopy may help monitor
patients better and improve guideline concordance.
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However, few studies have examined patient-related and endoscopist-related factors,
which may also influence the effectiveness of screening/surveillance colonoscopy.
Patient-related factors such as gender, age, and race are difficult to overcome. Also, other
patient factors such as poor bowel preparation, knowledge, or adherence to guidelines
influence the examination. Endoscopist-related factors are more related to endoscopy
skills because of the differences in training and credentialing processes, and
conscientiousness in performing the procedure which may cause inadequate polypectomy
or lower adenoma detection rates (Hewett et al., 2010; Hewett & Rex, 2010; Johnson et
al., 2015). Lack of knowledge or disagreements on guidelines may also drive nonadherence to recommended practices by providers (Saini et al., 2009).
Overall, one comment explaining compliance of surveillance colonoscopies
exclusively by adenoma risk-stratification at baseline colonoscopy. Other factors may
contribute to non-adherence to timing recommendations despite guidelines having been
widely published. Few data sources are available with information on patient and
endoscopist covariates. Even if data sources have complete information, most suffer from
selection bias, self-selected patients who may be more health-conscious or subjects
overestimate findings. Therefore, surveillance utilization and factors to be targeted to
improve guideline concordance should be aggressively identified. The contributions and
research gaps in this area are organized in figure 2.2.
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Quality indicators at initial screening
Polyp features
 Serrated lesions
 Number
 Size
 Location
 High-grade dysplasia
 TVA, TA, villous

Measures at follow-ups

Endoscopist factors
 Procedure volume
 Specialty of
endoscopist
 Follow involvement

Weak**

Procedure factors
 Bowel preparation
 Cecal intubation

Weak

Patient factors
 Gender
 Age
 Race
 Education

Weak

CRC screening
 Colonoscopy

Adenoma status
 High-risk*
 Low-risk
 Normal



Other factors
 Time intervals
 Missing
lesions

Figure 2.2 Conceptual framework: current research contributions and research gaps.
*
High-risk is defined as ≥ 3 adenomas, tubular adenoma ≥ 10 mm, adenoma with
villous histology, or high-grade dysplasia (HGD); Low-risk is defined as 1-2 tubular
adenomas <10 mm. Abbreviations: TVA, tubulovillous adenoma; TA, tubular
adenoma.**Weak: Little or no research documentation exists.
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2.7 Contributions and knowledge gaps remaining despite recent studies
on surveillance colonoscopy
This section discusses the significant findings of two related studies, the research
gaps remaining, and the potential contributions from our study. A Netherlands study
examined adherence to postpolypectomy surveillance guidelines in community-based
clinical practice and evaluated the influence of a change in the guidelines on adherence
rates (van Heijningen et al., 2015). This country has a universal healthcare access system.
Another study identified the predictors of guideline-concordant surveillance colonoscopy
recommendations and factors associated with overuse or underuse of surveillance
colonoscopy (Kahn et al., 2015).
2.7.1 Summary of approaches and findings of recent studies on surveillance colonoscopy
use
The study from the Netherlands by Van Heijningen et al discussed adherence to
recommended intervals in community-based clinical practice. Researchers studied
patients with a first adenoma diagnosis from 1998 to 2002 and followed them up to 2008
(n=2,997). The significant finding was that underuse relative to the postpolypectomy
surveillance guidelines was high in the Netherlands population. Less than 25% of
surveillance-eligible patients underwent surveillance at the appropriate time. The study
showed significant proportions of delayed surveillance among patients with high-risk
adenomas and early surveillance for patients with low-risk adenomas. The study did not
evaluate the prevalence of surveillance among patients without polyps or with
hyperplastic polyps. Therefore, inappropriate overuse was not studied. Another research
gap is that despite most of the patients in the Netherlands usually attending the same
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hospital for surveillance and all other health purposes, the factors associated with low
adherence rates were not explored. Finally, their outcomes do not generalize to the US
population because the researchers used the Netherlands guidelines for their study. They
used the 2002 guidelines which recommended that patients with one or two adenomas
should have surveillance at six years, one year later than recommended by US guidelines
(Snel & de Wolf, 1988).
A study from the USA by Kahn et al identified the predictors of guideline-concordant
surveillance recommendations after adenoma polypectomies. Researchers studied
subjects who underwent a polypectomy between 2011 and 2013 at an academic medical
center’s safety-net health system in Dallas in the US (n=1,822). However, the study
sample consisted of only those who were eligible for surveillance as per guidelines, and
excluded those who were not eligible. They reported that nearly 25% of cases were not
concordant with the surveillance guidelines. Patients with ≥ 3 adenomas, aged > 65 years,
or with piecemeal resection of polyps at initial colonoscopy were more likely to have
guideline-inconsistent surveillance colonoscopies. Although they determined the
reasons/factors for low adherence to surveillance colonoscopy, the reported rates pertain
to a safety net population covered by an academic medical center. Further the authors did
not evaluate the appropriateness of surveillance colonoscopy timing given the
recommended time intervals, and they did not account for provider factors in the
variations in surveillance colonoscopy use.
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2.7.2 Contribution of the current study
Based on the contributions of the reported studies some research gaps remain. This
study examines the overall use of surveillance and premature repeat screenings of a total
cohort of patients with an initial colonoscopy at a community-based endoscopy center in
South Carolina. It uses a large sample of 26,523 consecutive colonoscopies performed
from September 4, 2001, to February 12, 2011 to study the pattern of surveillance
colonoscopy use. We use the 2006 U.S. Multi-society Task Force guidelines to determine
appropriate or inappropriate timing of surveillance and evaluate overuse, underuse and
appropriate use among all patients and stratified by risk status at baseline colonoscopy.
Inappropriate overuse will also be studied among patients without polyps or with
hyperplastic polyps. More in-depth exploration of the relationship between timeliness of
surveillance colonoscopy and baseline findings on polyp, patient, and colonoscopy
characteristics will be determined.
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CHAPTER 3
METHODS
This chapter describes the research questions and methodology used in the study,
including sample selection process and statistical analysis methods. There are 5 sections:
(1) study questions, (2) data source and description, (3) study variables, (4) statistical
methods, and (5) steps of data analysis.

3.1 Study questions
To address the knowledge gap regarding surveillance based on prior literature, the
following are the research objectives, study questions, and hypotheses.
3.1.1 Research objectives
There are few data sources available to study surveillance frequency due to very few
colonoscopy series reporting on surveillance colonoscopies. A few studies evaluated the
status of surveillance colonoscopy use relative to the recommended guidelines, and the
great variation in surveillance utilization. One reason could be differences in the
populations covered by the colonoscopy series – with selection bias in some populations
towards more educated or health-conscious subjects rather than randomly selected
members of the general population as in a randomized clinical trial or academic systems.
The consistency of surveillance frequency with the professional society recommendations
remains a little-studied topic (Laiyemo et al., 2009; Pinsky et al., 2009).
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Studies that examined the utilization of surveillance colonoscopy have not reported
on patient-related or endoscopist-related factors that may affect the risk of colorectal
polyps’ recurrence, which drives surveillance timing decisions. The lack of this
information limits the ability to study surveillance timeliness adjusted for polyp risk
factors. Although a recent study documented an influence of a change in colonoscopy
guidelines on practice, they did not examine the reasons that may affect the findings of
surveillance colonoscopy (van Heijningen et al., 2015). Our study will address this gap.
Another study documented that patients with ≥ 3 adenomas, aged >65 years, or with
piecemeal resection of polyps at initial colonoscopy were more likely to have guidelineinconsistent follow-ups. However, this study was mainly based on guideline
recommendations and not all categories of patients (Kahn et al., 2015).
Therefore, the study research objectives are as below. It will use the data on initial
colonoscopies to evaluate the appropriateness of surveillance use and timeliness relative
to 2006 joint guidelines of the U.S. Multisociety Taskforce Guidelines [the American
College of Gastroenterology (ACG) and the American Society for Gastrointestinal
Endoscopy(ASGE)] (Winawer et al., 2006).
Study objectives:
(1) To compare the appropriateness of surveillance colonoscopy timing at a major
endoscopy center in SC among patients with an initial colonoscopy in the pre2006 period (pre-guideline) vs. 2006 and later, relative to the recommended
surveillance intervals. The appropriateness is determined based on concordance of
timing with the 2006 guidelines.
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(2) To study the demographic, insurance and polyp-related factors at initial
colonoscopy associated with the likelihood of timely surveillance.
To address these objectives, the study will mainly use the adenoma status (advanced
adenoma and non-advanced adenoma), adenoma features (number, size, location, and
histology), and period relative to guideline date (pre-2006, and 2006 and later) of these
variables at initial colonoscopy will be used to explore the relationship with timely
surveillance.
3.1.2 Research questions
The original contribution of this work and how it addresses the research gaps have
been explained in the previous chapter. The study purpose is to evaluate the impact of
professional society guidelines on practice at a setting that is highly invested in highquality colonoscopy services as evidenced by very high CRC prevention among its
screening colonoscopy clients compared to almost any other practice-based cohort
documented in the literature. It has to achieve CRC prevention rates similar to the only
clinical trial documented in the literature. Given the quality focus of the center, we seek
to study the impact of the 2006 guidelines on the center’s surveillance or re-screening
frequency. Before 2006, there were no official guidelines firmly recommending timings
of surveillance based on characteristics of patients and polyps found at initial screening.
The study will address the following research questions to achieve the objectives.
(1) Is the timing of surveillance colonoscopies relative to the 2006 recommended
interval different for initial colonoscopies done pre-2006 vs. post-2006 and later
procedures?
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(2) Are the post-2006 repeat colonoscopy procedures concordant in timing with the
2006 guidelines?
(3) Is the timing of surveillance associated with initial adenoma status, adenoma
features, and patient-related factors, and how does this differ in the pre-2006
period vs. post-2006 and later?
3.1.3 Research hypotheses
Those research questions are studied by testing the following hypotheses:
(1)Hypotheses on the timing of surveillance colonoscopies at guideline date
a. The surveillance colonoscopy interval is different among patients with initial
colonoscopy in the pre-2006 period compared to those screened 2006 and later
after adjusting for baseline adenoma features. (We include patients with an initial
colonoscopy in 2006 in the post-guideline group because their earliest possible
surveillance would be in 2007 when guidelines were operational.)
b. Predictive factors for the timing of surveillance colonoscopies relative to baseline
colonoscopy in terms of adenoma features and demographic characteristics will
be different for patients with initial colonoscopy before 2006, and those of 2006
and later.
(2) Hypothesis on the predictors of timely surveillance colonoscopy
a. The likelihood of appropriate timing of surveillance colonoscopy is associated with
initial adenoma status, adenoma features, patient demographic characteristics, and
guideline date.
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3.2 Description of methods
The section introduces the data source and builds the study structure based on
research objectives. The sample selection process is also presented.
3.2.1 Data source
Data for the study comes from a licensed ambulatory surgery center for endoscopy,
South Carolina Medical Endoscopy Center (SCMEC), in Columbia, South Carolina, now
known as Carolina Colonoscopy Center (CCC). Data was extracted on colonoscopies
performed from September 4, 2001 to February, 2011. A notable feature is that the
Center mainly uses primary care physicians (PCPs) to perform procedures. About 72.7%
of procedure were done by PCPs. Involving PCPs can help expand colonoscopy capacity
to meet the demand for screening colonoscopy. The center also uses a unique protocol.
One feature is search and removal of polyps during both scope insertion and withdrawal.
The center has documented higher CRC prevention rates than other community-based
centers, and comparable to that of the only clinical trial in the literature (Xirasagar et al.,
2010; Xirasagar et al., 2015). Shifting some of the screening workloads to PCPs may
enhance the US populations access to cancer prevention if they have the proper training.
In this study, ≥25% ADR was achieved by PCPs, 36.6% among males and 27% among
females, exceeding the performance benchmark of the U.S. Multisociety Task Force (Rex
et al., 2015; Xirasagar et al., 2015).
Post-training, the procedure performance protocol, and hands-on technical support
provided to PCPs compensate for potential skill deficiencies of PCPs due to lack of
formal gastroenterology training (They do not have pre-training). The center’s training
process is similar to gastroenterology fellows’ fellowship training for credentialing in
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colonoscopy. It ensures hands-on supervision and achieves participation by a credentialed
expert by the University of South Carolina Medical School teaching hospital for the first
140 procedures of the PCP-in-training. The training procedure number is identical to the
ASGE-specified number of procedures for hospital credentialing (Faigel, Baron, Lewis,
Petersen, & Petrini, 2007). At the center, the supervising specialist/expert is a
gastroenterologist, colorectal surgeon, or the colonoscopy-credentialed director of the
center’s colonoscopy training program, an internal medicine specialist with extensive
experience in independently performed colonoscopies board-credentialing. The
specialist/expert trains PCPs, providing hands-on endoscope management to advance the
scope through the colon, tip manipulation to expose mucosal fields hidden in the colonic
folds, viewing the video screen to coach the trainee on identifying tissue abnormalities
and polyp recognition, and directing the performing of the patient and endoscope to
enable safe and complete polypectomies. Hand on assistance is gradually reduced until
the PCP is fully proficient with these operations and achieves mastery in the above skills
over the 140 training procedures. Prior to completing 140 procedures, the manual
assistance is gradually replaced by verbal assistance to help navigate flexures, difficult
colonic segments, and/ or diverticula.
Post-training, the PCP performs procedures without specialist oversight. However,
an expert is always available on-site while any PCP is performing at the center to provide
rescue assistance. The specialist’s rescue assistance may be navigational or therapeutic
when called for by the PCP, particularly to safely remove large or vascular adenomas,
polyps at difficult locations, to control bleeding, or manage spasms. Training of PCPs
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was started in 2001 and 54 PCPs performed colonoscopies at the center as of February 12,
2011.
The center has implemented a polyp detection-maximizing protocol that has been
updated regularly consistent with professional society guidelines and based on findings of
published studies since 2001 (Sweeney & Lloyd, 2007; Xirasagar et al., 2010). The
procedure protocol requires a 2-person technique for all PCPs since 2001. The center also
encourages the use of the 2-person technique by colonoscopy-credentialed specialists and
experts (bringing their cases to the center or hired by the center as back-up experts). The
main features of the colonoscopy protocol at the CCC are: “(1) an endoscopy technician
advances the colonoscope while the physician manipulates the scope tip for polyp search
and removal. This can minimize the missing of polyps and ensure more persons watching
the video screen for polyps; (2) at least 3 additional persons view the video screen to
identify abnormal areas; (3) polyp search and removal takes place since March 2006
during both the insertion and withdrawal phases; (4) propofol sedation was implemented
to replace the conventional midazolam-meperidine combination sedation. The advantages
of propofol sedation are that enable vary rapid induction of deep sedation and rapid
recovery. Because there is more efficient utilization of the endoscopist’s time, it can
reduce additional costs of the associated staff and infrastructure while patients’ gradual
recovery with midazolam-meperidine or others (Cohen et al., 2007). Intravenous propofol
is administered by a nurse-anesthetist; (5) Gradual insertion and circumferential
withdrawal which is 6 minutes or greater of the colonoscope is done to maximize
mucosal surface inspection. In preoperative preparation, patients received a phone call
reinforcing bowel preparation instructions 2 days before the colonoscopy.” (Xirasagar et
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al., 2015). In addition patient positioning assistance to enable complete targeting of
abnormal tissue for safe and complete removal or destruction in place is an important
function served by the additional personnel in the room, especially the assisting
endoscopy technician and the nurse anesthetist.
3.2.2 Study design and structure
This is a retrospective cohort study to study the timing of surveillance colonoscopy
as related to the initial examination. Data for this study comes from a total of 26,523
procedures performed by the 54 PCPs and 5 experts at the center from September 4, 2001,
up to February 12, 2011. The study objectives are to evaluate the relationship between the
timing of surveillance and patient, colonoscopy procedure, and adenoma characteristics at
baseline colonoscopy (Figure 3.1). Hypothesized factors affecting surveillance timing
are baseline adenoma status, adenoma features, patient characteristics, and professional
society guideline date relative to the initial colonoscopy. Adenoma status includes
advanced adenoma and non-advanced adenoma. Adenoma features that would influence
surveillance timing are the presence of advanced adenoma features, which are the number,
size, location, and histology (tubular, tubulovillous /villous, hyperplastic, or dysplasia
features). Patient characteristics include gender, age, race, and insurance status. Because
specific and detailed surveillance guidelines were established in 2006, comparison of
surveillance timing between screening colonoscopies pre and post-guidelines is important.
The time interval to surveillance is the key variable of interest for this study.
3.2.3 Study sample selection and preparation of data
The Patient, Polyp, and Procedure datasets were linked by the procedure identifier
(ID). In addition to the procedure ID, the patient ID was used to identify multiple
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procedures of the same patient. To populate missing data in several fields and resolve
discrepant information between datasets, over 10,000 patient charts were reviewed
manually. Updates were done in 2011, 2012, and 2014 and will be continued in 2016 to
populate any other missing data. After merging the datasets and resolving discrepancies
as mentioned above, duplicate entries of procedures were removed. Some variables were
recoded from a text format into categorical form, and some categories were regrouped.
Variables for which recording was done included: dysplasia level, pathology text, and
pathology results. Pathology results were updated again in October 2012 because of
missing data for polyps during a certain period due to alternate fields used by temporary
CCC staff.
After updating, the final datasets for analysis were: a) Procedure dataset which had
patient characteristics and procedure information, and b) Polyp dataset which included
colorectal segment-wise polyp histology. Polyp ID or procedure ID was used to link to
patient characteristics. Each patient has unique procedure ID in a procedure, which can
be used to link procedure information between Polyp and Procedure datasets. Figure 3.2
shows the relationship of two datasets for linking procedure information in a patient.
A total of 26,523 colonoscopies were performed from September 4, 2001, to
February 12, 2011. Of those 997 procedures were 3rd or higher order procedures of a
single individual. The next step was to designate the second procedure is done within 6
months of the first colonoscopy as the first procedure (n=255) and assign their 3rd order
procedures to become 2nd or surveillance procedures. Then, we integrate both polyp
findings into one record. This is done because a second procedure within 6 months is
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almost always due to the incomplete or unsatisfactory colonoscopy for whatever reason
(Schoen et al., 2010; van Heijningen et al., 2015; Winawer et al., 2006).
The remaining 25,271 procedures were considered for the study. There were 20,912
adults with a first procedure. Of these, 4,359 had a second procedure more than 6 months
after the first procedure (Figure 3.3). Of patients with an initial colonoscopy, we excluded
2,343 adults due to a) being aged below 40 years (not within the age group normally
expected to undergo the adenoma-cancer sequence), aged more than 74 years (not
recommended for routine screening and surveillance as per standard guidelines). We also
excluded those with cancer at baseline procedure (n=103). This led to a potential sample
of patients is 18,466. However, of these patient 1,569 had not yet completed the
recommended surveillance interval as per the 2006 guidelines, as of February 11, 2011.
The surveillance recommendation recommends that adults with different risk
adenomas at initial colonoscopy should undergo surveillance examination at <1-year, 1year, 3- year, and 5-year intervals, respectively. Based on these criteria 1,569 patients
were excluded. We allowed an additional 6 months over the recommended intervals to
classify patients as surveillance completion eligible, as documented in the literature (van
Heijningen et al., 2015). After exclusions, the study sample consisted of 16,897 eligible
adults with a first procedure, of whom 4,234 eligible patients for surveillance. 1,793 of
12,571 total patients who are not eligible for surveillance have come back early (Figure
3.3).
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Initial colonoscopy

Timing of surveillance colonoscopy

Adenoma status per guidelines
 Advanced adenoma
 Non-advanced adenoma
Potentially influential not
captured adenoma features
 Number
 Size
 Location
 Histology
Patient factors
 Gender
 Age
 Race
 Insurance status

Surveillance time interval
since initial colonoscopy

Provider specialty
 PCP
 GI specialist
 Expert
Availability of surveillance
guidelines
 Pre-2006 period
 2006 and later

Figure 3.1 Study conceptual framework: predictors of surveillance time interval
since initial colonoscopy
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Summed each polyp’s information
by procedure ID in Polyp dataset,
and then merge with Procedure
dataset by procedure ID

Polyp dataset: each polyp’s
histology was show separately

Procedure dataset: each patient
may have several procedures


Procedure ID



Polyp ID



Patient ID



Procedure ID

Figure 3.2 IDs used to link the two datasets to link procedure and patient
information
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26,523 total procedures for 20,912 patients
997 3rd or higher order procedures for 800 patients
(1) AA: 77 procedures for 57 patients
(2) NAA: 423 procedures for 332 patients
(3) HP/Normal tissues: 252 procedures for 209 patients
(4)No polyp: 247 procedures for 202 patients
25,526 1st and 2nd procedures for 20,912 patients
255 had 2nd procedure within 6 months, data merged
into 1st procedure

20,912 1st procedures

4,359 2nd procedures

20,912 patients
Excluded patients
(4,015 for 1st procedure/343 for 2nd procedure):
2,343/307 aged < 40 or ≥ 75 years
103/36 with carcinoma
1,569/0 patients no 2nd procedure due to not
completing recommend surveillance interval

4,234 eligible for surveillance

Done
2,195

Not done
2,039

12,571 not eligible for surveillance
(Hyperplastic polyp or no polyp)

Not done
10,778

Done early
1,793

92 without histology

Done
28

Not done
64

1,045 hyperplastic polyp
748 no polyp

Figure 3.3 Identification of study eligible patients with baseline and first surveillance
colonoscopy. Abbreviations: AA, Advanced adenoma; NAA, Non-advanced adenoma;
HP, Hyperplastic polyp.
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3.3 Study variables
This section describes the dependent, independent, and control variables of interest.
All study variables of interest are summarized in Table 3.3 and 3.4, showing variable
names, description, variable categories, and attributes.
3.3.1 Dependent variables of interest and definition
The time interval to surveillance colonoscopy is our key variable of interest. It is
defined as the interval from initial colonoscopy to the second colonoscopy. It is
calculated from the database variable Procdate, the procedure dates of baseline and
second colonoscopy. The calculated interval is named InterTime. Patients with a
Procdate each for baseline and surveillance colonoscopy are those who had surveillance.
Otherwise, Surveillance = zero (no surveillance).
The third variable is appropriate surveillance, defined by the USMSTF on Colorectal
Cancer (ACG and ASGE keep expand joint guidelines) of 2006. Table 2.2 of chapter 2
presents the guidelines for various risk groups based on screening colonoscopy findings.
To summarize, the guidelines recommend 2-6 months for patients with sessile adenomas
are removed piecemeal, 1-year surveillance for patients with hyperplastic polyposis
syndrome or > 10 adenomas, 3-year surveillance for patients with 3-10 adenomas, ≥ 1 cm
adenoma, or any adenoma with villous features, or high-grade dysplasia, 5-year
surveillance for patients with 1 or 2 small tubular adenomas or any adenoma without
advanced features, and 10-year surveillance for patients with small rectal hyperplastic
polyps or normal tissues (hyperplastic or no polyp). The updated guidelines were
published in 2006, which updated the criteria on histology and number of polyps detected.
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We defined the timing of surveillance colonoscopies as appropriate if the
surveillance was within a range of ±3 months for the ≤ 1-year surveillance group and ±6
months for ≥ 2-year surveillance time interval as per recommendations. The allowance of
3 or 6 months before or after is consistent with the documented literature on communitybased series (van Heijningen et al., 2015). Those with surveillance earlier than these dates
were classified as Overuse and later than these dates as Underuse. If patients had multiple
polyp characteristics, the most severe one is used as the main indicator for determining
time intervals. The corresponding appropriate surveillance intervals followed with the
2006 guidelines and are presented in Table 3.1 (Winawer et al., 2006). We grouped
different time intervals as per guidelines into 5 levels: <1-year surveillance, 1-year
surveillance, 3-year surveillance, 5-year surveillance, and 10-year rescreening. Patients
were classified into these groups under the variable, TimeGroup. For guidelineconcordance, the variable was coded into Overuse, Appropriate, Underuse, and No need
for surveillance, called TimelySur. The overall compliance with timely surveillance
colonoscopy was regrouped into guideline-inconsistent, and guideline-concordant, under
the variable, GuideConcordant.
3.3.2 Independent variables of interest and definition
There are three key predictor variables of interest. These are adenoma features at
baseline, guideline date (pre-2006 vs. 2006 and beyond), and insurance status.
(A)Adenoma related variables at baseline colonoscopy
1) Presence of adenoma/ advanced adenoma/ polyp
We identified patients who had an adenoma or polyp detected at surveillance
colonoscopy. Each adenoma has a Polypid and a Procedureid to link each polyp
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to the patient. All polyp information is documented in the Polyp dataset. If a
patient ID exists in the Polyp dataset, it indicates this patient had a polyp. If the
polyp was a histological adenoma, these patients were coded as” yes” for the
variable “Adenoma” in the Procedure dataset. If a patient ID was not found in the
Polyp dataset, or if the polyp showed normal tissue or hyperplastic tissue the
patient was coded as” no” for the Adenoma variable.
A similar method was used to create a variable for the presence of advanced
adenoma and any polyp, called AdvAdenoma and Polyps, respectively. The
presence of advanced adenoma is defined as yes/no, yes=at least one advanced
adenoma was found. Advanced adenoma is defined as villous features, the size of
1 cm or more, high-grade dysplasia, or early invasive cancer by Winawer et al
recommendations (Winawer & Zauber, 2002). We defined another variable as
AdvAdenomaPlus to add patients of a recently added high-risk category, these
with ≥ 3 adenomas. Polyp presence is defined as yes/no. Yes= at least one polyp
was found which were not normal tissues. Finally, we categorized patients by the
most advanced adenoma found at baseline colonoscopy: advanced adenoma, nonadvanced adenoma, and no adenoma, called AdenoStatus.
2) Number of polyps/adenomas (summarized at patient/ procedure level)
The number of polyps found in the patient was summarized within each
patient using the patient ID in the Polyp dataset. The count of polyps was summed
into the Procedure dataset, called SumPolyp by patient ID (using only hyperplastic
or adenomatous polyps to count; polyps found to be of normal tissue of any kind
were coded as no polyp in the Procedure dataset). SumAdenoma and
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SumAdvAdenoma were created using a similar method. Another variable, polyp
quantity is available, the total number of polyps found in the same colonic
segment. These were summed across hyperplastic and adenomatous polyps and
called SumPolypQuantity in the Procedure dataset. We also summed adenomatous
polyps only to separate variable, called SumAdenoPolypQty. We created a
categorical variable, in the polyp dataset AdenoPolypQty with 3 levels: no
adenoma, 1-2 adenomas, 3-6 adenomas, and ≥ 7 adenomas.
3) Largest adenoma size (coded at the level of each adenoma)
The size of the adenoma was extracted from the Polyp dataset, polyp size in
millimeters, called Polypsizemm. It was merged into Procedure dataset based on
procedure ID, and the size taken in was based on hierarchically ordering all polyp
size of the patient and selecting the largest adenoma. The largest adenoma size was
categorized into ≥ 10 mm, 5.1-9.9mm, and ≤ 5mm, under the variable, AdenoSize.
4) Polyp anatomic location
The anatomic location of the polyp was extracted from Polyp dataset, which is
PolypLocation. It is the original variable from primary data from the center, used to
create the intermediate variables. The definition of the left colon is a location in the
splenic flexure or descending colon. The location was defined as right if located in
the cecum, ascending colon, hepatic flexure, or transverse colon. The remaining
locations were defined as rectum and sigmoid if located in the rectum and sigmoid,
respectively.
Two variables were created in the Polyp dataset for identifying: (1) The
location of the largest adenoma, and (2) Number of colonic locations with an
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adenoma. We created a variable for the location of largest adenoma, using three
intermediate variables, PolypLocation, Adenoma, and LargestPolyp. LargestPolyp
was created to identify the size of the polyp by hierarchical order in a procedure.
Another intermediate variable was created to produce the number of locations with
adenomas, PolypLocation. Those new variables were summarized at the procedure
level based on procedure ID, called LargAdenoLoc and SumNumLocAdeno,
respectively. LargAdenoLoc had four categories: “Largest adenoma located in the
right colon”, “Largest adenoma located in the left colon”, “Largest adenoma located
in the rectum colon”, and “Largest adenoma located in the sigmoid colon”.
SumNumLocAdeno was categorized into 2 levels: adenomas at 1-3 locations, and
adenomas at 4 locations.
5) Variables on histology of the polyp (tubular, tubulovillous/villous adenomas,
polyps with dysplasia features, and hyperplastic polyps)
The polyp characteristics were extracted from the Polyp dataset, from the
fields of Pathologytext and Path_result (These two variables fields were used by
the center to record histology during different time periods or a study period). Data
from both fields were drawn into a new intermediate Polyp_result variable with
three values, tubulovillous/villous, hyperplastic, and tubular. For
tubulovillous/villous and tubular adenoma, we also used the adenoma variable to
capture, called TubVillous and Tubular. A new variable HyperPolyp (yes/no) was
recoded directly from Polyp_result to designate whether it was a hyperplastic polyp.
A dysplasia variable was coded from Pathologytext and Path_result, which
was initially coded based on raw date into 8 levels: Not mentioned (a level of
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dysplasia not mentioned but stated to have dysplasia), Mild or no dysplasia,
Moderate, Severe, Carcinoma in situ, Invasive carcinomas, Carcinoid tumor, and
Probably invasive. We also coded patients with 2 or more advanced adenoma
characteristics, which include ≥ 1cm adenoma, tubulovillous/villous adenomas, or
any adenoma with high-grade dysplasia. The variable AdcAdenoFea (yes/ no) was
created.
(6) Variable in polyp type (based on U.S. MSTF surveillance guidelines, Winawer
et al 2006)
Variables on polyp type were created to align with the 2006 guidelines of
surveillance colonoscopy timing. (1) small (< 1cm) rectal hyperplastic polyp,
SmallRtHP, (2) 1 or 2 small (<1 cm) tubular adenoma with low-grade dysplasia,
TwoSmallTA, (3) 3-10 adenomas, ThreeToTenAdenoma, (4) ≥1 cm adenoma,
BigAdenoma, (5) tubulovillous/villous adenomas, TubVillous, (6) high-grade
dysplasia, HGD, (7) hyperplastic polyposis syndrome, HPPS, (8) > 10 adenomas,
TenPlusAdenoma, and (9) sessile adenomas removed piecemeal,
SessileAdenPiecemeal, respectively (Table 3.2).
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All those combinations were created from different source variables
(TubVillous was mentioned earlier). SmallRtHP was coded based on HyperPolyp,
Polypsizemm, and PolypLocation from the Polyp dataset. TwoSmallTA was coded
from Tubular and Polypsizemm. ThreeToTenAdenoma and TenPlusAdenoma were
coded from SumAdenoPolypQty. BigAdenoma was coded from Polypsizemm.
Patients had high-grade dysplasia feature was coded from Dysplasia. HPPS was
coded from HyperPolyp, Polypsizemm, and PolypLocation. Finally, patients with
sessile adenomas removed piecemeal were coded from PeduncSessile and
Destroyed. PeduncSessile was itself created from the text in the field, Morphology
which has polyp morphological characteristics recorded by the performing
physician, supplemented by additional notes from Pathologytext. The definition of
FullDestroyed is: was the polyp completely removed in the procedure. All were
extracted into the Procedure dataset based on the procedure ID where these new 9
variables were created. These patients were coded as” yes” for each variable of they
had those features.
(B) Variable to designate initial colonoscopy, pre- or post- 2006 guideline
Prevalence of surveillance guideline at the time of baseline colonoscopy was coded
based on Procdate (procedure date at baseline colonoscopy) into a variable,
PreGuideDate. If the initial procedure date was before 2006, PreGuideDate was coded
“Pre-2006 period”; if the initial colonoscopy took place in 2006 and later, it was coded
“2006 and later”.
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(C)Insurance status at baseline colonoscopy
Patient’s insurance information was collected at the time of initial colonoscopy
from the original variable in the Procedure dataset, called Inscarrier. Insurance carriers
were grouped into 4 groups: Medicare, Medicaid, private, and uninsured, called
Insurance2.
3.3.3 Control variables
Patient demographic characteristics were adjusted in the models to examine their
associations with the timeliness of surveillance.
(A) Patient demographic variables
Patient gender (female and male) was titled PatGender. Patient age was calculated
from the patient’s date of birth extracted from the CCC’s administrative billing system,
called PatAge. PatAge was recorded as a categorical variable, AgeGro into 3 age groups:
40-49, 50-59, and 60-74 years. Patient race was coded as Whites, Blacks, Other or
unknown, called PatRace.
(B) Number of observation years available
It is defined as the interval from initial colonoscopy to the end of the study period. It
is calculated from the database variable Procdate, the procedure dates of baseline and
February 11, 2011. The variable is called NumOfYrAvailable.
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Table 3.1 Operational criteria definitions used for classifying surveillance colonoscopy
timing since initial colonoscopy to define Appropriate timing, Underuse, and Overuse
category*
Interval recommendation
No surveillance needed
(in years)
(time interval in years)
Polyp types
Overuse Appropriate Underuse
Normal tissues
10
<9.5
9.5-10.49
NA
(include few hyperplastic
polyps or no polyp) –Not
eligible for surveillance
Small rectal hyperplastic
10
<9.5
9.5-10.49
NA
polyps
Surveillance timelines category
(time interval in years)
1 or 2 small (<1 cm)
5
<4.5
4.5-5.49
>5.5
tubular adenomas with
low-grade dysplasia
Any adenoma without
5
<4.5
4.5-5.49
>5.5
advanced features
3-10 adenomas,
3
<2.5
2.5-3.49
>3.5
adenoma ≥1 cm,
any adenoma with
villous features,
or high-grade dysplasia
Hyperplastic polyposis
1
<0.75
0.75-1.25
>1.25
**
Syndrome
>10 adenomas
1
<0.75
0.75-1.25
>1.25
Sessile adenomas that
<1
0-0.75
>0.75
are removed piecemeal
*
Winawer et al 2006; Levin et al 2008.
**
Hyperplastic polyposis was defined by Burt and Jass for the World Health Organization
International Classification of Tumors as: (1) at least 5 histologically diagnosed
hyperplastic polyps proximal to the sigmoid colon, of which 2 are greater than 1cm in
diameter, or (2) any number of hyperplastic polyps occurring proximal to the sigmoid
colon in an individual who has a first-degree relative with hyperplastic polyposis, or (3)
more than 30 hyperplastic polyps of any size distributed throughout the colon. Since our
study did not have information on first-degree relatives, we included first and third
definitions in hyperplastic polyposis (Burt & Jass, 2000).
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Table 3.2 Study variable definitions used to create polyp types as the 2006 guidelines*: baseline colonoscopy
Variable name
Description
Categories
Attribute
Adenoma characteristics
Polyps
Does this patient have any polyp?
No, Yes
Dichotomous
Adenoma
Does this patient have any adenoma?
No, Yes
Dichotomous
AdvAdenomaPlus
Does this patient have advanced
No, Yes
Dichotomous
**
adenoma?
SmallRtHP
Any polyp is small (< 1cm) rectal
No, Yes
Dichotomous
hyperplastic polyp?
TwoSmallTA
Is any 1 or 2 small (<1 cm) tubular
No, Yes
Dichotomous
adenoma with low-grade dysplasia?
ThreeToTenAdeoma
Are any 3-10 adenomas?
No, Yes
Dichotomous
BigAdenoma
Is any ≥1 cm adenoma?
No, Yes
Dichotomous
TubVillous
Any polyp is tubulovillous/ villous
No, Yes
Dichotomous
#
adenoma?
HGD
Is any adenoma with high-grade
No, Yes
Dichotomous
dysplasia?
HPPS
Is any hyperplastic polyposis
No, Yes
Dichotomous
syndrome?
TenPlusAdenoma
Are any >10 adenomas?
No, Yes
Dichotomous
SessileAdenPiecemeal
Any polyp is sessile adenomas that are No, Yes
Dichotomous
removed piecemeal?
*
The polyp types were created as follow the guidelines by Winawer et al 2006.
**
Advanced adenoma is defined as villous features, the size of 1 cm or more, high-grade dysplasia, 3 or more adenomas, or early
invasive cancer.
#
According to the 2006 guidelines, we mainly considered patients who had sessile adenoma that are removed piecemeal. Therefore,
we did not consider other morphology.
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Table 3.3 Study variable definitions used in analysis: baseline colonoscopy (all variables at the patient level)
Variable name
Description
Categories
Patient characteristics
PatGender
Patient gender
Female, Male
AgeGro
Patient age
40-49, 50-59, 60-74
PatRace
Patient race
Whites, Blacks, Other or unknown
Insurance2
Insurance status
Medicare, Medicaid, Private,
Uninsured
Colonoscopy characteristics
PreGuideDate
When does this patient take first
Pre-2006 period, 2006 and later
procedure?
NumOfYrAvailable
The number of years from initial
colonoscopy to the end of the study
period
Adenoma characteristics
AdenoStatus
The most advanced of adenoma found Advanced adenoma, Non- advanced
adenoma, No adenoma
LargAdenoLoc
The location of largest adenoma found Right colon, left colon, rectum,
sigmoid colon
SumNumLocAdeno
The number of locations with
1-3 locations, 4 locations
adenomas found
AdenoSize
The largest size of adenoma found
≥ 10 mm, 5.1-9.9mm, ≤ 5 mm
AdenoPolypQty
The number of adenomas found in the 1-2 adenomas,3-6 adenomas, ≥ 7
same colonic segment
adenomas
AdcAdenoFea
Any 2 or more advanced adenoma
No, Yes
characteristics found?

Attribute
Dichotomous
Categorical
Categorical
Categorical

Dichotomous
Continuous
(Numeric)

Categorical
Categorical
Categorical
Categorical
Categorical
Dichotomous

83

Table 3.4 Study variable definitions used in analysis: surveillance colonoscopy
Variable name
Description
Categories
Attribute
SurveillanceStatus*
The status of surveillance colonoscopy Event = Yes or No
Categorical
by the end of study period
InterTime
Time interval (years) to surveillance
Continuous
colonoscopy
(Numeric)
TimeGroup
Time interval (years) to surveillance/
<1-year, 1-year, 3-year, 5-year, 10Categorical
rescreening colonoscopy by 2006
year rescreening for overuse,10-year
guidelines
rescreening
TimelySur
Timing of surveillance colonoscopies
Overuse, appropriate, underuse, no
Categorical
with 2006 guidelines
surveillance needed
GuideConcordant
Does this patient have surveillance
No (Guideline-inconsistent),
Dichotomous
colonoscopy concordant with the
Yes(Guideline-concordant)
guideline?
*
SurveillanceStatus variable is used in Kaplan-Meier (KM) curves estimation and the definition is described under section 3.4
Statistical Methods.

3.4 Statistical methods
This section describes the process of data management and analysis including
statistical methods. The study used descriptive and inferential analysis. Finally, the
preliminary findings on sample distribution are presented to assist further recoding of
variables in answering the research questions.
3.4.1 Data management and analysis
The study uses data on all colonoscopies conducted from September 4, 2001, to
February 12, 2011, imported from the CCC’s Microsoft Excel databases. The primary
datasets were Physician (no names imported), Procedure, Polyp, and Patient datasets
(without patient identifiers except a numeric patient ID corresponding to the number on
their medical record at CCC). The Procedure dataset consisted of data entered by CCC
staff into Excel based on clinical procedure notes. Procedure data fields used for the
study were based on raw variables: total procedure time (time of scope insertion, time out
of anus, time of starting withdrawal), sequential number of the physician’s procedure if it
was < 140th for that physician, and cecum reached status; The Polyp data used are
histology of the polyp, whether this polyp an adenoma, size, dysplasia level, whether the
polyp was removed, how was the polyp removed, and location of the polyp. The Patient
fields used were the patient age at the initial procedure date, gender, and race.
Data preparation on to satisfy the study objectives, for all patients with a first
procedure up to February 12, 2011, first surveillance procedures if done is described in
section 3.2. We excluded those who are not eligible for surveillance colonoscopy and
those who did not have any second procedure due to not completing the surveillance
interval as of the end of the study period. The following statistical analyzes were used to
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examine associations between the dependent and independent variables of interest as
defined earlier. SAS v9.4 was used.
3.4.2 Descriptive statistics
Descriptive statistics are used to describe the patients, procedures, and polyps and to
examine bivariate associations between the dependent and independent variables of
interest. Chi-square and analysis of variance (ANOVA) are used. In the descriptive tables,
distribution of patients, procedures, and polyps are shown using percentages for
categorical variables and means with standard deviation (mean±SD) for continuous
variables.
(1)Chi-square test
A chi-square test (X2) is used to determine whether there is a significant difference
between the expected and observed frequencies in one or more categories.
(2)Fisher’s exact test
The Fisher’s exact test is a statistical significance test used in the analysis of
contingency tables. It is applied when we plan to conduct a chi-square test, but one or
more cells have an expected frequency of 5 or less (Fisher, 1922).
(3)ANOVA test
The ANOVA test is used to analyze differences between group means and their
associated procedure. It provides a statistical test of whether or not the means of several
groups are equal, of generalizes the t-test to more than two comparison groups, using
0.05 levels of significance.
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3.4.3 Inferential statistics
Inferential statistics is used to judge the probability that an observed difference
between groups is not merely a matter of chance. Kaplan-Meier (KM) curves with logrank test, logistic regression model, and multinomial logistic regression model are used.
(1) Kaplan-Meier (KM) curves
The original definition of the Kaplan-Meier curves was published for dealing with
those incomplete observations with an incomplete event by the end of study period by
Edward L. Kaplan and Paul Meier in 1958. Kaplan-Meier (KM) curves have become a
familiar way of dealing with differing survival times (time-to-event), especially when not
all the subjects continue in the study. In the use of KM curves, survival time does not
need to relate to death as the event. The event may be any event of interest (Kaplan &
Meier, 1958). It has also been applied to estimate the surveillance probability (getting a
colonoscopy) or any adenoma recurrence by time to surveillance, using adenoma features
at index screening (Huang et al., 2010; Schoen et al., 2010; van Heijningen et al., 2015).
In preparing the data for KM survival analysis, each subject is characterized by three
elements: (1) their period in the study, (2) the status at the end of their time, and (3) the
study group they are in. Time-to-event is defined as time duration for each subject having
a beginning and an end anywhere along the timeline of the complete study. It can begin
when the subject is enrolled into a study or when treatment begins (in this case initial
colonoscopy date), and ends when the end-point is reached (surveillance) or is censored
from the study for other reasons. Censoring occurs when the subject’s total time duration
at risk for the event cannot be accurately determined, such as in the case of dropouts, lost
to follow-up, or required data is not available. KM curves illustrate the change in the
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cumulative probability of the event in a given length of time while breaking up time into
many small intervals, which was used to calculate a step-wise estimate (Rich et al., 2010).
Based on these features, KM estimates can be applied to surveillance colonoscopy
use, which is the simplest way to compute surveillance use over time, despite the
challenge of subjects lost to follow-up in the study period. It is a nonparametric statistic
used to estimate the surveillance function from lifetime data. The main purpose is to
measure the fraction of patients who have surveillance colonoscopy over a certain
amount of time after the initial colonoscopy in clinical practice. Our study estimated
probability curves to compare the pattern of timing of surveillance colonoscopies relative
to recommended intervals for patients with an initial colonoscopy in the pre-2006 period
vs. post-2006(includes those with the first procedure in 2006). InterTime variable is our
main dependent variable for comparison of surveillance colonoscopy use pre- and postguideline. The comparisons are also adjusted for the differences in patient gender, age,
and race by time interval groups to surveillance colonoscopy.
The survival time is defines as the time lapsed from a defined starting point (initial
colonoscopy in this study) to the occurrence of a given event (surveillance). Subjects who
did not undergo surveillance are counted as right censoring since they may have
surveillance in the future. Variable SurveillanceStatus was created to identify censoring
status on surveillance colonoscopy use. It defined as an event (SurveillanceStatus
variable=1) when patients had the second procedure by the end of the study period.
SurveillanceStatus =0 if they had no second procedure until February 11, 2011.
The conditional probability of surveillance colonoscopy at any particular time (t) is
calculated by the formula as follow as:
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𝑆(𝑡) = 1 −

𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑 𝑠𝑢𝑟𝑣𝑒𝑖𝑙𝑙𝑎𝑛𝑐𝑒 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑒𝑙𝑖𝑔𝑖𝑏𝑙𝑒 𝑓𝑜𝑟 𝑠𝑢𝑟𝑣𝑒𝑖𝑙𝑙𝑎𝑛𝑐𝑒 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡

Surveillance probability at time t is calculated as the product of the conditional
probability till time t.
(2) Comparison of Kaplan-Meier (KM) estimates: log-rank test
The log-rank test is the most common method to compare the difference between
survival curves. Our study applied this test for comparing surveillance colonoscopy use
by patients with the first colonoscopy in two different periods, pre-2006 period vs. 2006
and later. Log-rank test is used to examine whether two periods are statistically different
on probability of surveillance colonoscopy use. This test is to calculate the expected
number of surveillance colonoscopy in the two periods (E1 and E2) against the actual
total number of observed surveillance colonoscopy events (O1 and O2) in the two periods,
respectively. The test statistic is as follow as:

𝐿𝑜𝑔 − 𝑟𝑎𝑛𝑘 𝑡𝑒𝑠𝑡 𝑠𝑡𝑎𝑡𝑖𝑠𝑡𝑖𝑐 =

(𝑂1− 𝐸1 ) (𝑂2− 𝐸2 )
+
𝐸1
𝐸2

Where O1 represents the sum of the observed number of surveillance colonoscopy for the
pre-2006 cohort and E1 represents the sum of the expected number of surveillance
colonoscopy this cohort. Similarly, we can define O2 and E2 with the post cohort.
The test statistic and significance can be drawn by comparing the calculated value
with the critical value, using chi-square tables, at one degree of freedom (Goel et al 2010;
Rich et al 2010) (Goel, Khanna, & Kishore, 2010; Rich et al., 2010).
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(3)Logistic regression model (Wang, Xie, & Fisher, 2009)
The logistic regression model is for binary outcome measures in non-hierarchically
structured data. It has been used in many surveillance colonoscopy studies predicting
adenoma recurrence, as mentioned in the prior chapter. Multinomial logistic regression is
used to predict categorical placement in, or the probability of category membership of a
multi-level dependent variable predicted by multiple independent variables. This model is
also a simple extension of binary logistic regression to accommodate more than two
categories of the dependent variable. Since multinomial logistic regression does
necessitate consideration of the sample size, we should follow sample size guidelines
which indicate a minimum of 10 cases per independent variable (Hosmer & Lemeshow,
1989).
Statistically in logistic regression, the probability of “event” is usually converted to
an odds ratio [p/ (1-p)], resulting in the following logistic regression or logit model:
𝑛

𝑝
𝑙𝑜𝑔𝑖𝑡(𝑝) = log [
] = 𝛽0 + ∑ 𝛽𝑛 𝑋𝑛
1−𝑝
𝑛=1

Where 𝛽𝑛 is the regression slope coefficient of the explanatory variable 𝑋𝑛
The logit model can be expressed in terms of the probability of an event occurring:
𝑝 = Pr(𝑦𝑖 = 1| 𝑋) =

exp(𝑧)
1+exp(𝑧)

or

𝑝=

1
1+exp(−𝑧)

Where z=𝛽0 + ∑𝑛𝑛=1 𝛽𝑛 𝑋𝑛 . Those equations called the logistic function have an S-shaped
distribution, which signifies a non-linear relationship between the outcome probability
and covariates.
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This study will use bivariate and multivariate logistic regression models to determine
the factors that drive the likelihood of having timely surveillance. The main dependent
variable is GuideConcordant, which is whether the surveillance colonoscopy is
guideline-concordant.
Therefore, we mainly test the association between surveillance concordance and the
variables of initial adenoma status, adenoma features (includes the location of largest
adenoma, number of locations with adenoma, the largest size of adenoma, number of
adenomas found in the same colonic segment, and with 2 or more advanced adenoma
characteristics) and insurance status, adjusting for the remaining variables. The model is
as follows:
YGuideline-concordant (Yes vs. No) =β0+ β1×patient gender+ β2×patient age+ β3×patient race+
β4×insurance status+ β5×period relative to guideline + β6×adenoma status+ β7× location
of largest adenoma+ β8× number of location with adenoma+ β9× the largest size of
adenoma+ β10× number of adenomas found in the same colonic segment+ β11× 2 or more
advanced adenoma characteristics+ ɛerror
Then, we use bivariate and multivariate multinomial logistic regression to determine
the factors that drive the likelihood of timely surveillance. The main outcome is
TimelySur, which is surveillance colonoscopy prevalence relative with the guidelines
being overuse, appropriate, or underuse. It mainly tests the association between initial
adenoma status, adenoma features (includes the location of largest adenoma, number of
locations with adenoma, the largest size of adenoma, number of adenomas found in the
same colonic segment, and with 2 or more advanced adenoma characteristics) and
insurance status in relation with timely surveillance, adjusting for the remaining variables.
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Since the outcome variables with 3 categories, we assign appropriate to be reference
group. There are two models are used to discuss. The first model is to compare overuse to
appropriate of surveillance colonoscopy, as follows:
YTimely Surveillance(Overuse vs. Appropriate) =β10+ β11×patient gender+ β12×patient age+ β13×patient
race+ β14×insurance status + β15× period relative to guideline + β16×adenoma status+ β17×
location of largest adenoma+ β18× number of location with adenoma+ β19× the largest
size of adenoma+ β110× number of adenomas found in the same colonic segment+ β111× 2
or more advanced adenoma characteristics+ ɛerror
The second model will compare underuse to appropriate surveillance colonoscopy, as
follows:
YTimely Surveillance(Underuse vs. Appropriate) =β20+ β21×patient gender+ β22×patient age+ β23×patient
race+ β24×insurance status + β25× period relative to guideline + β26×adenoma status+ β27×
location of largest adenoma+ β28× number of location with adenoma+ β29× the largest
size of adenoma+ β210× number of adenomas found in the same colonic segment+ β211× 2
or more advanced adenoma characteristics+ ɛerror

3.5 Steps of data analysis
This section describes the plan for applying the above statistical methods in our study
to answer the research questions. Statistical models are used to examine associations
between the timing of surveillance colonoscopies (dependent variable) and independent
variables of interest. For our two objectives, the following steps will be used for reporting
outcomes in Figures and Tables.
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3.5.1 Dependent and independent variables of interest
Time to surveillance colonoscopy is the dependent variable. Adenoma status,
adenoma features (includes the location of largest adenoma, the number of locations with
adenoma, the largest size of adenoma, number of adenomas found in the same colonic
segment, and with 2 or more advanced adenoma characteristics) and insurance status are
our key independent factors of interest. The control variables include patient
demographics (gender, age, and race), and number of observation years available. P
values of < 0.05 will be considered as statistically significant.
3.5.2 Analysis steps for objective 1
Our first objective is to compare the observed timing of surveillance colonoscopies
relative to the 2006 recommended intervals for patients with an initial colonoscopy in the
pre-2006 period vs. 2006 and later. This section presents the preliminary frequency
distributions to assess the feasibility of answering the research questions.
Identification of study eligible patients with a baseline colonoscopy showing
exclusions from the full patient sample is presented in Figure 4.1. It presents the number
with a second procedure by date of initial colonoscopy of the eligible initial
colonoscopies. The criteria of define appropriate surveillance interval as per guidelines
are shown in Table 4.1. Table 4.2 presents characteristics of the study population at
baseline colonoscopy, including patient gender, age, race, insurance status, and other
variables. The chi-square test will be used to examine the relationship of surveillance
appropriateness with the guideline date (pre-2006 period, vs. 2006 and later).
Then, Kaplan-Meier (KM) curves will be used to estimate the surveillance probability
over time since the initial colonoscopy. The analysis is stratified by the two cohort
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periods relative to guideline date, and by recommended time interval groups based on
findings baseline colonoscopy: ≤ 1-year surveillance, 3-year surveillance, and 5-year
surveillance (Figure 4.2-4.4). Patients who do not qualify for surveillance had a
premature second procedure will also be shown (Figure 4.5). Comparisons of
characteristics between groups will be presented by the log-rank test.
The study will further examine the timing of surveillance colonoscopies relative to
guideline-concordance among the pre-2006 period patients vs. 2006 and later patients,
and by time interval groups at initial colonoscopy. Timing of surveillance colonoscopy
will be stratified into 3 categories: overuse, appropriate, and underuse. A Pearson’s chisquare or Fisher’s exact test will be used to compare the percentages with timely
surveillance, overuse and underuse between pre-guideline and post-guideline cohorts
(Table 4. 3).
3.5.3 Analysis steps for objective 2
Our second objective is to study the factors that determine the likelihood of timely
surveillance. We test our independent variables of interest associated with timely
surveillance, adjusting for the remaining variables.
Characteristics of study subjects with a screening colonoscopy between September 4,
2001 and February 11, 2010 are presented in Table 5.1. Table 5.2 shows the percentage
of surveillance-eligible patients with guideline-concordant surveillance relative to
recommended guidelines (overuse, appropriate, late, and not done). We use the Pearson
chi-square test to profile the study population by features at initial colonoscopy that are
associated with surveillance use (Table 5.2). Then, we identify variables of interest that
drive the likelihood of having a 2nd procedure among total study sample and surveillance93

eligible patients after controlling for the remaining variables presented in Table 5.3 and
5.4. Logistic regression results will be used.
Association of surveillance timing intervals with polyp, patients, and procedurerelated characteristics among surveillance-eligible who completed surveillance by
recommended surveillance intervals are shown in Table 5.5-5.8. Linear regression results
will be applied. The variables of interest associated with the likelihood of the timing of
surveillance colonoscopy relative to recommended intervals after controlling for the
remaining variables will be presented in Table 5.9. Since our primary outcome of interest
has 4 levels, multinomial logistic regression will be performed.

3.6 Preliminary reviews of sample distribution by key dependent and
independent variables
The study presents the preliminary sample distribution by patient demographics,
utilization of surveillance colonoscopy, time intervals to surveillance colonoscopy, and
adenoma features at baseline colonoscopy (location of largest adenoma, number of
anatomic locations with an adenoma, the largest size of adenoma, number of adenomas
within the same colonic segment, and patients with 2 or more advanced adenoma
characteristics). The distributions and the changes made to variable categories for final
analyses, keeping in view cell sizes are shown below.
3.6.1 Characteristics of study population and utilization of surveillance colonoscopy
Of 16,897 eligible patients with an initial colonoscopy, about 56.4% of patients had
an initial colonoscopy in the pre-2006 period. All patients 4,016 (23.8%) had a second
colonoscopy after a mean of 3.5 years (SD 1.7). Majority of patients were female (54.1%),
aged ≥ 50 years (49.5% and 34.2% at age 50-59 years and 60-74 years, respectively), and
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were Black (51.9%). Having insurance coverage may affect the surveillance colonoscopy
use. About 70.7% of patients had private insurance and 17.8% had Medicare coverage.
The majority of the procedures were performed by PCPs (74.0%) (Table 3.5). Regarding
surveillance colonoscopy use, patients with adenoma and advanced adenoma found at
baseline colonoscopy had higher rates of repeat examinations (Table 3.6).
3.6.2 Bivariate distributions relevant to objective 1
Study objective is to compare the timing of surveillance colonoscopies relative to the
recommended surveillance intervals among the pre- and post-guideline cohorts. The time
interval to surveillance is our main dependent variable. Table 3.7 presents timeliness of
surveillance colonoscopy by recommended time interval groups. Among 4,234 eligible
patients for surveillance, most of the patients did not have follow-up screening at <1-year
(51.7%), 1-year (46.3%), and 3-year (48.9%) recommended time interval groups. The
frequency of overuse and underuse which is not done surveillance colonoscopy are
similar in 5-year groups. 1,793 of 12,571 total patients who are not eligible for
surveillance have come back early.
3.6.3 Bivariate distributions relevant to objective 2
Study objective 2 is to examine the factors associated with the likelihood of timely
surveillance. Timeliness of surveillance is our key dependent variable, which is
categorized into overuse, appropriate, and underuse. We pool the various polyp/adenoma
patient groups into the 3 categories based on each patient recommended time and
observed the timing of surveillance. This pooling was done as a Table 3.1. The
frequencies of independent variables of interest show that the majority of the patients had
1-2 adenomas (13.3%) and 3-6 adenomas (9.8%) in the same colonic segment (Table 3.8).
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Regarding the largest size of adenomas found, about 15.6% and 4.6 % of patients had
≤ 5 mm and ≥ 10 mm adenoma found (Table 3.9). Moreover, there were most of the
patients with the largest adenoma had it in the right colon (12.5%). The distribution is
similar for adenomas found in the left colon, rectum, and sigmoid colon (3.5%, 3.9%, and
4.7%, respectively) (Table 3.10). Several polyp features were also identified at the initial
colonoscopy. There were 454 of patients had any adenoma with tubulovillous/villous
(2.7%), 3,826 tubular (22.7%), and 149 high-grade dysplasia (0.9%) features at initial
colonoscopy (Table 3.11).
Overall, these preliminary reviews of the sample distributions guided our scheme for
recoding variables and the models used to address our research questions.
3.6.4 Potential limitations
Overall, our study has some potential limitations relative to our data characteristics.
Our findings may not generalize to the US because we use data comes from a single
endoscopy center in SC. Moreover, the retrospective study design may result in some loss
to follow-up because some patients will have surveillance colonoscopies at other
facilities. Another potential limitation is that the pathology report may not have clearly
identified the number of polyps with different histology because multiple polyps were
recorded within one colonic segment. Finally, our dataset does not document information
on a family history of CRC or comorbiditites, which may drive surveillance colonoscopy
appropriateness.
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Table 3.5 Characteristics of the study population at baseline colonoscopy (n=16,897)
All patients, N (%)
(n=16,897)
Gender
Male
7,673(45.41%)
Female
9,144(54.12%)
Missing
80(0.47%)
Age
40-49
2,755(16.30%)
50-59
8,367(49.52%)
60-74
5,775(34.18%)
Race
White
7,470(44.21%)
Black
8,771(51.91%)
Other/ Unknown
656(3.88%)
Insurance status
Medicare
3,008(17.80%)
Medicaid
525(3.11%)
Private
11,939(70.66%)
Uninsured
1,425(8.43%)
Initial procedure timing
Pre-2006 period
9,526(56.38%)
2006 and later
7,371(43.62%)

Table 3.6 Utilization of second colonoscopy by polyp status at initial colonoscopy
(n=16,897)
Surveillance colonoscopy
Total, N (%)
Yes, N (%)
No, N (%)
(N=4,016)
(N=12,881)
Advanced adenoma
1,683(9.96%)
900(53.48%)
783(46.52%)
Non-advanced
2,551(15.10%)
1,295(50.76%)
1,256(49.24%)
adenoma
Hyperplastic polyp or
5,654(33.46%)
1,045(18.48%)
4,609(81.52%)
normal tissue
No polyp
6,917(40.94%)
748(10.81%)
6,169(89.19%)
*
Missing
92(0.54%)
28(30.43%)
64(69.57%)
*
The definition of missing is without histology information for that polyp.
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Table 3.7 Timeliness of surveillance colonoscopy by time interval groups at initial
colonoscopy*
No
Recommended time
Underuse- Underuse- surveillance
interval groups
Overuse
Appropriate
late
not done
needed
9
357
391
< 1-year (n=757)
0
(1.19%)
(47.16%)
(51.65%)
2
11
16
25
1-year (n=54)
(3.70%)
(20.37%)
(29.63%)
(46.30%)
589
281
97
924
3-year (n=1,891)
(31.15%)
(14.86%)
(5.13%)
(48.86%)
763
43
27
699
5-year (n=1,532)
(49.80%)
(2.81%)
(1.76%)
(45.63%)
10-year rescreening
for overuse
1,793
10,778
10-year rescreening
*
92 missing are without histology information for that polyp. We excluded 1,569 patients
no 2nd procedure due to not completing recommended surveillance interval, including 0
for ≤ 1-year, 3 for 1-year, 556 for 3-year, and 1,010 for 5-year follow-ups.
Table 3.8 Number of adenomas found in the same colonic segment at initial colonoscopy
N (%)
No polyp
6,917 (40.94%)
Hyperplastic polyp or normal tissue
5,654 (33.46%)
1-2 adenomas
2,249 (13.31%)
3-6 adenomas
1,656 (9.80%)
≥ 7 adenomas
283 (1.67%)
Missing
138 (0.82%)
Table 3.9 The largest size of adenoma found at baseline colonoscopy
N (%)
No polyp
6,917 (40.94%)
Hyperplastic polyp or normal tissue
5,654 (33.46%)
≤5mm
2,635 (15.60%)
5.1-9.9mm
774 (4.58%)
≥10mm
768 (4.55%)
Missing
149 (0.88%)

98

Table 3.10 The location where the largest adenoma found at baseline colonoscopy
N (%)
No polyp
6,917 (40.94%)
Hyperplastic polyp or normal tissue
5,654 (33.46%)
Right
2,107 (12.47%)
Left
589 (3.49%)
Rectum
651 (3.85%)
Sigmoid
793 (4.69%)
Missing
186 (1.10%)
Table 3.11 Frequency of patients with any adenoma showing the features of
(1)Tubulovillous/villous adenomas, (2)tubular adenomas, and (3) high-grade dysplasia
features at baseline colonoscopy* (Total patients= 16,897; No polyp=6,917; Hyperplastic
polyp=5,654; Adenomatous polyp=4,234)
Tubulovillous/villous
Tubular adenomas, High-grade dysplasia,
adenomas,
N (%)
N (%)
N (%)
No
3,780(22.37%)
408(2.41%)
4,085(24.18%)
Yes
454 (2.69%)
3,826 (22.65%)
149 (0.88%)
Missing
92 (0.54%)
92 (0.54%)
92 0.54%)
*
Features are not mutually exclusive.

99

CHAPTER 4
AN ASSESSMENT OF COMPLIANCE WITH SURVEILLANCE
GUIDELINES ISSUED BY PROFESSIONAL SOCIETIES, AND
IMPLICATIONS FOR RESOURCE UTILIZATION
Abstract
Background
Colorectal cancer (CRC) can be prevented by population-wide colonoscopy
screening and polyp removal, followed by periodic surveillance of those with
adenomatous polyps. Both overuse (premature) and underuse of colonoscopy
(delayed/not done) are documented. Underuse may undermine CRC prevention while
overuse causes inefficient use of provider workforce and reduced system screening
capacity. We examined the impact of the 2006 U.S. Multi-Society Task Force guidelines
on surveillance timing.
Methods
We studied the timing of surveillance colonoscopies in a community-based cohort of
patients with a screening colonoscopy between September 2001 and February 2010 at a
large endoscopy center in South Carolina, followed through February 2011. We
compared patients with screening colonoscopy done in the pre- and post-2006 periods for
appropriate surveillance use, overuse (delayed surveillance), and underuse (premature or
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not done), classified by recommended surveillance interval category, using chi-square
tests and Kaplan-Meier (KM) estimation with the log-rank test.
Results
Of 16,897 study patients, 4,234 were found to have adenomatous polyps
(surveillance-eligible), of whom 2,195 (51.8%) had a surveillance colonoscopy.
Surveillance timing was inappropriate for 91.8% of patients, being similar in the pre-and
post-guideline periods. Underuse was more likely among ≤1- and 3-year recommended
surveillance groups (p<0.001), and overuse among 5-year recommended surveillance
(p<0.001). Among those without adenomas at screening colonoscopy, 14.3% (1,793 of
12,571 pre-period patients) had a premature second colonoscopy after a mean of 4.65
years, vs. the recommended 10-yearly repeat colonoscopy.
Conclusions
Premature repeat colonoscopies among low-risk patients who do not qualify for
surveillance per guidelines, and premature surveillance colonoscopies in patients with
low-risk polyps consume significant provider resources. Minimizing overuse will spare
scarce provider time for surveillance of high-risk patients at appropriate time intervals
which may improve population outcomes at no extra cost. Underuse among all risk
categories of surveillance-eligible patients should be addressed.
Keywords: Surveillance colonoscopy, time intervals, adenoma features, guideline date.
Introduction
Colorectal cancer (CRC) is the third most common cancer in the United States, and
the second leading cause of cancer death in men and women combined. In South Carolina
during 2015, an average of 2,220 adults are diagnosed and 830 adults die from CRC
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(Siegel, Miller, & Jemal, 2016). Individuals with adenomatous polyps are at risk of
recurrence (metachronous lesions), which may increase the likelihood of cancer.
Screening colonoscopies followed by periodic surveillance is recommended by the joint
guidelines issued by the US Multi-Society Task Force on Colorectal Cancer (USMSTF)
and the American Cancer Society (Winawer et al., 2006).
Surveillance guidelines have changed significantly since 1997, a summary of which is
provided in Table 4.1. In 1997, 3-year surveillance was recommended for patients with
large (>10mm) or multiple adenomas, and no specific guidelines were given for those
with lower-risk adenomas (Winawer et al., 2006). There was no mention of person
without adenomas or those with only hyperplastic polyps. The guidelines became more
specific for the lower risk group (persons with 1-2 small, tubular adenomas) in 2003,
recommending surveillance colonoscopy at 5 years rather than 3 years for this group
(Winawer et al., 2003). In addition, the guidelines cautioned that evidence was still
evolving, and that the interval could be changed with new evidence. The surveillance
recommendations keep updated in the joint guidelines issued in 2006, which remains
valid to date. The increased and lower risk groups were definitively recommended for 3year and 5-year surveillance with an expectation that such definitive risk stratification
would reduce the intensity of surveillance procedures in a substantial proportion of
patients (Winawer et al., 2006). In the US, an estimated 25% of all colonoscopies were
performed for surveillance purposes (Lieberman et al., 2000; Lieberman et al., 2005).
Both overuse (or premature) and underuse (or delayed/not done) of surveillance are
reported, underuse among high-risk adults and overuse among low-risk adults (Cooper et
al., 2013; Schoen et al., 2010). In the Netherlands, which has a universal access, single-

102

payer health system, less than 25% of patients with adenomas received appropriately
timed surveillance as per the Netherlands guidelines (van Heijningen et al., 2015). They
also assessed the influence of a change in the Netherland’s guidelines issued in 2002.
They found that was consistent with the recommendation in 24% of before the guideline
date, vs. 11% of after the guideline date. The practice changed in favor of overuse after
the guideline, while the percentage with underuse remained similar. Underuse threatens
CRC prevention, while overuse causes inefficient use of colonoscopy resources and
reduced screening capacity.
Few studies have evaluated actual adherence to the surveillance guidelines in the US
on a large enough scale to identify patterns stratified by risk group, based on communitybased patient cohorts. The documented studies are based on self-reported patient surveys
(Schoen et al., 2010), small sample sizes (Schreuders et al., 2013), academic medical
center data (Kahn et al., 2015), and nation-wide histopathology registry data from other
countries (the Netherlands) (van Heijningen et al., 2015). One study on surveillance
compliance with guidelines was based on physicians’ self-reported practices in a survey
(Mysliwiec et al., 2004). All studies have excluded persons without adenomas (low risk
population not recommended for surveillance), except for two studies (Menees et al.,
2014; Schoen et al., 2010).
This study evaluated adherence to the 2006 USMSTF-ACS joint guidelines in a
community-based screening cohort stratified by risk, and including surveillanceineligible patients. We used data from a community endoscopy center in South Carolina,
with a documented high CRC prevention rate (Xirasagar et al., 2015). The purpose was to
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document the surveillance practice before the 2006 guidelines and evaluate whether the
guidelines resulted in surveillance practice changes to confirm to guideline.
Methods
We used data from a licensed ambulatory surgery center for endoscopy in Columbia,
South Carolina. The center is largely focused on providing screening and surveillance
colonoscopies to average risk persons. Specifically, patients with inflammatory bowel
disease, prior cancer history, or syndromic, inherited colorectal cancers are not served at
the center. We obtained patient, procedure, and polyp data from the center’s databases
populated by the center staff from patient charts. The center trains primary care
physicians’ (PCPs) in colonoscopy using the gastroenterology fellowship training
protocol used in academic medical centers for credentialing in colonoscopy. Training
includes simulation on a mannequin followed by hands-on training by an endoscopycredentialed expert for the first 140 procedures. Post-training, performance quality and
patient safety are ensured through a clinical performance protocol and technical support
mechanisms that are designed to compensate for PCPs’ lack of formal gastroenterology
training. The center’s polyp detection-maximizing clinical protocol involves a two-person
engagement in the procedure, required to be used by all trained PCPs. PCPs are
credentialed to perform procedures at the center with an expert available on-site for backup or rescue assistance (Xirasagar et al., 2015).
Study design
This is a retrospective cohort study to evaluate the timing of surveillance
colonoscopy based on findings at initial examination. The study period was September 4,
2001 to February 11, 2011. A total of 26,523 screening and second procedure
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colonoscopies were provided to 20,912 patients during the study period. We excluded
997 procedures that were the third or higher colonoscopy for the index patient. We
combined data on second procedures performed within 6 months of the first into the first
procedure data, as those are make-up colonoscopies for sub-optimal completion of the
first procedure, e.g. poor bowel preparation. The exception to this rule was a surveillance
colonoscopy within 6 months recommended for specific risk individuals described below.
The 2006 surveillance guidelines recommend surveillance 2-6 months following the
initial examination for patients with sessile adenomas that were removed piecemeal. We
identified piecemeal removal by a variable “Destroyed=no” in the polyp dataset. The
guidelines recommend 1-year surveillance for patients with hyperplastic polyposis
syndrome or > 10 adenomas; 3-year surveillance for patients with 3-10 adenomas, ≥ 1 cm
adenoma, or any adenoma with villous or tubulovillous features, or high-grade dysplasia;
and, 5-year surveillance for patients with 1 or 2 small (<1cm) tubular adenomas or any
adenoma without advanced features. No surveillance is recommended for patients
without adenomatous polyps or less than 3 small hyperplastic polyps, only rescreening
after 10 years. Based on these timing criteria, we excluded patients without a second
procedure who had not completed the recommended surveillance interval during the
study period (n=1,569). The final study sample consisted of 16,897 eligible study patients
with a screening colonoscopy.
Measures
Time interval to surveillance colonoscopy was the main outcome measure. Patients
without adenomatous polyps or less than 3 small hyperplastic polyps were defined as not
eligible for surveillance. Appropriate surveillance was defined based on the 2006
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guidelines (S. J. Winawer et al., 2006). Timing was classified as appropriate if the
surveillance was within 3 months before or after the recommended due date for the ≤ 1year surveillance group, and within 6 months before or after the due date for the ≥ 2-year
surveillance group (van Heijningen et al., 2015). Early surveillance before the 3- or 6month window was overuse (premature, before due), and delayed beyond the window
was underuse (delayed, or not done). Table 4.2 summarizes the 2006 guidelines
recommending surveillance at five different intervals: <1-year, 1-year, 3-year, and 5-year
surveillance, and 10-year rescreening. The table also shows the operational definitions
used in the study. For patients with multiple polyps, the most severe polyp characteristic
was used to determine the surveillance interval category. Pre-guideline screening
colonoscopies were those done in 2005 or earlier, and the remaining was classified as
post-guideline patients.
All patients, pre- and post-guideline patients were evaluated for surveillance finding
against the 2006 recommendations. Because the purpose was to evaluate provider
practice changes once clear guidelines was issued, the 2006 recommended surveillance
timings was used to assign a patient to overuse, underuse, and appropriate use category.
Statistical analysis
Kaplan-Meier (KM) curves were used to estimate the cumulative probability of
surveillance procedures over time following the screening colonoscopy. Patients were
stratified into pre- and post- 2006 periods, and observed for the second procedure timing
since the initial colonoscopy. The event of interest was having the second procedure
during the study period. Subjects without surveillance are considered censored.
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Study group differences were assessed using chi-square, Fisher’s exact test, and
ANOVA test with a p-value of 0.05 for statistical significance. The log-rank test was
used to compare KM curves of the pre- and post-2006 cohorts on the time-related
probability of surveillance colonoscopy. SAS Version 9.4 statistical software was used
for all analyses. The study was approved by the University of South Carolina Institutional
Review Board.
Results
Study sample characteristics
Of study-eligible procedures, 20,912 were first (screening) procedures and 4,359
were second procedures. Of 20,912 patients, we excluded patients aged below 40 years
and more than 74 years (n=2,343), and cancer detected at first procedure (n=103).
There were 9,526 patients with initial colonoscopy in the pre-guideline period (2005 or
earlier) and 7,371 in the post-guideline period, 2006 and later (Figure 4.1). We classified
patients screened in 2006 into the post guideline group because the earliest possible
surveillance would have been due in the post guideline period (2007 or later) and could
have complied with the guideline.
A total of 16,897 patients were included in the study. The mean follow-up period
was 7.25 (SD, 1.22) years for the pre-guideline cohort and 2.85 (SD, 1.43) years for the
post-guideline cohort. The majority were: female (54.1%), aged ≥ 50 years (83.7%), and
Black (51.9%). Of total screened patients, 4,234 were surveillance-eligible (i.e., had
adenomatous polyps). Of them 2,195 (51.8%) completed a surveillance colonoscopy,
1,635 pre-guideline patients and 560 post-guideline patients. Among those without
adenomas at screening colonoscopy, 14.3% (1,793 of 12,571 patients) had a premature
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second colonoscopy after a mean of 4.65 years. Of the total cohort, 4.8%, 11.2% and
9.1%, were eligible for surveillance at ≤ 1 year, 3 years and 5 years, respectively, and
74.4% were not eligible for surveillance (Table 4.3).
Timeliness of surveillance in the pre- and post-guideline periods
The mean surveillance interval was 2.52 years among surveillance-eligible patients
who completed the procedure, 2.71 years (SD, 1.22) and 1.95 years (SD, 0.99) for the
pre- and post- guideline cohorts, respectively (p<0.001). Among patients who did not
qualify for surveillance and had a premature second colonoscopy, their mean interval was
4.82 years (SD, 1.27) and 2.35 years (SD, 1.22) in the pre- and post- periods, respectively
(p<0.001).
Kaplan-Meier analysis showed that post-guideline patients had, on average, earlier
surveillance compared to the pre-2006 cohorts among the 5-year recommended
surveillance group (p<0.001). Among the no-surveillance recommended group, preguideline patients had a higher probability of premature second colonoscopy than postguideline patients (p<0.001). There was no difference in surveillance timing of the preand post-guideline cohort among the ≤1-year and 3-year surveillance groups. The
Kaplan-Meier surveillance probability curves are shown in Figures 4.2a, b, c, d.
Overall, surveillance timing was inappropriate for 91.8% of patients, similar in the
pre-and post-guideline periods, with 2.8%, 14.9%, and 2.8% of patients recommended for
≤ 1-year, 3-year, and 5-year follow-ups, receiving appropriately timed surveillance.
Delayed or no surveillance occurred for 96.8% and 54.0% of ≤ 1-year and 3-year
recommended surveillance groups. By contrast, among the 5-year recommended group,
49.8% of total group showed overuse, higher among post-guideline patients (61.4%).
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Among patients without adenomas at screening, 1,793 of 12,571(14.3%) patients had a
premature second colonoscopy, 25.7% of pre-guideline patients, and 2.0% of postguideline patients (p<0.001) (Table 4.4).
Discussion
The study found a high rate of deviation (91%) from the 2006 guidelines in a
community-based cohort in South Carolina. About 50% of the cohort did not complete
surveillance within the study period, which is concerning because of the risk of adenoma
recurrence and cancer over their lifetime (Laiyemo et al., 2009; Morelli et al., 2013;
Pinsky et al., 2009; Robertson et al., 2009). However, one study limitation is the
possibility that some of these patients may have undergone surveillance with a different
provider and therefore were not captured by the study.
Among ≤ 1-year and 3-year surveillance recommended groups, delay was the most
common finding (96.8% and 54.0%, respectively). However, 48.7% and 51.1% had
completed surveillance by the end of study period. Overuse (premature) surveillance was
high among the 5-year surveillance groups (49.8% of patients). Overuse was higher in the
post-2006 period (61.4%). Our findings are consistent with another community-based
cohort study, high-risk patients with advanced adenomas (Schoen et al., 2010). The
surveillance timeline adherence rate of 15.8% among the surveillance-eligible is lower
than the rates reported in Canada (33%) and the Netherlands (21%) (Schreuders et al.,
2013; van Heijningen et al., 2015). Both countries have single-payer health systems and
nation-wide, integrated claims or registry databases. In the Netherlands, 63.5% of
surveillance-eligible patients completed surveillance; of whom 21% adhered to the
timeline. Both rates are higher than our study cohort rate of 51% surveillance completion,
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and, among them, 15.8% timeline adherence. The Netherlands guidelines recommend 6year surveillance for patients with one or two adenomas, one year later than the 2006 US
guidelines (Snel & de Wolf, 1988). Both the Canadian and Netherlands studies did not
assess second procedures among patients who do not qualify for surveillance due to lack
of adenomas at screening. In the US, a Medicare claims study documented a second
procedure rate of 61.3% over 5-years among patients with a polypectomy aged over 70
years (histology not known) or having a family history of gastrointestinal neoplasm
(Cooper et al., 2013).
A recent study examined provider adherence to the 2012 USMSTF guidelines in the
physician’s follow-up notes recommending surveillance (Kahn et al., 2015). This study
used data on a 2011-2013 cohort from an academic medical center and reported that
providers recommended surveillance as per the guidelines for 77.4% of patients in the
follow-up notes (Kahn et al., 2015).
Delayed colonoscopy is reasonable and anticipated among ≤ 1-year and 3-year
surveillance groups because the recommended intervals are short. Possible reasons for
delay may be procrastination due to the patient’s experience of discomfort or dislike of
the bowel prep process, or a busy personal schedule (Jones, Devers, Kuzel, & Woolf,
2010; Jones, Woolf, et al., 2010; Medina, McQueen, Greisinger, Bartholomew, & Vernon,
2012). Our finding of overuse (premature surveillance) among the 5-year group in the
post-guideline period, may be due to providers being cautious and defaulting to the
earliest 1997 guidelines (3-year surveillance for patients with large or multiple adenomas,
no recommendation for patients with small adenomas or other advanced histology
features that were acknowledged in the 2003 guidelines) (Winawer et al., 2003; Winawer
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et al., 1997; Winawer et al., 2006). In the 2003 guidelines, high-grade dysplasia is not
mentioned as a surveillance criterion, and a tentative recommendation was made for 5yearly surveillance for patients with 1-2 small adenomas (Table 4.1). These factors,
together with the fast-changing adenoma risk perceptions published during the study
period may have contributed to the heightened, post-2006 overuse of colonoscopy among
the 5-year surveillance group.
Studies have documented providers’ lack of knowledge of guideline revisions, and a
preference for a cautious interpretation of the research evidence used to support the
revised recommendations (Imperiale, 2011; Kruse et al., 2015; Saini et al., 2009). A
recent survey assessed gastroenterologists’ opinions about the 2006 guidelines and the
factors driving their own follow-up recommendations. It found that 11% of
gastroenterologists felt that the guidelines were not adequate to prevent cancer (Patel,
Tong, Ahn, Singal, & Gupta, 2015). Some authors have supported shorter surveillance
intervals because of potentially missed adenomas at screening colonoscopy (Kim et al.,
2012; Nakao et al., 2013). Increasing CRC risk with age, particularly the high risk
beyond 70 years of age may heighten this concern and contribute to early surveillance
(Goodwin et al., 2011; Imperiale, 2011). These factors may explain the significant
overuse observed in our study. To address providers’ lack of knowledge of the guidelines,
it has been suggested that electronic medical record (EMR) systems may provide a
solution, by triggering automated reminders to patients and providers when follow-up is
due (Leffler et al., 2011). Increasing patients’ awareness of the significance of their
adenoma findings and about timely surveillance is also necessary (Sint Nicolaas et al.,
2012).
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An important finding is that 14.3% of patients without adenomas at screening
colonoscopy had a premature second colonoscopy after a mean period of 4.65 years. Of
those, 37.1% (665 out of 1,793) had hyperplastic polyps, mostly small, in the left colon,
and less than three in number. The distribution of these patients by pathology findings at
screening is shown in Table 4.5. A family history of CRC and bowel symptoms could
have caused these premature second procedures. However our data lack this information
that could explain part of the overuse.
There are few studies on the rate of premature second screening colonoscopies in the
US. A Veterans Administration study of physicians’ notes reported that about 9.2 % of
patients with 1 to 2 small (<1cm) non-adenomatous polyps were recommended for a
second colonoscopy before the recommended 10-year interval (Menees et al., 2014).
Because bowel symptoms may prompt a colonoscopy in this age group regardless of the
originally planned follow-up schedule, the actual rate of second colonoscopies may be
similar to the rate observed in our study.
Our study has several strengths. It is one of the few studies to evaluate changes in
surveillance practice in a community-based practice setting in the United States following
the issuance of definitive guidelines. Despite 74.4% (12,571 of 16,897 patients) not
qualifying for surveillance, 14.3% of them had a premature second procedure. This
contributes a large volume of procedures that may occupy provider time with minimal
cancer-reducing value. Another strength of our study is the availability of data on the
total number of adenomatous polyps, including numbers found within a colonic segment
that are typically sent for histology in a single jar. This data field resulted in reclassifying 712 patients from the 5-year surveillance group to the 3-year surveillance
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group (16.8% of the surveillance-eligible sample). Most prior studies of adenoma
characteristics base the number of adenomas on a count of the polyp jars, which is the
data typically found in claims data or the Clinical Outcomes Research Initiative (CORI)
database that is the most widely reported dataset in colonoscopy studies (D. A.
Lieberman et al., 2008).
Our study has several limitations. Our findings may not generalize to the US
population or other endoscopy centers because we used data from one center. The
retrospective study design also entails some loss to follow-up because some patients may
have undergone surveillance colonoscopy at other facilities. However, the center’s
surveillance completion rate of 51.8% is close to the Netherlands’ population-based rate
of 63.5%, and the rate of 61.3% among Medicare beneficiaries with a polypectomy in the
US. Additionally, the study center has a surveillance colonoscopy proportion of 23.8% of
all colonoscopies, compared to 25%, nationally, documented in the US (Lieberman et al.,
2000; Lieberman et al., 2005). These similarities may suggest that the observed
surveillance completion rate at the center may be close to the true surveillance
completion of the cohort.
Another limitation is that because of study period constraints we have shorter followup for post-guideline patients, which may misclassify some of the tardy surveillance
cases as not completed, if they completed it after the study period. Finally, our data lack
family history data and symptomatology data which may account for part of the early
surveillance or premature second screening cases (Schoen et al., 2010). Approximately
11.2% of the population aged 45-70 years has at least one first-degree relative with CRC
(de Jong & Vasen, 2006).
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In conclusion, less than 10% of surveillance-eligible patients received timely
surveillance. Less than 50% surveillance rate (after counting tardy surveillance) among
high-risk patients (recommended ≤1- or 3-year surveillance) indicates that active followup among these patients should be a priority. To accommodate the increased load due to
needed surveillance cases, the current pattern of overuse among the 5-year surveillance
group and no-surveillance recommended group should be addressed. Minimizing overuse
will spare scarce provider time for surveillance of high-risk patients at appropriate time
intervals, which may improve colorectal cancer prevention at no extra cost.

20,912 eligible patients with a 1st procedure
Excluded patients (n=4,015):
2,343 aged < 40 or ≥ 75 years
103 with carcinoma
1,569 patient no 2nd procedure due to not
completing recommend surveillance interval

16,897 study patients*

Screening done Post-2006
7,371

Screening done Pre-2006
9,526

2nd procedure done
(n=3,306)
1,635 surveillance-eligible
1,671 rescreening

No 2nd procedure
(n=6,155)
1,334 surveillance-eligible
4,821 rescreening

2nd procedure done
(n=682)
560 surveillance-eligible
122 rescreening

No 2nd procedure
(n=6,662)
705 surveillance-eligible
5,957 rescreening

Figure 4.1 Study-eligible patients with a screening colonoscopy, and use of
second procedure, pre- and post-2006 guidelines.*92 patients without polyp
histology were not shown.
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Figure 4.2a Cumulative probability of surveillance colonoscopy among the ≤1year surveillance recommended group (pre vs. Post guideline) (P=0.778)

Figure 4.2b Cumulative probability of surveillance colonoscopy among the 3year surveillance recommended group (pre vs. Post guideline) (P=0.169)
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Figure 4.2c Cumulative probability of surveillance colonoscopy among the 5year surveillance recommended group (pre vs. Post guideline) (P<0.001)

Figure 4.2d Cumulative probability of surveillance colonoscopy among the nosurveillance recommended group (pre vs. Post guideline) (P<0.001)
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Table 4.1 Details of the 1997, 2003, and 2006 surveillance guidelines recommendations
Surveillance interval
recommendation
1997 recommendations
Large (≥1cm), multiple adenomas
3 years
Lower-risk adenomas (1-2 small adenoma,<1cm)
No specific guidelines
High-grade dysplasia or villous features
No specific guidelines
2003 recommendations
Numerous adenomas, a malignant adenoma (with
A short interval (based on
invasive cancer), a large sessile adenoma
clinical judgment)
Large (≥1cm), villous adenoma, ≥3 adenomas
3 years
1-2 small (<1 cm) tubular adenomas
5 years (but noted that
change in light of evidence
is evolving)
High-grade dysplasia
No specific guidelines
2006 recommendations
Sessile adenomas that are removed piecemeal
2-6 months
a) Hyperplastic polyposis syndrome*
1 years
b) >10 adenomas
a) 3-10 adenomas
3 years
b) adenoma ≥1 cm
c) any adenoma with villous features or high-grade
dysplasia
a) 1 or 2 small (<1 cm) tubular adenomas with low-grade
5 years
dysplasia
b) Any adenoma without advanced features
a) Small (<1 cm) rectal hyperplastic polyps
10-year rescreening
b) Normal tissues (include few hyperplastic polyps or no
(no surveillance)
polyp)
*

Hyperplastic polyposis is defined as: (1) at least 5 histologically diagnosed hyperplastic polyps proximal
to the sigmoid colon, of which 2 are greater than 1cm in diameter, or (2) any number of hyperplastic polyps
occurring proximal to the sigmoid colon in an individual who has a first-degree relative with hyperplastic
polyposis, or (3) more than 30 hyperplastic polyps of any size distributed throughout the colon. Since our
study does not have data on first-degree relatives, we included the first and third criteria to define
hyperplastic polyposis (Burt & Jass, 2000).
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Table 4.2 Operational definitions used for classifying surveillance colonoscopy as
appropriate, overuse, and underuse *
Surveillance interval
Operational study definitions of
recommendation
appropriate timing
(in years)
(in years)
Polyp types
1) Small (<1 cm) rectal
No surveillance,109.5-10.49
hyperplastic polyps
years rescreening
2) Normal tissues
(include few hyperplastic
polyps or no polyp)
Surveillance timelines category
(time interval in years)
1) 1 or 2 small (<1 cm)
5
4.5-5.49
tubular adenomas with
(<4.5 years=overuse,
low-grade dysplasia,
>5.49 years=underuse)
2) Any adenoma without
advanced features
1) 3-10 adenomas,
3
2.5-3.49
2) adenoma ≥1 cm,
(<2.5 years=overuse,
3) any adenoma with
>3.49 years=underuse)
villous features or highgrade dysplasia
1) Hyperplastic polyposis
1
0.75-1.25
**
Syndrome
(<0.75 years=overuse,
2) >10 adenomas
>1.25 years=underuse)
Sessile adenomas that are
2-6 months
0-0.75
removed piecemeal
(<0 years=overuse,
>0.75 years=underuse)
*

The criteria used for classifying surveillance colonoscopy timing are based on the 2006 guidelines
{Winawer, 2006 #62}.
**
Hyperplastic polyposis is defined as: (1) at least 5 histologically diagnosed hyperplastic polyps proximal
to the sigmoid colon, of which 2 are greater than 1cm in diameter, or (2) any number of hyperplastic polyps
occurring proximal to the sigmoid colon in an individual who has a first-degree relative with hyperplastic
polyposis, or (3) more than 30 hyperplastic polyps of any size distributed throughout the colon. Since our
study does not have data on first-degree relatives, we included the first and third criteria to define
hyperplastic polyposis {Burt, 2000 #227}.
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Table 4.3 Study population at screening colonoscopy, classified by date of screening
colonoscopy, pre- or post-guideline (n=16,897) **
Date of screening colonoscopy
Pre-2006
Total
period
2006 and later
(n=16,897)
(n=9,526)
(n=7,371)
Patient characteristics
Gender*
7,673(45.4%)
Male
4,304(45.2%)
3,369(45.7%)
9,144(54.1%)
Female
5,143(54.0%)
4,001(54.3%)
80(0.5%)
Missing
79(0.8%)
1(0.0%)
*
Age(years)
2,755(16.3%)
40-49
1,447(15.2%)
1,308(17.8%)
8,367(49.5%)
50-59
4,642(48.7%)
3,725(50.5%)
5,775(34.2%)
60-74
3,437(36.1%)
2,338(31.7%)
*
Race
7,470(44.2%)
White
4,166(43.7%)
3,304(44.8%)
8,771(51.9%)
Black
4,829(55.1%)
3,942(44.9%)
656(3.9%)
Other or unknown
531(5.6%)
125(1.7%)
*
Insurance status
525(3.1%)
Medicaid
322(3.4%)
203(2.8%)
3,008(17.8%)
Medicare
1,750(18.4%)
1,258(17.1%)
11,939(70.7%)
Private
6,238(65.5%)
5,701(77.3%)
1,425(8.4%)
Uninsured
1,216(12.8%)
209(2.8%)
*
Recommended surveillance interval
757(4.5%)
<1-year surveillance
523(5.5%)
234(3.2%)
54(0.3%)
1-year surveillance
23(0.2%)
31(0.4%)
1,891(11.2%)
3-year surveillance
1,132(11.9%)
759(10.3%)
1,532(9.1%)
5-year surveillance
1,291(13.6%)
241(3.3%)
No surveillance recommended
12,571(74.4%)
(10-year rescreening only)
6,492(68.2%)
6,079(82.5%)
92(0.5%)
Missing
65(0.7%)
27(0.4%)
5.33(2.55)
Mean person year of observation
7.25(1.22)
2.85(1.43)
*

P<0.05 for tests of difference between guideline date and characteristics of study population, using Chisquare tests.
**
Mean screening follow-up was 7.25 years for pre-guideline group (range,5.11-9.44; SD,1.22) and 2.85
years for post-guideline group (range,0.02-5.11, SD,1.43).

119

120

Table 4.4 Timing of surveillance colonoscopy relative to the 2006 recommended surveillance intervals among the pre-guideline and
post-guideline cohorts (pre- vs. post- guidelines)
Overuse
Appropriate
Late
Not done
10-year
Recommended surveillance
(Premature before
(Timing as
(Delayed relative to
(by end of
rescreening group
interval group
being due)
recommended)
recommendation)
study period)
(Not screening)
Total all surveillance groups
(n=4,234) *
1,355(32.0%)
347(8.2%)
493(11.6%)
2,039(48.2%)
Total Pre-2006(n=1,291)
970(32.7%)
255(8.6%)
410(13.8%)
1,334(44.9%)
Total Post-2006(n=241)
385(30.4%)
92(7.3%)
83(6.6%)
705(55.7%)
Total ≤ 1-year surveillance
(n=811) *
3(0.4%)
23(2.8%)
369(45.5%)
416(51.3%)
Pre-2006 (n=546)
2(0.4%)
9(1.7%)
297(54.4%)
238(43.6%)
Post-2006 (n=265)
1(0.4%)
14(5.3%)
72(27.2%)
178(67.2%)
Total 3-year surveillance
(n=1,891) *
589(31.2%)
281(14.9%)
97(5.1%)
924(48.9%)
Pre-2006 (n=1,132)
353(31.2%)
203(17.9%)
86(7.6%)
490(43.3%)
Post-2006(n=759)
236(31.1%)
78(10.3%)
11(1.5%)
434(57.2%)
Total 5-year surveillance
(n=1,532) *
763(49.8%)
43(2.8%)
27(1.8%)
699(45.6%)
Pre-2006(n=1,291)
615(47.6%)
43(3.3%)
27(2.1%)
606(46.9%)
Post-2006(n=241)
148(61.4%)
0
0
93(38.6%)
Total 10-year rescreening
group(No need for surveillance)
(n=12,571) *
1,793(14.3%)
10,778(85.7%)
Pre-2006 (n=6,492), Mean
follow-up period=7.27 (1.25)
1,671(25.7%)
4,821(74.3%)
Post-2006(n=6,079) , Mean
follow-up period=2.70 (1.44)
122(2.0%)
5,957(98.0%)
*

P<0.05 for tests of difference between guideline date and appropriateness of interval time, using Chi-square test and Fisher's exact test.

CHAPTER 5
PATIENT VARIABLES AND PROFESSIONAL SOCIETY
GUIDELINES DRIVING THE TIMING OF SURVEILLANCE
COLONOSCOPY AMONG AVERAGE-RISK SCREENING
PATIENTS
Abstract
Background
Well-performed colonoscopy can prevent colorectal cancer (CRC). Because of the
higher risk of adenoma recurrence or CRC, surveillance colonoscopy is recommended in
all patients with a history of high-risk polyps. The factors driving the actual patterns of
surveillance use remain unclear. Understanding the extent to which individual risk factors
influence surveillance compliance and the timing decision is important to improve
adherence and reduce cancer incidence.
Methods
This is a retrospective, cohort study of patients with a screening colonoscopy at a
community-based endoscopy center between September, 4, 2001 and February, 11, 2010,
observed through February 2011. Surveillance overuse (premature) and underuse
(delayed or not done) were defined based on surveillance completion earlier, or later than
guideline-recommended intervals (5-year and ≤3-year recommended groups based on
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risk2006 guidelines). We used logistic and linear regression modeling to identify the
patient, polyp and procedure factors associated with surveillance timing, including
possible risk factors not specified in the guideline in making the recommendations.
Results
Of 16,805 study-eligible patients, majority were female (54.1%), aged 50-59 years
(48.5%), Black (51.9%), and had Medicare or private insurance (88.5%). Of 4,234
surveillance-eligible patients, 2,195 patients (51.8%) had a surveillance colonoscopy.
Only 8.2% (347 of 4,234) surveillance-eligible patients were compliant with guidelinerecommended timing. Adjusted analysis showed that overuse was more likely among the
5-year surveillance group (OR: 14.39; 95%CI: 10.03-20.64) relative to the ≤3-year
surveillance group. Other significant factors predicting overuse were having a large
adenoma (OR: 1.81; 95%CI: 1.25-2.63), having multiple advanced adenoma
characteristics (OR: 2.26; 95%CI: 1.30-3.93), and post-guideline period (OR: 1.73;
95%CI: 1.30-2.31). Delayed surveillance was more likely among patients with the largest
adenoma found in the right colon (OR: 1.49; 95%CI: 1.12-1.98) and Medicaid
beneficiaries (OR: 3.22; 95%CI: 1.14-9.09). Within the ≤3-year surveillance group,
patients with adenomas larger than 5 mm, or multiple advanced characteristics were more
likely to have early surveillance. Among those not eligible for surveillance, premature rescreening (before 10 years) was associated with having a non-adenomatous polyp (vs. no
polyp) and higher age.
Conclusions
Contrary to expectations, surveillance overuse increased following the issuance of
surveillance guidelines, after adjusting for adenoma-based risk factors at screening
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colonoscopy. The findings suggest that concerns about individual patients’ cancer risk
beyond the criteria used in surveillance guidelines may underlie many decisions of
premature surveillance. Lack of family history data is a study limitation, which could
account for part of the premature surveillance cases. Significant underuse among
Medicaid beneficiaries exists, and should be explored to identify the barriers to
surveillance in this group.
Keywords: Surveillance colonoscopy, polyp features, insurance status, initial procedure
year.
Introduction
Colorectal cancer (CRC) is the third leading cancer in the United States, with nearly
50,000 deaths in 2015 (ACS, 2015). In South Carolina, an estimated 2,220 new cases and
830 deaths are expected in 2016 (Siegel et al., 2016). Well-performed screening
colonoscopies help prevent cancer through visualization of the entire colonic surface and
removal of precancerous polyps (adenomas) (Winawer et al., 1993; Xirasagar et al., 2015;
Zauber et al., 2012). Screening colonoscopy followed by colonoscopic surveillance for
patients with adenomatous polyps is recommended, because of the risk of adenoma
recurrence and cancer (Leung et al., 2010; Pinsky et al., 2009). Surveillance guidelines
were updated by the U.S. Multi-Society Task Force (USMSTF) and American Cancer
Society in 2006, which emphasized risk stratification by polyp features at screening
colonoscopy in recommending surveillance intervals following screening colonoscopies
(Winawer et al., 2006).
Although evidence supports that colonoscopic polypectomy can reduce cancer
incidence, the time to surveillance colonoscopy in practice varies from the guideline
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recommended intervals. The literature shows overuse of surveillance (too early) among
low-risk adults and underuse (delayed) among high-risk adults (Schoen et al., 2010; Sint
Nicolaas et al., 2013). The purpose of efforts to increase guideline concordance is to
achieve higher adenoma detection, and to emphasize that overuse of surveillance does not
increase cancer prevention (Sint Nicolaas et al., 2013). Understanding the factors driving
overuse or underuse may help to identify patient groups at risk for inappropriate
surveillance timing, and alert providers and patients about the risks of unnecessary
colonoscopies or delaying surveillance.
Previous studies of surveillance have mostly examined pre-2006 cohort data
(Lieberman et al., 2008; Lieberman et al., 2007; Martinez et al., 2009). Most studies did
not account for patient and screening procedure characteristics that may influence
physicians’ recommendations for follow-up procedures (Ko et al., 2010; Laiyemo et al.,
2010; Lieberman et al., 2008). Moreover, studies of surveillance practice compared to
guidelines have used patient survey data with no data on polyp features (Saini et al.,
2009), small sample sizes (Kim et al., 2012), or cohorts from academic medical centers
which may be more up-to-date with the latest practice guidelines (Kahn et al., 2015).
There is little documentation on surveillance practices as compared to guideline
recommendations at community-based endoscopy centers, and no literature on
“surveillance” of patients who do not qualify for surveillance based on the professional
society guidelines.
This study seeks to identify the patient-level factors associated with surveillance
colonoscopy completion and timing, adjusting for the professional society guideline date.
Patient-level factors may be: polyp features at screening that are not used as risk criteria
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by the guideline issuing society in recommending the surveillance intervals, patient
demographics, or procedure-related factors. We used data from a large cohort served at a
community endoscopy center in South Carolina, which has a documented high rate of
CRC prevention among its screened patients (Xirasagar et al., 2015).
Methods
Study population and sample selection
This is a retrospective cohort study of patients provided screening colonoscopy at a
community-based endoscopy center between September 4, 2001, and February 11, 2010,
observed through February 2011. The center mainly uses colonoscopy-trained primary
care physicians (PCPs) who bring their screening-eligible, primary care patients for
screening and surveillance colonoscopy at a licensed endoscopy center. As a general
policy, the center mainly focuses on screening colonoscopies of average-risk patients and
their surveillance (those without inflammatory bowel disease, prior cancer history, or
syndromic, inherited colorectal cancers). The center’s polyp detection-maximizing
clinical protocol requires a 2-person technique, required to be used by all PCPs who
perform procedures at the center, with an expert on site for back-up assistance (Xirasagar
et al., 2015).
Polyp features at screening, patient demographics, and procedure-related
characteristics were obtained from center’s administrative and medical databases. We
reviewed a total of 26,523 screening and second procedure colonoscopies provided to
20,912 patients during the study period. Third or higher order procedures provided to a
patient were excluded (n=997). Further, we combined data from 225 second procedures
performed within 6 months of the first procedure into the first procedure data because
these are make-up procedures for sub-optimal first procedure. Of study-eligible
125

procedures, 20,912 were the screening procedure. Of those 20,912 patients, we excluded
2,343 aged < 40 or ≥ 75 years, and 103 patients with cancer found at screening
colonoscopy.
We adjusted for guideline date by classifying patients into a variable, guideline
concordance. The variable categories were overuse, delayed, and not done relative to the
recommended surveillance interval per the 2006 joint guidelines of the U.S Muti-Society
Task Force (USMSTF) on Colorectal Cancer and the American Cancer Society (Winawer
et al., 2006). The guidelines recommend surveillance examinations after <1-year, 1-year,
3- years, and 5-years, depending on polyp characteristics at screening. Based on these
timings, 1,569 patients who had not completed their recommended surveillance interval
by the end of study period were excluded from study.
Measures
We had three primary outcomes of interest: any second colonoscopy (yes/no), the
timing of the second colonoscopy relative to the screening procedure (categorized into
overuse, appropriate, late or not done), and time interval since screening (continuous
variable, years). Consistent with a documented study, we defined guideline concordant
surveillance if the procedure took place within a range of ±3 months from due date for
the ≤ 1-year surveillance-recommended group, and ±6 months for >1 year surveillance
group (van Heijningen et al. 2015). Overuse was surveillance earlier than the range,
(premature relative to guideline), delayed (later than the range), and not done, as of the
end of study period.
Polyp findings at screening colonoscopy, patient insurance status, and screening
procedure year (pre- or post-guideline) were our main independent variables of interest.
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Patient adenoma status was defined by their most advanced adenoma at screening
procedure (if they had more than one adenoma). Patients with advanced characteristics
were those with ≥ 3 adenomas of any size, an adenoma with >25% villous features,
adenoma of 1 cm or more, or high-grade dysplasia (Winawer & Zauber, 2002; Winawer
et al., 2006). According to the 2006 guidelines, patients with advanced adenoma
characteristics by histology and ≥3 adenomas are recommended surveillance at 3 years.
We identified patients with 3 or more adenomas using two variables; we summed the
polyp jars reported with adenoma histology, and identified those with 3 or more
adenomas in the same colonic segment using another data field, Polyp quantity which is
specified for each segment represented by a single polyp jar.
We explored the potential role of adenoma features that are not assigned as high-risk
adenomas meriting a specific surveillance recommendation. These were: location of the
largest adenoma (right vs. left), number of colon anatomic locations found to have
adenoma,(1-2 vs. 3-4 locations), the largest size of the patient’s adenomas (≤5mm, 5.19.9mm, and ≥10mm), number of adenomas found in the same colonic segment (1-2
adenomas and ≥ 3 adenomas), and presence of ≥ 2 advanced adenoma characteristics
(yes/ no). Insurance was classified into Medicaid, Medicare or private, and uninsured.
Finally, we defined patients based on their screening year, before 2006, pre-guideline,
and 2006 or later, post-guideline.
Statistical analysis
Multiple logistic and multinomial logistic regressions were performed to identify the
factors associated with the likelihood of any second procedure, and of timely surveillance
(overuse, late, not done). We also assessed the association of surveillance interval as a

127

continuous variable (in years) with the patient, procedure, and polyp characteristics. SAS
Version 9.4 was used for statistical analysis and a p-value < 0.05 was used.
Results
Patient characteristics
A total 16,805 patients with a screening colonoscopy were studied after excluding
92 patients with missing histology. The demographic distribution of patients, screening
period (pre- or post- guideline) and polyp characteristics at screening colonoscopy are
presented in Table 5.1. Of the total sample, 4,234 (23.7%) were eligible for surveillance,
and 2,195 (51.8%) had completed surveillance colonoscopy. Of 12,571 patients who
were not eligible for surveillance, 1,793 (14.3%) had a premature second procedure
(within 10 years).
Of the total sample, majority (54.1%) were female, Black (51.9%), and the largest age
group (48.5%) was 50-59 years. Most had private or Medicare insurance (88.5%). The
majority of the sample (56.3%) had their screening procedure in the pre-2006 period. Of
surveillance-eligible patients, 48.7%, 51.1% and 54.4% of the 1-year, 3-year and 5-year
surveillance groups had completed the second procedure (Table 5.2). The mean followup period was 5.3 years (±2.6), 7.25 years for the pre-guideline cohort (±1.2) and 2.85
years for the post-guideline cohort (±1.4), not reported in the table.
Adherence to recommendations among surveillance-eligible patients
Table 5.2 shows that overall, 8.2% (347 of 4,234) had appropriate timing of
surveillance, 32.0% had overuse, 11.6% had delayed procedures, and 48.2% of
surveillance-eligible patients did not complete it by the end of the study period. Overall
among the surveillance-eligible, 61.7% (1,355 of 2,195) of those who completed
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surveillance had overuse (earlier than recommended surveillance). Table 5.2 also shows
the demographic distribution of adherent and non-adhering patients. The mean
surveillance interval was 2.37, 2.22, and 2.94 years among the ≤1-year, 3-year, and 5year surveillance groups, respectively (not shown in the tables).
Table 5.3 presents the adjusted likelihood of a second procedure among the sample.
Older persons (aged over 50 years, ORs, 1.42,1.23), and Blacks (OR: 1.22; 95% CI: 1.071.39) were more likely to complete the second procedure, as was the 5-year surveillance
group (compared to the ≤1-year group, OR, 1.26, 95%CI 1.06-1.51), patients with
multiple advanced adenoma characteristics (OR, 1.64; 95% CI, 1.28-2.11), undergone
screening in the pre-guideline period (OR: 1.61), and those with private/Medicare
insurance (OR 1.29 95%CI: 1.04-1.61).
Predictors of earlier surveillance than recommended within risk categories
Analyses were done within each risk category represented by the recommended
surveillance interval. Table 5.4 presents the associations of surveillance time interval
(continuous variable) among those who completed surveillance. Post-guideline patients
had, on average, 6-6.8 months earlier surveillance. Patients with adenomas larger than
5mm, and those with multiple advanced adenoma characteristics were associated with
earlier surveillance (2.8-7.8 months earlier, represented by coefficient estimates 0.23 and
0.65 respectively).
Table 5.5 presents the results of adjusted analyses of overuse (early), delayed
surveillance, and surveillance not done among the surveillance eligible. Factors driving
overuse were post-guideline period, being in the 5-year surveillance group, larger
adenoma size, and having multiple advanced adenoma characteristics. Factors driving
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delayed surveillance were Medicaid, and adenoma located in the right colon. Factors
associated with not completing surveillance were post-guideline period, and being in the
5-year surveillance group.
The odds of non-completion of surveillance (vs. completion) are shown in Table 5.6.
Non-completion was less likely among those of younger age (50-59 years), Blacks,
Medicare or private insurance, belonging to the 5-year surveillance group, and having
multiple advanced adenoma characteristics, all consistent with the findings for overuse.
Non-completion was more likely among post-guideline patients.
Premature second procedure among those not eligible for surveillance
Table 5.7 shows the adjusted likelihood of a second procedure among those who
were not eligible for surveillance. Older persons (aged over 50 years, ORs, 1.33-1.58),
Blacks (OR: 1.59; 95% CI: 1.41-1.78), pre-guideline period (OR: 16.7), and having a
polyp (hyperplastic or normal tissue, ORs, 2.03 and 2.47, respectively) were associated
with increased likelihood of a second procedure. Of 1,793 persons who had a second
procedure, 93.2 % were from the pre-guideline period, and 37.1 % (665 patients) had
hyperplastic polyps (table not shown).
Discussion
Our study found that 51.8% of surveillance-eligible patients had completed a
surveillance procedure, although guideline-concordance of timing was very low (8.2%).
The surveillance completion rate is similar to the documented rate of 53.9% among a
National Cancer Institute - recruited community-based screening cohort of the Prostate,
Lung, Colorectal, and Ovarian (PLCO) cancer screening trial, followed up for a median
period of 8.9 years, compared to 5.3 years of mean follow-up in our study (Schoen et al.,
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2010). Within the risk sub-groups, our study found that 51.1% of the 3-year surveillance
group and 54.4% of the 5-year surveillance group had completed surveillance, compared
to 58.2% and 46.7% respectively among the PLCO study participants. The differences in
rates are consistent with the shorter follow-up period in our study; this is supported by
our finding that the post-guideline cohort had a lower adjusted likelihood of surveillance
completion. The post-guideline cohort had a mean follow-up period of 2.9 years
compared to 7.3 years for the pre-guideline cohort.
Regarding surveillance timing concordance, a Canadian academic medical center
study reported a 33% rate of guideline timing concordance among 265 patients who
completed surveillance (Schreuders et al., 2013). Comparatively our rate of guideline
concordant timing among those who completed surveillance is 15.8% (347 out of 2,195
patients). A Netherlands study reported 21% timing concordance among 2,997
surveillance-eligible patients in their national registry, compared to our corresponding
rate of 8.2% (van Heijningen et al., 2015). The US has a shorter recommended
surveillance interval for persons with 1-2 adenomas (5 years) compared to the
Netherlands (6 years). The Netherlands and Canada have a universal healthcare coverage
system. Among patients with advanced adenomas, the Canadian study reported 29%
completing surveillance on time, and the Netherlands reported 18%, compared to 29.1%
in our study (281 out of 967) (Schreuders et al., 2013; van Heijningen et al., 2015).
The PLCO study of the US did not explore timing concordance with the guidelines.
Our study adds to the literature by presents the timing concordance with guidelines in the
US, and further, examined the role of specific polyp and patient characteristics that may
have influenced the physician’s individual patient recommendation or the patient’s
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compliance. We found that within each surveillance risk group, polyp characteristics that
are not identified as risk criteria in the surveillance guidelines may be driving at least a
part of the earlier-than-recommended surveillance. Patients with larger adenoma sizes,
and those with multiple advanced adenoma characteristics are receiving earlier than
recommended surveillance, about 6 months earlier. These findings suggest that the
practicing clinician may be considering the individual patient’s risk of developing cancer
based on polyp features in tailoring the surveillance recommendation.
Our finding is also consistent with a recent study of physician recommendations for
surveillance following screening at an academic medical center. They showed that
patients with more than three adenomas were more likely to be recommended earlier than
guideline-suggested surveillance (overuse) (Kahn et al., 2015). Our findings are also
consistent with another study that reported increased overuse among patients with dual
advanced features (co-existing high-grade dysplasia and large size) (Zhan et al., 2015). A
higher risk of adenoma recurrence or cancer among patients with advanced adenomas is
documented by several authors (Laiyemo et al., 2008; Lieberman et al., 2007; Saini et al.,
2006).
Our finding of overuse (early surveillance) among patients with 5-year recommended
intervals (compared to 3-year) is consistent with other studies (Saini et al., 2006;
Schreuders et al., 2013; van Heijningen et al., 2015). The high overuse rate among the 5year group, post-guideline (which changed the recommendation for this group from 3
years to 5-years) may reflect a persistent effect of the 1997 guidelines. These guidelines
recommended 3-year surveillance among patients with large (>10mm) or multiple
adenomas and remained silent about patients with 1-2 small adenomas (Winawer et al.,
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1997). While the 2003 guidelines indicated a timing of 5 years for “lower-risk” patients
(1-2 small tubular adenomas), it also emphasized that the evidence was still evolving and
that the recommended interval could change with new evidence. Part of the 14.3%
“surveillance” among the no-surveillance recommended group may be attributable to a
family history of CRC (data not available) and the lack of definitive guidelines before
2006. It should be noted that 93.2% of patients who underwent premature second
procedures were screened before 2006.
Other authors have suggested that overuse may partly be driven by concerns about
interval CRCs arising from lesions missed at screening colonoscopy, prompting earlier
surveillance among patients with elevated risk status (Saini et al., 2009). Concurrent with
overuse, underuse is also a problem, with 48.2% not completing surveillance. A new
finding is that right colon adenomas are associated with delayed surveillance (compared
to left-sided adenoma). This is contrary to the expected overuse for this group, they have
a 2-fold risk of advanced neoplasia at surveillance (Laiyemo et al., 2008; Martinez et al.,
2009). Notably, this finding appears to be confounded by race. When race was included
in the model and anatomic location was excluded, Black race was associated with the
same coefficient estimate as anatomic location. When both were included, the anatomic
location showed significance and race lost significance. Because Blacks are more likely
to have right-sided adenomas (Nouraie et al., 2010) and given the nearly 50% excess
CRC mortality experienced by Blacks, our finding needs further study with a larger
sample size and multi-center studies.
Medicaid was associated with delayed surveillance, which is consistent with studies
showing underuse of screening for all cancers, presentation with later stage CRC, and
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worse CRC survival among Medicaid beneficiaries (Parikh, Robinson, Zaydfudim,
Penson, & Whiteside, 2014; Shapiro et al., 2012; Ward et al., 2008). Our finding may
support why late stage diagnosis and poorer survival is taking place among Medicaid
beneficiaries. Further analysis of our data showed that Medicaid beneficiaries have a
higher frequency of advanced adenoma than private insurance (11.8% vs. 9.2%,
respectively, p<0.001), which may play into late-stage CRC diagnosis and poorer
survival when combined with delayed surveillance.
An important new contribution is our reporting on “surveillance” among those not
eligible for surveillance, with a 14.3% rate of second procedures that represent premature
re-screening. This needs further exploration in datasets with family history data. One
study reported that 9.2 % of surveillance-ineligible patients were recommended by their
physician for an early second procedure. No data was reported on completed second
procedures (Menees et al., 2014). Another new contribution of our study is that it
accounted for all adenomas including multiple adenomas within a colonic segment, and
accounted for co-existing, multiple advanced adenoma characteristics. Most studies have
not reported on co-existing multiple characteristics that qualify for an advanced adenoma
designation. They identified one advanced characteristic among a patient’s adenomas and
used a single feature for analysis (Lebwohl, Capiak, Neugut, & Kastrinos, 2012). Unlike
studies based on claims data or the Clinical Outcomes Research Initiative (CORI)
database (Lieberman et al., 2008), our data has complete information on the number of
polyps removed from each anatomic segment, enabling us to more accurately account for
all adenomas found. We identified an additional 712 patients as increased risk patients
based on the criterion of ≥ 3 adenomas, beyond what was possible with counting the
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number of polyp jars with a reported adenoma histology. Our study also did not limit
analysis to the features of the largest adenoma, typical of other studies on colonoscopy
findings (Lebwohl et al., 2012).
The reason for significant overuse in the post-guideline period among the 5-year
surveillance group, 61.4% vs. 47.6% in the pre-period (not shown in tables) needs further
study based on regional or multi-center samples. We could not explore the possible role
of a family history of CRC due to lack of this data, a major study limitation. One study
showed that screened patients with a family history of CRC are twice more likely to have
completed surveillance than those without a family history (Schoen et al., 2010).
Comorbidity is may be another consideration among both patients and providers in the
surveillance decision. We could not study its role as data are not available. We also did
not study provider factors in surveillance timing adherence as this is a single-center study.
Provider factors are important due to varying levels of awareness, knowledge, and
attitudes about practice guidelines across providers (Imperiale, 2011; Kruse et al., 2015;
Saini et al., 2009).
Another study limitation is that the pathology reporting did not specify the number of
polyps with differing histology within the same jar. The center transports multiple small
polyps within a colonic segment with similar morphologic appearance in one polyp jar
for histology, per standard practice consistent with insurer reimbursement criteria
(Zauber, 2010). We assumed that reported adenoma histology applied to all polyps in the
same jar. We also had fewer observation years to track surveillance use among postguideline patients (post-2006 period). This may have biased the observed completion rate;
post-guideline patients indeed had higher odds of non-completion. Finally, we did not
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distinguish patient’s insurance status at surveillance colonoscopy, which may play a role
in surveillance use.
In conclusion, patients with adenomas larger than 5 mm, and multiple advanced
characteristics, not captured by the 2006 guideline criteria, were associated with
premature surveillance. Further, surveillance overuse was most prevalent among the 5year recommended surveillance group. These factors need more exploration in multicenter studies, and data with family history, comorbidities, and symptomatology
information. Finally, our study also suggests a need to understand and reduce the barriers
to surveillance colonoscopy faced by Medicaid beneficiaries.
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Table 5.1 Study eligible patients with screening colonoscopy between Sep 4, 2001 and
Feb 11, 2010 (n=16,805)
Had 2nd colonoscopy

Patient characteristics
Gender*
Male
Female
Missing
Age at screening colonoscopy (years) *
40-49
50-59
60-74
Race*
White
Black
Other or unknown
Insurance status at screening colonoscopy*
Medicaid
Medicare or Private
Uninsured
Procedure-related characteristics
Initial procedure year*
Pre-2006 period (pre
guideline)
2006 and later
No surveillance recommended
(10-year rescreening only)
Total surveillance-eligible*
≤1-year surveillance **
3-year surveillance **
5-year surveillance **
Number of observation years per patient#
(mean, SD)

Total
(n=16,805)

Yes
(n=3,988)

No
(n=12,817)

7,629(45.4%)
9,096(54.1%)
80(0.5%)

1,993(26.1%)
1,993(21.9%)
2(2.5%)

5,636(73.9%)
7,103(78.1%)
78(97.5%)

2,746(16.3%)
8,322(48.5%)
5,737(34.1%)

476(17.3%)
1,945(23.4%)
1,567(27.3%)

2,270(82.7%)
6,377(76.6%)
4,170(72.7%)

7,433(44.2%)
8,721(51.9%)
651(3.9%)

1,678(22.6%)
2,178(25.0%)
132(20.3%)

5,755(77.4%)
6,543(75.0%)
519(79.7%)

522(3.1%)
14,866(88.5%)
1,417(8.4%)

113(21.7%)
3,465(23.3%)
410(28.9%)

409(78.4%)
11,401(76.7%)
1007(71.1%)

9,461(56.3%)
7,344(43.7%)

3,306(34.9%)
682(9.3%)

6,155(65.1%)
6,662(90.7%)

12,571(74.8%)
4,234
811(4.8%)
1,891(11.3%)
1,532(9.1%)

1,793(14.3%)
2,195
395(48.7%)
967(51.1%)
833(54.4%)

10,778(85.8%)
2,039
416(51.3%)
924(48.9%)
699(45.6%)

5.33(2.55)

6.62(1.76)

4.93 (2.62)

*

Chi-square test and ANOVA P<0.001.**Recommended surveillance interval as per 2006 guidelines; the
interval is based on adenoma findings at screening colonoscopy;≤1 year for those with sessile adenomas are
removed piecemeal, hyperplastic polyposis syndrome, or > 10 adenomas; 3 years for those with advanced
adenoma status, 3-10 adenomas, ≥ 1 cm adenoma, villous features, or high-grade dysplasia; 5 years for
those with 1 or 2 small tubular adenomas or any adenoma without advanced features. #Refers to number of
years of observation, from screening colonoscopy to the end of study period, Feb 11, 2011.
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Table 5.2 Surveillance-eligible study subjects classified by surveillance use relative to
recommended guidelines (n=4,234)

Patient characteristics
Gender
Male
Female
Missing
Age at screening
colonoscopy (years)*
40-49
50-59
60-74
Race*
White
Black
Other or unknown
Insurance status at
screening colonoscopy
Medicaid
Medicare or Private
Uninsured
Procedure-related
characteristics
Initial procedure year*
Pre-2006 period (pre
guideline)
2006 and later
Recommended
surveillance interval*
≤1-year surveillance

Overuse
(Premature
before due)
(n=1,355)

Appropriate
(Timing as
recommended)
(n=347)

Late
(Delayed relative
to due date)
(n=493)

Not done
(by end of
study period)
(n=2,039)

728(31.8%)
627(32.5%)
0

198(8.6%)
149(7.7%)
0

267(11.7%)
226(11.7%)
0

1,098(47.9%)
926(48.0%)
15(100.00%)

131(27.2%)
651(34.1%)
573(31.1%)

41(8.5%)
157(8.2%)
149(8.1%)

49(10.2%)
232(12.1%)
212(11.5%)

260(54.1%)
871(45.6%)
908(49.3%)

623(30.3%)
691(34.2%)
41(25.6%)

166(8.1%)
170(8.4%)
11(6.9%)

228(11.1%)
248(12.3%)
17(10.6%)

1,038(50.5%)
910(45.1%)
91(56.9%)

39(27.1%)
1,191(32.5%)
125(29.5%)

6(4.2%)
301(8.2%)
40(9.4%)

19(13.2%)
431(11.8%)
43(10.1%)

80(55.6%)
1,743(47.6%)
216(50.9%)

970(32.7%)
385(30.4%)

255(8.6%)
92(7.3%)

410(13.8%)
83(6.6%)

1,334(44.9%)
705(55.7%)

3(0.4%)

23(2.8%)

369(45.5%)

416(51.3%)

*

Chi-square test P<0.05 for the difference between surveillance use and the respective characteristic of the
study population.
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Table 5.2 Surveillance-eligible study subjects (continued)

3-year surveillance
5-year surveillance
Number of observation
years available* (Mean,
SD)
Polyp characteristics
Adenoma status*
Advanced adenoma/
≥ 3 adenomas
Non-advanced
adenoma
Location of the largest
adenoma*
Right
Left
Missing
Number of anatomic
segments with
adenoma*
1-2 locations
3-4 locations
Missing
Size of largest
adenoma*
≤ 5mm
5.1-9.9 mm
≥10 mm
Missing
Number of adenomas*
1-2 adenomas
3+ adenomas
Missing
Has ≥ 2 adv. adenoma
characteristics*
No
Yes

Overuse
(Premature
before due)
(n=1,355)
589(31.2%)
763(49.8%)

Appropriate
(Timing as
recommended)
(n=347)
281(14.9%)
43(2.8%)

Late
(Delayed relative
to due date)
(n=493)
97(5.1%)
27(1.8%)

Not done
(by end of
study period)
(n=2,039)
924(48.9%)
699(45.6%)

6.06(2.02)

6.36(1.81)

6.65(1.55)

6.01(2.13)

592(24.15%)

304(12.4%)

333(13.6%)

1,222(49.9%)

763(42.79%)

43(2.4%)

160(9.0%)

817(45.8%)

639(30.3%)
680(33.5%)
36(38.3%)

172(8.2%)
160(7.9%)
15(16.0%)

302(14.3%)
186(9.2%)
5(5.3%)

994(47.3%)
1,007(49.5%)
38(40.4%)

1167 (34.1 %)
152 (21.2 %)
36 (38.3%)

240 (7.0 %)
92 (12.8%)
15 (16.0%)

376 (11.0 %)
112 (15.6 %)
5(5.3%)

1640 (47.9%)
361 (50.4%)
38(40.4%)

816(31.0%)
271(35.0%)
244(31.8%)
24(42.1%)

215(8.2%)
55(7.1%)
64(8.3%)
13(22.8%)

321(12.2%)
83(10.7%)
86(11.2%)
3(5.3%)

1,283(48.7%)
365(47.2%)
374(48.7%)
17(29.8%)

925(41.1%)
408(21.0%)
22(47.8%)

89(4.0%)
245(12.6%)
13(28.3%)

199(8.9%)
293(15.1%)
1(2.2%)

1,036(46.1%)
993(51.2%)
10(21.7%)

1,230(31.3%)
125(41.5%)

326(8.3%)
21(7.0%)

460(11.7%)
33(11.0%)

1,917(48.7%)
122(40.5%)

*

Chi-square test P<0.05 for test of the difference between surveillance use and the respective characteristic
of the study population.
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Table 5.2 Surveillance-eligible study subjects (continued)

Location of the largest
adenoma*
Right
Left
Missing
Number of anatomic
segments with
adenoma*
1-2 locations
3-4 locations
Missing
Size of largest
adenoma*
≤ 5mm
5.1-9.9 mm
≥10 mm
Missing
Number of adenomas*
1-2 adenomas
3+ adenomas
Missing
Has ≥ 2 adv. adenoma
characteristics*
No
Yes

Overuse
(Premature
before due)
(n=1,355)

Appropriate
(Timing as
recommended)
(n=347)

Late
(Delayed relative
to due date)
(n=493)

Not done
(by end of
study period)
(n=2,039)

639(30.3%)
680(33.5%)
36(38.3%)

172(8.2%)
160(7.9%)
15(16.0%)

302(14.3%)
186(9.2%)
5(5.3%)

994(47.3%)
1,007(49.5%)
38(40.4%)

1167 (34.1 %)
152 (21.2 %)
36 (38.3%)

240 (7.0 %)
92 (12.8%)
15 (16.0%)

376 (11.0 %)
112 (15.6 %)
5(5.3%)

1640 (47.9%)
361 (50.4%)
38(40.4%)

816(31.0%)
271(35.0%)
244(31.8%)
24(42.1%)

215(8.2%)
55(7.1%)
64(8.3%)
13(22.8%)

321(12.2%)
83(10.7%)
86(11.2%)
3(5.3%)

1,283(48.7%)
365(47.2%)
374(48.7%)
17(29.8%)

925(41.1%)
408(21.0%)
22(47.8%)

89(4.0%)
245(12.6%)
13(28.3%)

199(8.9%)
293(15.1%)
1(2.2%)

1,036(46.1%)
993(51.2%)
10(21.7%)

1,230(31.3%)
125(41.5%)

326(8.3%)
21(7.0%)

460(11.7%)
33(11.0%)

1,917(48.7%)
122(40.5%)

*

Chi-square test P<0.05 for test of the difference between surveillance use and the respective characteristic
of the study population.
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Table 5.3 Logistic regression model of the likelihood of completing the surveillance
procedure among surveillance-eligible patients (n=4,234)
OR (95%CI)
Patient characteristics
Gender: Female vs. male
Age (years) (Ref:40-49)
50-59**
60-74**
Race (Ref: White)
Black**
Other or unknown
Insurance status (Ref: Uninsured)
Medicaid
Medicare or Private **
Procedure-related characteristics
Initial procedure timing
Post guideline* (vs. pre-2006 period) **
Recommended surveillance interval
(Ref: ≤1-year surveillance)
3-year surveillance
5-year surveillance**
Polyp characteristics
Anatomic location of the largest adenoma : Right (vs. Left)
Patient has ≥ 2 advanced adenoma characteristics**
Hosmer and Lemeshow Goodness-of-Fit statistic
*

Post guideline: screening colonoscopy done in 2006 or later.
P<0.05 are statistical significance.

**
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0.98(0.86,1.11)
1.42(1.16,1.74)
1.23(1.00,1.51)
1.22(1.07,1.39)
0.89(0.63,1.27)
0.87(0.59,1.30)
1.29(1.04,1.61)

0.62(0.54,0.72)

1.14(0.96,1.35)
1.26(1.06,1.51)
1.08(0.95,1.22)
1.64(1.28,2.11)
p=0.147

Table 5.4 Association of surveillance time interval (in years) with patient, procedure, and
polyp characteristics among surveillance-eligibles who completed surveillance
(n=2,195)*
Total,
≤1-year,
3-year,
5-year,
n=2,195
n=395
n=967
n=833
Estimate
Estimate Estimate Estimate
Patient characteristics
Age(years) (Ref: 40-49)
0.02
-0.27
-0.05
0.24
50-59
#
#
-0.16
-0.48
-0.21
0.03
60-74
Procedure-related characteristics
Initial procedure timing: Post
guideline(vs. pre-2006 period)
-0.56#
-0.57#
-0.54#
-0.51#
Recommended surveillance interval :
0.11
3-year surveillance (vs. ≤1-year)
Recommended surveillance interval :
0.19
5-year surveillance (vs. ≤1-year)
Polyp characteristics
Anatomic location of the largest
0.06
-0.16
0.08
0.16#
adenoma : Right (vs. Left)
Size of largest adenoma :
-0.30#
-0.53#
-0.23#
≥10 mm (vs. <10mm)
Size of largest adenoma :
-0.65#
5.1-9.9mm (vs. ≤ 5 mm)
Number of adenomas:
0.15
-0.13
0.19#
≥3 adenomas (vs. 1-2)
Patient has ≥ 2 advanced adenoma
-0.50#
-0.39
-0.53#
characteristics (vs. 1)
R square

0.185

*

0.165

0.186

0.103

Gender, race, insurance status were not statistically significant (P>0.05), and exclude from the field
models (data not shown).
#
P<0.05 are statistical significance.
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Table 5.4a Association of surveillance time interval (in years) with patient, procedure,
and polyp characteristics among the sub-group recommended to undergo surveillance at 5
years per 2006 guidelines (n=833)
Model 1*
Model 2*
Estimate
SE
Estimate
SE
Patient characteristics
0.07
0.08
0.06
0.08
Gender : Female vs. male
Age(years) (Ref: 40-49)
0.18
0.13
0.24
0.13
50-59
-0.02
0.14
0.03
0.13
60-74
Race (Ref: White)
-0.16**
0.08
-0.14
0.08
Black
0.12
0.23
0.13
0.22
Other or unknown
Insurance status (Ref: Uninsured)
-0.14
0.25
0.10
0.24
Medicaid
-0.03
0.13
0.20
0.13
Medicare & Private
Procedure-related characteristics
Initial procedure timing
-0.63**
0.10
-0.51**
0.10
2006 and later (vs. Pre-2006 period)
Polyp characteristics
Anatomic location of the largest
0.16**
0.07
adenoma : Right (vs. Left)
Size of largest adenoma :
-0.65**
0.11
5.1-9.9 mm (vs. ≤5mm)
R2=0.058,
R2=0.103,
2
Adj R =0.049
Adj R2=0.092
*

Model 1 includes patient and colonoscopy characteristics, and Model 2 includes patient,
colonoscopy, and adenoma characteristics.
**

P<0.05, statistically significant.
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Table 5.5 Likelihood of overuse, delayed and not completed surveillance among
surveillance-eligible patients (n=4,234)
Overuse
(Premature before
Late
due vs.
(Delayed vs.
Not done
recommended
recommended
(by end of
timing)
timing)
study period)
OR (95%CI)
OR (95%CI)
OR (95%CI)
Patient characteristics
Gender: Female vs. male
1.08(0.83,1.39)
1.06(0.80,1.42)
1.10(0.86,1.40)
Age(years) (Ref: 40-49)
50-59
1.49(0.98,2.26)
1.23(0.77,1.98)
0.95(0.65,1.39)
60-74
1.51(0.99,2.30)
1.12(0.70,1.81)
1.08(0.73,1.59)
Race (Ref: White)
Black
1.01(0.78,1.31)
1.04(0.78,1.39)
0.83(0.66,1.06)
Other or unknown
0.85(0.41,1.75)
0.96(0.43,2.14)
0.99(0.51,1.94)
Insurance status
(Ref: Uninsured)
Medicaid
1.85(0.70,4.90)
3.22(1.14,9.09) *
2.27(0.90,5.69)
Medicare or Private
1.30(0.84,2.00)
1.52(0.93,2.50)
1.00(0.67,1.49)
Procedure-related
characteristics
Initial procedure timing
2006 and later
(vs. Pre-2006 period)
1.73(1.30,2.31) *
0.50(0.35,0.70) * 1.86(1.42,2.43) *
Recommended
surveillance interval
5-year surveillance
(vs. ≤3-year surveillance) 14.39(10.03,20.64) *
0.31(0.18,0.53) * 4.41(3.11,6.25) *
Polyp characteristics
Anatomic location of the
largest adenoma :
Right (vs. Left)
0.86(0.67,1.11)
1.49(1.12,1.98) *
0.94(0.74,1.19)
Size of largest adenoma :
≥10 mm (vs. <10mm)
1.81(1.25,2.63) *
0.83(0.55,1.26)
1.28(0.91,1.80)
Patient has ≥ 2 advanced
adenoma characteristics
(vs. 1)
2.26(1.30,3.93) *
1.15(0.60,2.20)
1.02(0.59,1.76)
*

P<0.05 are statistical significance.
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Table 5.6 Logistic regression model of the likelihood of non-completion surveillance (vs.
any surveillance use) among surveillance-eligible patients (n=4,234)
Non-completion
patients
OR (95%CI)
Patient characteristics
Gender
Male
(ref)
Female
1.03(0.90,1.16)
Age at screening colonoscopy (years)
40-49
(ref)
*
50-59
0.71(0.57,0.87)
60-74
0.81(0.66,1.00)
Race
White
(ref)
*
Black
0.82(0.72,0.93)
Other or unknown
1.12(0.79,1.59)
Insurance status at screening colonoscopy
Medicaid
1.14(0.77,1.70)
Medicare or Private
0.78(0.62,0.97)
Uninsured
(ref)
Procedure-related characteristics
Initial procedure timing
Post guideline(vs. pre-2006 period)*
1.60(1.39,1.85)
Recommended surveillance interval
(Ref: ≤1-year surveillance)
3-year surveillance
0.88(0.74,1.04)
*
5-year surveillance
0.80(0.66,0.96)
Polyp characteristics
Anatomic location of the largest adenoma : Right (vs. Left)
0.93(0.82,1.05)
Size of largest adenoma : ≥10 mm (vs. <10mm)
1.05(0.86,1.28)
*
Patient has ≥ 2 advanced adenoma characteristics
0.59(0.44,0.79)
*

P<0.05 are statistical significance.
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Table 5.7 Logistic regression model of the likelihood of a 2nd procedure among those
who were not eligible for surveillance (n=12,571)
Had 2nd procedure
OR (95%CI)
Patient characteristics
Gender
Male
(ref)
*
Female
0.83(0.74,0.92)
Age at screening colonoscopy (years)
40-49
(ref)
*
50-59
1.33(1.13,1.56)
*
60-74
1.58(1.34,1.87)
Race
White
(ref)
*
Black
1.59(1.41,1.78)
Other or unknown
0.80(0.59,1.07)
Insurance status at screening colonoscopy
Medicaid
0.74(0.52,1.07)
Medicare or Private
0.98(0.83,1.17)
Uninsured
(ref)
Procedure-related characteristics
Initial procedure timing
Pre-2006 period
(ref)
2006 and later
0.06(0.05,0.07)
Polyp characteristics
Polyp status
Hyperplastic polyp*
2.03(1.80,2.94)
*
Normal tissue
2.47(2.13,2.87)
No polyp
(ref)
*

P<0.05 are statistical significance.
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